key: cord-0020119-urm3ajfl
authors: nan
title: Abstracts des 73. Kongresses der Deutschen Gesellschaft für Urologie e. V.
date: 2021-08-24
journal: Urologe A
DOI: 10.1007/s00120-021-01626-1
sha: 371d778ff96aab5bc7cadd589f445b5a9257fd19
doc_id: 20119
cord_uid: urm3ajfl

nan

(25/38) positiv. In 63 % (24/38) der Fälle zeigte sich eine Diskrepanz zwischen Harnkultur und Kultur der DJ-Enden. In 21 % (8/38) war die Harnkultur negativ bei positiver Kultur am DJ-Ende (proximal/distal oder beide). In 13 % (5/38) war die perioperative Antibiose bei negativer Harnkultur und positiver Kultur des DJ nicht resistenzgerecht. Eine Patientin verstarb postoperativ an Urosepsis, in 5 Fällen traten postoperative Komplikationen (Clavien-Dindo Grad 2) auf. Schlussfolgerung: Im Vergleich der präoperativen Harnkultur mit der bakteriellen Besiedlung der DJs zeigen sich teils erhebliche Differenzen, sodass ein Teil der Patienten vor Steinsanierung nicht resistenzgerecht antibiotisch abgeschirmt zu sein scheint. Dies könnte insbesondere nach verlängerter Liegedauer der DJs zu einer erhöhten perioperativen Komplikationsrate führen. V01.7 Prophylaxe für wiederkehrende Harnwegsinfekte bei Frauen mittels StroVac -Effektivität und Compliance in einem 2 Jahres Follow-up Hintergrund: Ein Hauptproblem von Patienten mit neurogener Dysfunktion des unteren Harntraktes ( NLUTD) stellt die rezidivierende katheterassoziierte Harnwegsinfektion ( CAUTI) dar. Ziel: Unter der zunehmenden Bedeutung von Antibiotic Stewardship war Ziel der Studie, eine alternative Therapiemaßnahme zur Antibiotikaeinnahme für Patienten mit NLUTD und rezidivierenden Harnwegsinfektionen zu finden. Die Behandlung sollte lokal anwendbar und gut verträglich sein. Gleichzeitig sollte die Entwicklung einer Antibiotika-Resistenz vermieden werden. Studiendesign und Methodik: Retrospektive Analyse von individuellen Heilversuchen bei 12 Patienten mit NLUTD und CAUTI (Ethikvotum des UK Bonn EK183/20) . Alle Patienten befanden sich stationär in einer neurologischen Rehabilitationseinrichtung. Die Therapieentscheidung wurde individuell zur temporären Keimeliminierung vor einer diagnostischen oder therapeutischen Intervention getroffen. Dazu wurde elektrochemisch aktivierte Lösung ( ECAS) als Blasenspülung verwendet. Es wurden jeweils Urinkulturen mit Antibiogramm vor und nach der Behandlung angelegt, das Ausmaß von Leukozyt-und Erythrozyturie bestimmt und klinische Parameter erhoben. Ergebnisse: Eine Keimeliminierung oder die Zunahme der sensibel getesteten Antibiotika wurde bei 50-70 % der Patienten beobachtet. Nebenwirkungen traten nicht auf. Limitationen: Aufgrund der Durchführung als individueller Heilversuch war die Teilnehmerzahl limitiert und es gab keine Kontrollgruppe. Schlussfolgerung: Bei Patienten mit NLUTD und rezidivierenden Harnwegsinfektionen scheint die Anwendung von ECAS als Blasenspülung zur temporären Keimeliminierung vor invasiven Maßnahmen eine viel versprechende Alternative zur Antibiotikaeinnahme zu sein. Eine randomisierte kontrollierte Studie ist erforderlich. V01.9 Phage therapy in the treatment of urinary tract infections-In vitro testing of commercial phage preparations using isothermal microcalorimetry M. Max 1a , A. P. Sigg 1a , A. Grütter 1 , T. Lafranca 1 , M. Rieken 1, 2 , O. Braissant 1, 3 , G. Bonkat 1*, 2, 3 1 Faculty of Medicine, University of Basel, Basel, Switzerland; 2 alta uro AG, Basel, Switzerland; 3 Department of Biomedical Engineering, University of Basel, Allschwil, Switzerland Background & Objectives: Antimicrobial resistance is drastically increasing worldwide. As the antibiotic pipeline is rather narrow, valuable alternatives are desperately needed. Phage therapy might be such an alternative. However, the efficacy of phage therapy for urinary tract infections (UTIs) has not sufficiently been investigated yet. We used isothermal microcalorimetry ( IMC) to assess the efficacy of commercial phage preparations against E. coli and P. mirabilis in sterile filtered and artificial urine. Material and methods: A microcalorimetry instrument (TAM48, TA Instruments, New Castle, DE) equipped with 48 channels was used to follow bacterial growth (or its absence). Bacteria were incubated in sterile filtered urine and artificial urine together with different dilutions (1% and 5%) of bacteriophage solution (E. coli/Proteus bacteriophage solution, NPO Microgen, 44, Gruzinskaya str., Nizhny Novgorod, Nizhny Novgorod region, 603950 Russia). Positive controls were performed using 3 mL of inoculated urine and negative (sterility) controls were prepared using uninoculated urine (i. e., filter sterilized urine). Measurement started after thermal equilibration procedure as recommended by the manufacturer and lasted until the signal rose and returned to baseline or for at least 120 h. Results: A clear drop of metabolic activity-representing bacterial deathwas visible for each concentration (1% and 5%) of phage solution used. The metabolic heat rate of E. coli returned after to baseline after 3-4 h. The growth of Proteus mirabilis growth was strongly reduced (growth rate decreased by 50% and lag phase increased by 4.6 h) but not fully suppressed. Conclusions: The commercial phage product used in our study was very effective in inducing bacterial death in E. coli and P. mirabilis in sterile fil-Abstracts tered urine and artificial urine, respectively. IMC provides valuable additional information such as kinetics of bacterial death as well as preypredator behavior. Furthermore, a phagogram might be obtained within 4-7 h. In conclusion, IMC confirmed the potential of bacteriophages to induce death in uropathogens in urine. Es liegen keine gesicherten Erkenntnisse darüber vor, ob es für UKMH eine Korrelation der beruflichen Zufriedenheit mit dem Wunsch gibt, die Fachrichtung bzw. das Land ihrer gegenwärtigen Tätigkeit wieder verlassen zu wollen. Erstmalig sollen diese Daten in Deutschland mittels Survey erhoben werden. Material und Methoden: Ein Survey-Monkey® mit 101 Items zu charakterisierenden Kriterien des Studienteilnehmers und Fragen zur beruflichen Zufriedenheit (n = 39) wurde zwischen 8-10/2020 für UKMH geöffnet. Der Einfluss verschiedener Dimensionen beruflicher Zufriedenheit auf den Wunsch, die urologische Tätigkeit u/ o Deutschland ggf. verlassen zu wollen, wurde analysiert (Gr. A: möchte nicht die urologische Tätigkeit und ebenfalls nicht Deutschland verlassen, und Gr. B: kann sich das Verlassen der urologischen Tätigkeit u/ o Deutschlands zumindest vorstellen). Ergebnisse: 81 UKMH verteilten sich in den Gr. A (50,6 %) und B (49,4 %) nahezu paritätisch. Die berufliche Zufriedenheit war in mehreren Dimensionen höher in der Gr. A. Aus drei im Gruppenvergleich signifikant unterschiedlichen Dimensionen beruflicher Zufriedenheit: (1) Verhältnis zu den Vorgesetzten (p = 0,014), (2) Karrieremöglichkeiten in der Klinik (p < 0,001), und (3) Möglichkeiten zur Weiterentwicklung der chirurgischen Fähigkeiten (p = 0,006) wurde ein Summenscore mit einer Range von 3-15 Pkt. gebildet. Pro Punktwert dieses Summenscores nahm der Wunsch des UKMH, die Urologie u/ o Deutschland verlassen zu wollen (bzw. zumindest unsicher in dieser Frage zu sein) um 34, 6 % ab ( OR 0, 654, 861, p = 0, 002) . Schlussfolgerungen: Es wurden verschiedene Dimensionen beruflicher Zufriedenheit identifiziert, deren Verbesserung zu einer langfristigen Tätigkeit der UKMH an deutschen urologischen Kliniken beitragen könnte. V02.9 Einfluss graphisch-radiologischer Annotierung suspekter Läsionen auf die Ergebnisse der zielgerichteten MRT/ Ultraschall-Fusionsbiopsie der Prostata Strukturierte Berichterstattung von Ergebnissen multiparametrischer Magnetresonanztomographien der Prostata (mpMRT) verbessert die interdisziplinäre Kommunikation und Detektion von Prostatakarzinomen ( PCA). Wir analysierten den Einfluss der zusätzlichen graphischen Annotierung auffälliger Läsionen in der mpMRT auf die Ergebnisse gezielter MRT/Ultraschall-Fusionsbiopsien der Prostata ( TB). 268 biopsie-naive und 84 vorbiopsierte Männer mit Verdacht auf ein PCA wurden untersucht. Erfahrene Uroradiologen bewerteten und berichteten MRT-Ergebnisse von 106 Patienten gemäß dem PI-RADS-Standard Version 2.1. In der Vergleichsgruppe wurden die Läsionen in den MRT-Bildern (Markierung in T2-gewichteten und diffusionsgewichteten Sequenzen) für 246 Männer zusätzlich annotiert. Läsionen der PI-RADS Kategorie ≥3 wurden biopsiert. Prostatakarzinome mit ISUP-Werten (International Society of Urological Pathology) ≥2 wurde als klinisch signifikant (csPCA) definiert. Die Daten wurden prospektiv erhoben und die Gesamt-PCA-Detektionsrate ( CDR) und Erkennungsrate von csPCA verglichen. Die Verteilung der PIRADS-Bewertung war in beiden Gruppen vergleichbar. Die CDR der TB gemäß dem Standardansatz, basierend auf den PI-RADS-Kategorien 3, 4 und 5, betrug 5 %, 39 % und 72 % für PCA bzw. 5 %, 36 % und 68 % für csPCA. Durch zusätzliche Annotierung der Ziele in den MRT-Sequenzen verbesserte sich die CDR auf 17 %, 53 % und 93 %. Hervorzuheben ist, dass sich die CDR von csPCA signifikant erhöhte ( PPCA < 0,021; P csPCA < 0,001). Die radiologische Berichterstattung mitsamt Annotation suspekter Areale in MRT-Bildern führt zu signifikant besseren diagnostischen Ergebnissen der TB. Wir schlussfolgern daher, dass diese multimodale Befundung in die nächste PI-RADS-Version integriert werden sollte.

16.09.2021, C7.2, 08:00-09:30 V03.1 Dissecting the mechanistic role of PBRM1 loss to inflammatory signals within the tumor microenvironment of clear cell renal cell carcinoma Fragestellung: Autophagie verknüpft zelluläre Abbauprozesse mit dem Stoffwechsel und stellt eine innovative therapeutische Strategie in der Tumortherapie dar. Material und Methoden: Für diese Studie wurde Tumor-(n = 324), Normal-und Metastasengewebe (n = 164) von Patienten mit Nierenzellkarzinom ( NZK) verwendet. Es wurden Analysen der Transkriptomdaten von Autophagie-Kandidatengenen (n = 129) durchgeführt und die Expression für ATG5, ATG7, LC3B & SQSTM1 untersucht. In Zellkulturexperimenten wurde die Wirkung des neuen Autophagie-Inhibitors ROC-325 allein und in Kombination mit Metformin auf die Zellviabilität, Genexpression und mitochondriale Atmung in etablierten und primären NZK-Zelllinien untersucht. Ergebnisse: Die 4 untersuchten Proteine zeigten eine höhere Expression im Metastasen-verglichen zum Primärtumorgewebe. Aktivierte Autophagie Signalwege fanden sich im Primärtumor und Metastasen vom klarzelligen NZK sowie in primären NZK-Zelllinien. Am höchsten exprimiert waren CTSD und RAB7A. In der TCGA-Vergleichskohorte waren CTSD und RAB7A ebenfalls hoch exprimiert, zusätzlich aber auch SQSTM1 und LAMP1&2. Die Behandlung mit ROC-325 zeigte konzentrationsabhängig sowie in Kombination mit Metformin eine signifikant geringere Viabilität in den Zellexperimenten. Die Wirkung von ROC-325 auf die mitochondriale Atmung ergab widersprüchliche Ergebnisse. Die Fähigkeit der Zellen auf einen energetischen Bedarf zu reagieren, wurde bei Kombination von ROC-325 mit Metformin reduziert. Schlussfolgerung: Die Inhibition der Autophagie im Tumormicroenvironement des NZK ist eine neue therapeutische Strategie in der Beeinflussung metabolischer Signalwege. Gefördert durch ein Ferdinand Eisenberger-Forschungsstipendium der DGU, Fördernummer StV1/ FE-19 und durch die Robert Bosch Stiftung, Stuttgart V03.3 Zirkuläre RNA: Bedeutung als Biomarker für Patienten mit einem klarzelligen Nierenzellkarzinom activated receptor MET and the coupled proteins, Src and STAT3, followed by an impairment of Erk ½ and FAK. Under the same conditions MET was efficiently inhibited in Caki-2/ WT cells, along with the mTOR markers, AKT and S6. As second-line drug, Cbz had lower efficacy in 786-O/S cells (IC 50 of 13 µM, p value 0.02), but no in Caki-2/S (IC 50 of 12.6 µM). The Sun-pretreatment enhanced the level of MET only in 786-O/ S. After the Cbz treatment a delayed inhibition of MET (72 h) was compensated by the boost of Src and STAT3 in 786-O/ S. By contrast, Cbz impaired MET in Caki-2/S, as in the Caki-2/ WT. In both Sun-pretreated cell lines, the endogenous activation of FAK was not affected by Cbz. Still, the drug altered mTOR, especially in Caki-2/ S. Finally, the anti-apoptotic protein Bcl-2 was enhanced at the maximum inhibition of MET, notably in 786-O/S and Caki-2/ WT. Conclusions: Following MET inhibition, the activation of Src-FAK protein axis and Bcl-2 might suggest a synergy that could weaken Cbz's antitumor activity. This ongoing work will provide a better knowledge of cellular signaling in mRCC therapy sequencing.

V03.8 CMTM6 expression as a potential biomarker for immunotherapy in metastatic renal cell Carcinoma Recently human chemokine-like factor ( CKLF)-like MARVEL transmembrane domain containing family member 6 (CMTM6) has been identified as a key regulator of PD-L1 cell surface expression across various cancer entities. Thus, CMTM6 is supposed not only to refine the prognostic value of PD-L1, but also to play an independent role as a predictive factor for response to immune checkpoint inhibition. For the first time we evaluated expression of CMTM6 within the tumour microenvironment TME (tumour cells ( TC) and tumour-infiltrating immune cells ( IC)) of RCC and its predictive role when compared to PD-L1 in primary tumours of sixteen patients with metastatic RCC patients receiving nivolumab. A high intratumoural heterogeneity of both CMTM6 and PD-L1 expression, with a significantly higher expression of both markers on IC compared to TC (CMTM6: p < 0.001; PD-L1: p = 0.008) was found. Focusing on IC, CMTM6 expression was significantly higher compared to PD-L1 (p = 0.0016). Moreover, CMTM6 expression was positively correlated with PD-L1 on TC (r s = 0.441; p = 0.047) and IC (r s = 0.487; p = 0.057). Further, patients with CMTM6-IC high scores (CMTM6-IC high ) had a significantly shorter PFS on nivolumab when compared to patients with CMTM6-IC low scores (CMTM6-IC low ), (median, low vs. high: 24 vs. 7 months; p = 0.032). Our data suggest that CMTM6 plays an important role in the RCC tumour microenvironment. Although both markers CMTM6 and PD-L1 were more frequently expressed on IC than on TC, CMTM-IC expression was significantly higher compared to PD-L1. Moreover, in contrast to PD-L1, CMTM6-IC expression appears to predict PFS in patients receiving nivolumab. Thus, PD-L1 IHC may be supplemented by IHC measurement of CMTM6 to increase its prognostic role as predictive biomarker.

Fluoreszenz-In-Situ-Hybridisierung zur Differenzierung zwischen Onkozytomen und chromophoben Nierenzellkarzinomen Die eindeutige Diagnose von Onkozytomen ( OZ) ist eine wichtige Voraussetzung für die Therapieentscheidung und Nachsorge, insbesondere bei kleinen Nierentumoren. Die Differenzierung zwischen Onkozytomen ( OZ) und chromophoben Nierenzellkarzinomen (chrNZK) ist jedoch durch alleinige Histopathologie nicht immer möglich. Ziel dieser Studie war die Analyse chromosomaler Alterationen von OZ vergleichend zu chrNZK mittels FISH. Es wurden Tissue Microarrays ( TMA) von 59 chrNZK und 36 Onkozytomen mit je 2 Tumorarealen und z. T. Normalgeweben verwendet. Die FISH wurde auf Schnitten der TMAs unter Verwendung von Zentromersonden für die Chromosomen (Chr) 1, 2, 6, 10 und 17 durchgeführt. Pro Gewebestanze wurden 100 Zellkerne ausgewertet. Die Cut-off-Werte wurden für jede Sonde an 10 Normalgeweben definiert. Die chrNZK wiesen Verluste der Chr 1, 2, 10 und 17 in je 100 % und von Chr 6 in 94 % der Proben auf. In allen Fällen waren mindestens 4 Chromosomen verändert. Bei den OZ fanden sich Verluste von 1 in 100 %, von 2 in 26 %, von 6 in 11 %, von 10 in 8 % und von 17 in 12 % der Proben. Jedoch war der Anteil veränderter Zellen für die Chr 2, 6, 10 und 17 bei den OZ signifikant geringer (6-11 % vs. 52-85 %) . Es bestand keine Korrelation zur Tumorgröße. Für die chrNZK wurde eine hohe (Korrelations-koeffizient> 0,86) und für die OZ eine mittlere bis hohe Übereinstimmung (Korrelationskoeffizient 0,34-0,89) der Veränderungen zwischen 2 Tumorarealen festgestellt. Während Onkozytome durch den Verlust des Chr 1 charakterisiert sind, weisen chrNZK immer kombinierte Verluste von mindestens 4 Chromosomen auf. Diese Ergebnisse belegen, dass die FISH an Schnittpräparaten eine wichtige Technik zur Absicherung der histopathologischen Diagnose und damit zur individuellen Therapieentscheidung darstellt.

16.09.2021, C4.2, 08:00-09:30 V04.1 Präoperative Ankerdraht-Markierung vor robotischer Salvage-Lymphadenektomie bei "in-field" Lymphknotenrezidiven nach radikaler Prostatektomie: erste Erfahrungen V04.3 Roboter-assistierte Nierenteilresektion unterschiedlich komplexer Nierentumore unter Verwendung von Fluoreszenz -Imaging mit Firefly TM -Technik R. Ganzer * , W. Brummeisl, A. Mangold, J. König, L. M. Szyper Asklepios Stadtklinik Bad Tölz, Klinik für Urologie, Bad Tölz, Deutschland Fragestellung: Hilft der standardisierte Einsatz der Firefly TM -Technik bei der Roboter -assistierten Nierenteilresektion ( NTR) bei Nierentumoren unterschiedlicher Komplexität? Material und Methoden: Prospektive Analyse von Patienten nach NTR ab 07/2017. Zur Überprüfung der Ischämie des Exzisionsbereichs wurde nach Ausklemmen der Nierenarterie(n) eine Fluoreszenzdiagnostik mit Indocyaningrün -Firefly TM -Technik durchgeführt. Bei persistierender Perfusion erfolgte eine weitere Präparation der Gefäßversorgung. Die Einteilung der Nierentumore erfolgte anhand des R. E. N. A. L. Scores. Komplikationen wurden nach der Clavien-Dindo Klassifikation erfasst. Ergebnisse: 117 Patienten wurden untersucht. In 77,7 % lagen Tumore intermediärer (n = 71) und hoher (n = 20) Komplexität vor (multifokal n = 5, Einzelniere n = 3). In den Gruppen mit niedrigem, intermediärem und hohem R. E. N. A. L. Score lagen die mittleren Tumorgrößen bei jeweils 28 , 40 und 52 (24-103) mm. In 19,2 %, 33,8 % und 45 % fanden sich ≥2 Nierenarterien. Die mittlere (partielle) Ischämiezeit betrug 14 (0-22) , 16 (0-28) und 21 Minuten. Eine postoperative Bluttransfusion erfolgte in 0 %, 2,8 % (2/71) und 10 % (2/20) . Interventionspflichtige Clavien IIIb Komplikationen traten in 4/71 (5,6 %) auf. Der mittlere Krankenhausaufenthalt betrug 7,1 (5-15), 7,2 (5-19) und 6,6 (5-8) Tage. Es erfolgte keine intraoperative Konversion. Schlussfolgerungen: Der Einsatz der Firefly TM Technik ist eine einfache technische Erweiterung, um bei der Roboter-assistierten NTR eine Ischämie des Exzisionsbereiches zu gewährleisten. Mit dieser Technik zeigte sich an unserem Patientenkollektiv mit Tumoren überwiegend intermediärer und hoher Komplexität eine niedrige Komplikationsrate ohne intraoperative Konversion und ohne Nierenverlust. V04.4 Der kardiale Notfall (kN) während roboterassistierter ( RA) Eingriffe: Simulationstraining verbessert die Teamkoordination J. Moellers * , K. Wenker, J. H. Witt St. Antonius Hospital Gronau GmbH, Gronau, Deutschland Fragestellung: Bei RA Eingriffen im kleinen Becken kann es durch die Lagerung und den angedockten Roboter während eines kN zu einem Zeitverlust zwischen Herzstillstand und Beginn der Wiederbelebung kommen. Ziel der Arbeit war es, die Zeit vom Eintritt des kN bis zur Defibrillation ( DEF) zu verkürzen. Material und Methoden: Ein multidisziplinäres Team wurde in die Notfallschritte eingewiesen. Die einzelnen Teams wurden in einem mit komplettverkabelten und OP-üblich abgedecktem Kunststofftorso in 30° Trendelenburglagerung präparierten OP gebracht. Der Anästhesist gibt das Stichwort "Stopp Notfallabdocken". Gemessen wurden folgende Zeiten: erste Herzdruckmassage ( HDM), Zurückziehen des Roboters und der ersten DEF. Zusätzlich wurde die Selbsteinschätzung ( SE) des Handelns im kN vor und nach dem Training abgefragt. Ergebnisse: 2019 haben 42, im folgenden Jahr 35 Personen (P) teilgenommen und insgesamt 35 Durchgänge absolviert. Mediane Zeiten in Sekunden (s) 2019: HDM 39s, Zurückziehen des Roboters 37s, DEF 125s. Mediane Zeiten 2020: HDM 29s, Zurückziehen des Roboters 37s, DEF 134s. SE 2019 vor Training: 32 von 42 P schätzen ihre Fähigkeit korrekt zu Handeln "sehr gut" bis "befriedigend" ein. Nach Training schätzen sich alle Teilnehmer so ein. SE 2020 vor Training: 22 von 35 schätzen ihre Fähigkeiten "sehr gut" bis "befriedigend" ein. Nach Training haben wieder alle Teilnehmer eine entsprechende Einschätzung. Schlussfolgerung: Um eine schnelle und effektive Reanimation während RA Eingriffen zu gewährleisten, ist ein praktisches Notfalltraining sinnvoll. Die gleichartige Selbsteinschätzung vor und nach dem Training nach 1 Jahr legt nahe dass derartige Simulationen in kürzeren Abständen erfolgen sollten. V04.5 Ergebnisse der Harnröhrenplastik mit Mundschleimhaut bei penilen Strikturen mit und ohne Meatusrekonstruktion V04.6 Neue TRUS-geführte Hydrospacing-Technik erleichtert die Präparation des Neovaginalkanals bei genitalangleichenden Operationen von Mann zu Frau Zur intraoperativen Visualisierung wurde der hydrodistendierte Raum mit 2 ml Methylenblau gefärbt. Die erhobenen Daten wurden retrospektiv mit einer klinisch und demographisch vergleichbaren Serie von 84 Transfrauen, die zwischen 06/2016 und 06/2018 eine GAO ohne HST (Kontrollgruppe, KG) erhielten, gegenübergestellt. Alle Eingriffe wurden vom selben Chirurgen durchgeführt. Das perioperative Setting war vergleichbar. Ergebnisse: Beide Gruppen unterschieden sich nicht bezüglich der Ausgangscharakteristika wie Alter (p = 0,44) und Body-Mass-Index (p = 0,73). Vaginale Tiefe und Breite waren in der HST-Gruppe signifikant größer (14,4 cm vs. 13,5 cm, p = 0,01 und 4,2 cm vs. 3,8 cm, p < 0,001) . Beide Gruppen unterschieden sich nicht bzgl. intraoperativer Rektumverletzungen (p = 0,26) und postoperativer Komplikationen (p = 0,55). Die mediane Gesamt-OP-Zeit war ähnlich in beiden Gruppen (211 min vs. 218 min; p = 0,19). Schlussfolgerung: HST ist ein minimalinvasives und leicht anzuwendendes Verfahren zur sicheren Präparation des Scheidenkanals während der MzF-GAO. Der zusätzliche operative Schritt vereinfacht die folgende Präparation, führt nicht zu einer Verlängerung der OP-Zeit und verbessert das Outcome. Längere, segmental obliterative Urethrastrikturen bedürfen beidseitiger Rekonstruktionen, prinzipiell einhergehend mit der Durchtrennung des Spongiosums und damit Beeinträchtigung der urethralen Perfusion. Diese Techniken wurden zuletzt i. S. weniger invasiver Methoden (nontransecting) verfeinert (End-zu-End-Anastomose + dorsales Transplantat). Wir präsentieren Technik und Ergebnisse unserer Modifikation mit dorsaler mukomukosaler Anastomose und ventraler Augmentation. Patienten mit bulbärer Striktur und hoch obliterativem Segment (≤2 cm) wurden mittels MANTA-Technik zwischen 2016-2019 rekonstruiert. Nach ventraler Inzision erfolgt hierüber die dorsale Exzision des obliterativen Segments und Anastomose der Mukosa. Ventrale Augmentation mit Mundschleimhaut. Prospektive Erfassung perioperativer Charakteristika inkl. Uroflowmetrie und validierter PROMs. Analyse postoperativer Verbesserung objektiver und funktioneller Parameter. Ein Rezidiv wurde definiert als Re-Intervention. Insgesamt 54 Patienten (medianes Alter 51 J). Voreingriffe: ≥1 Urethrotomie bei 83 %, Urethroplastik bei 26 %. Die mittlere Transplantatlänge betrug 4 cm. Uroflowmetrisch zeigte sich eine signifikante Besserung des medianen Qmax von 7,7 ml/s auf 31 ml/s postoperativ (p < 0,001). Die funktionellen Ergebnisse von 50 (93 %) Patienten nach medianem Follow-up von 40 Monaten zeigen eine signifikante Verbesserung des medianen 6-item LUTS Scores von [12] [13] [14] auf postoperativ 1 ( IQR 0-3; p < 0,001). Die Gesamterfolgsrate betrug 93 %, 4/54 Patienten erlitten ein Rezidiv. Die ventrale Urethroplastik mit dorsaler mukomukosaler Anastomose ohne Durchtrennung des Spongiosums ( MANTA Urethroplastik) zeigt eine exzellente Erfolgsrate in der komplexen Rekonstruktion bulbärer Harnröhrenstrikturen mit hochobliterativem Segment. Die Länge der Striktur war in der Gruppe I zwischen 1 und 7,56 cm (Median 3,5 cm) und in der Gruppe II zwischen 2 und 16 cm (Median 5 cm). Bei 5 Patienten der Gruppe I waren die Strikturen ausserhalb der Neourethra lokalisiert. 9 Patienten der Gruppe II hatten ein Lichen sclerosus. Die Neourthra wurde gebildet aus Mundschleimhaut bei 53, innerem Vorhautblatt bei 2 und als composite Graft bei 1 Patienten. Clavien III Komplikationen wurden bis 90 Tage nach der OP bei 7 Patienten beobachtet. Bei einer mittleren Beobachtungszeit von 48 Monaten traten in beiden Gruppen je 3 Rezidive auf. Weiterhin traten eine ventral penile Deviation und eine Störung der Sensibilität des Mundwinkel auf. Zusamenfassung: Die Rekonstruktion der Harnröhrenstrikturen nach vorausgegangener Hyp-OP bedarf einer Beherrschung des kompletten operativen Spektrums. Bei einem kurzen mittleren Follow-up war die Rate der Komplikationen vertretbar. V04.9 Interdisziplinärer Behandlungsansatz der totalen Exenteration und Defektdeckung mittels vertikaler Rectus-abdominis-Muskel-Haut-Lappenplastik ( VRAM) bei ausgedehnten urogenitalen Tumoren am Beispiel des Vulvakarzinoms J. Hammes 1* , S. Aufderklamm 1 , S. Kommoss 2 , J. Kolbenschlag Einleitung: Lokal fortgeschrittene Vulvakarzinome sind häufig mit Lebensqualitätsminderung mit Schmerzen bis hin zur Geruchsbildung verbunden. Therapeutisch kann eine radikale Resektion mit totaler Exenteration sinnvoll sein. Zur Deckung der lokalen Defekte kommen dabei gestielte Lappenplastiken zum Einsatz. Hier stellen wir den interdisziplinären Ansatz dieser Operation an einer Serie von Vulvakarzinomen vor. Material und Methoden: Bei vier Fällen wurde zwischen 2018 und 2020 eine Ano-/Vulvektomie mit totaler Exenteration sowie Ileum conduit-und Colostoma-Anlage bei fortgeschrittenem Vulvakarzinom interdisziplinär (Gynäkologie/Urologie/Chirurgie) durchgeführt. Die Defektdeckung er-folgte mittels VRAM-Lappenplastik und Bauchwandrekonstruktion mit Netz (Plastische Chirurgie). Ergebnisse: Das mittlere Alter betrug 71,25 Jahre (70-73). Karzinome lagen als Primärbefund oder Rezidiv nach Radiatio vor. Die lokale Ausbreitung umfasste urethrale und rektale Infiltration. Postoperativ wurden die Patientinnen bis zur Einheilung des Urostomas erst im Mittel 13,5 Tage (12) (13) (14) (15) urologisch, anschließend 20 Tage Tage) gynäkologisch betreut. Die Kontrolle des VRAM-Lappens erfolgte regelmäßig durch die Plastische Chirurgie. In allen 4 Fällen gelangen eine makroskopische Tumorkomplettresektion (3 × pR0, 1 × pR1) sowie das vollständige Einwachsen der Lappenplastik. Schlussfolgerung: Durch enge interdisziplinäre Kooperation kann die ausgedehnte Resektion mit Harn-und Stuhlableitung sowie Defektdeckung mit gestieltem Lappen erfolgreich umgesetzt werden. Die en bloc Vulvektomie mit Exenteration ermöglicht eine vollständige Tumorresektion mit Erhalt der Lebensqualität. Die VRAM-Lappenplastik kann auch bei vorbestrahltem Gewebe adäquat zum Wundverschluss angewendet werden. Hintergrund: Seit 2010 die rsRARP publiziert wurde, wurde die Technik nun in drei prospektiven RCT gegen die cRARP untersucht. Zur Vertiefung der Evidenz wurde von uns eine prospektiv, randomisierten, einseitig verblindete Studie durchgeführt. Patienten/Methoden: 202 Prostatakarzinom (PCa) Patienten (Alter 64, 2 ± 6, 9 J.) wurden in die Studie eingeschlossen und 1:1 randomisiert. Präoperativ sowie 1, 4 und 12 Wochen nach Katheterentfernung wurden funktionelle Daten (Kontinenz, Sexualfunktion) mittels Fragebögen ( ICIQ-UI SF, IPSS, IIEF-5, QoL) erhoben. Ergebnisse: 3 Monate postoperativ liegen komplette Datensätze zu 186 Patienten (cRARP n = 92, rsRARP n = 94) vor. Präoperative Charakteristika waren in den Gruppen gleich verteilt. Der stationäre Aufenthalt (4,1 ± 0,9 vs. 5,4 ± 5,8 d; p = 0,037) und Konsolenzeit (Prostatektomie 36, 8 ± 8, 8 vs. 46, 8 ± 12, 8 Min; p = 0, 017) waren in der rsRARP Gruppe signifikant kürzer. Patienten nach rsRARP zeigten ein signifikant schnelleres Wiedererlangen der Kontinenz (1 Woche p = 0.003, 3 Monate p = 0,022), einen geringeren Vorlagenverbrauch (p = 0.001, 0,011, 0,019) und eine geringere Beeinträchtigung der Lebensqualität durch ungewollten Urinverlust (p = 0,001, 0,002, 0,005) als Patienten nach cRARP. Onkologische Follow-up-Daten liegen zu diesem Kollektiv noch nicht vor. Nach rsRARP an unserer Klinik liegt die Rate der BCR gesamt bei 5,9 %, bei R1-Resektion bei 4,1 %. Zusammenfassung: Die technisch deutlich aufwändigere rsRARP ist mit einem signifikant höheren Erhalt bzw. früheren Wiedererlangung der Kontinenz, geringerem Vorlagenvebrauch und einer höheren Lebensqualität verbunden. Gleichzeitig geht die rsRARP mit einer niedrigen BCR-Rate und somit gutem onkologischem Outcome einher. V05.2 Continence recovery at 3, 6 and 12 months following robotic-assisted vs laparoscopic surgery: outcome from the first multicentre randomised patient blinded controlled trial in radical prostatectomy ( LAP-01) S Ziel: Beurteilung der klinisch signifikanten Verbesserung der präoperativen Symptome des unteren Harntrakts( LUTS) und der damit verbundenen Lebensqualität( QoL) nach roboterassistierter radikaler Prostatektomie ( RARP) bei Prostatakarzinompatienten. Methoden: Wir identifizierten 6866 RARP Patienten mit präoperativ moderaten vs. schweren ( IPSS 20-35) LUTS. Eine deutliche klinische Verbesserung wurde als eine negative IPSS-Differenz von 8 Punkten definiert. Multivariable logistische Regressionsanalysen ( LRM) zur Prädiktion von ΔIPSS≤-8 beinhalteten das Alter, präoperatives PSA, präoperative LUTS (moderat [ REF.] vs. schwer), Drüsengewicht (g), CAPRA-S-Score, Nervenschonung (keine vs. uni-vs. bilateral) und Blasenhalsrekonstruktionsbreite (1-5 cm) . Resultate: Präoperative LUTS wurden bei 37 %(n = 2556) bzw. 5,8 %(n = 400) als moderat und schwer eingestuft. Hier wurde eine post-operative Verbesserung bei 36 % bzw. 89 % berichtet, was mit einer Score-Veränderung von -2,0 vs. -15,1 einherging (p < 0,001). Ein ΔIPSS ≤-8 vs. >-8 ging mit einer Score-Veränderung der Lebensqualität von +0,28 vs. -1,5 einher (p < 0,001) . In der LRM waren der präoperative LUTS-Grad ( OR 14; 95 % CI 10-19; p < 0,001) und das Drüsengewicht (pro 10 g, OR 1, 12; 95 % CI 1, 16 ; p < 0,001) unabhängige Prädiktoren für klinisch signifikante LUTS-Verbesserung. Schlussfolgerungen: In unserer Kohorte mit präoperativen LUTS zeigte den großen Anteil von Patienten eine klinisch signifikante Verbesserung der LUTS-Beschwerden bereits 6 Monate nach RARP. Dies wirkt sich zudem auf eine verbesserte Lebensqualität aus. LRM zeigte den größten Vorteil bei Patienten mit präoperativer schwerer LUTS und großvolumiger Drüse. Diese Parameter sind bei der Therapieberatung neben onkologischen Variablen zu berücksichtigen. Fragestellung: Wir untersuchen den Einfluss des Alters ≥75 Jahre auf das progressionsfreie Überleben( PFS) nach roboter-assistierter radikaler Prostatektomie( RARP). Es ist kontrovers, ob das Alter per se das onkologische Outcome beim Prostatakarzinom negativ beeinträchtigt. Methoden: Wir analysierten 8159 RARP-Patienten, eingeteilt in zwei Gruppen: <70 (n = 7578) vs. ≥75 Jahren (n = 581). Das Alter wurde in multivariablen Cox-Regressionsanalysen( MVA) untersucht, die auch initiales PSA, neoadjuvante Androgendeprivation, Charlson Comorbidity Index, Jahr der Operation, pathologischer Gleason-Score, Tumor-, Lymphknotenund Tumorrand-Status beinhalteten. Die Analysen wurden nach Propensity Score Matching( PSM) wiederholt, welche die gleichen Variablen beinhaltete. Ergebnisse: Die Senior-Patienten ≥75 Jahren wiesen im Vergleich zu den jüngeren Patienten < 70 Jahren folgende onkologische Unterschiede auf: ISUP Grade ≥3 (55 vs. 35 %; p < 0,001), ≥pT3 (53 vs. 34 %; p < 0,001), pN1 (13 vs. 7,6 %; p < 0,001) und R1 (13 vs. 10 %, p = 0,04). Das mediane Follow-Up war 60 ( IQR 25-97) vs. 36 Monate ( IQR 5, . vs. 77 % (95 % CI 74-81; p < 0,001). Nach PSM wurden keine statistisch signifikanten Unterschiede bei den pathologischen Variablen bei Gruppen ≥75 vs. < 70 Jahren beobachtet. In der MVA war das Alter kein statistisch signifikanter Risikofaktor für kürzeres PFS, weder vor noch nach der PSM. Schlussfolgerungen: Die Patienten im Alter von ≥75 weisen nach der RARP ungünstigere pathologische PCa-Parameter als jüngere Patienten auf. Das Alter selbst ist jedoch kein negativer Risikofaktor für eine kürzere PFS nach der RARP. Basierend auf unseren onkologischen Daten sollte ein fortgeschrittenes Patientenalter alleine kein Ausschlusskriterium für RARP darstellen.

V05.5 Ändert die Zweitbeurteilung des Probenmaterials der Erstdiagnose eines Prostatakrebses durch einen spezialisierten Pathologen die Therapieplanung? tienten mit 0 in 67 %, 1 in 21 %, 2 in 8 % und >2 in 5 % an. Die ärztliche Einschätzung stimmte in 69 % mit diesen Angaben überein, überschätzte die HI in 23 % und unterschätzte sie in 8 %. Die Belastung durch die HI wurde in 43 % richtig eingeschätzt, in 21 % überschätzt und in 37 % unterschätzt. Die von den Patienten angegebene ED war in 75 % schwer oder sehr schwer. Die ärztliche Einschätzung stimmte in 56 % hiermit überein, überschätzte die ED in 12 % und unterschätzte sie in 32 %. Die Belastung durch die ED wurde in 32 % korrekt eingeschätzt, in 27 % überschätzt und in 41 % unterschätzt. Schlussfolgerung: Die Belastung der Patienten durch HI und ED wurde bei 4 von 10 Patienten unterschätzt. Der konsequente Einsatz von PROMs sollte UrologInnen helfen, den Behandlungsbedarf ihrer Patienten besser zu erkennen. Patienten (n = 22) waren mit der Therapieentscheidung zufrieden. Der mittlere Decision Regret-Score betrug 6, 6 ( SD 18, 0) . 19 Patienten (65, 5 %) waren aktiv an der Entscheidungsfindung beteiligt und 72,4 % der Patienten (n = 21) entschieden gemeinsam mit ihrem Arzt. Der mittlere globale Gesundheitszustand betrug 79, 5 ( SD 18, 8) . Die Harnsymptome ( EORTC PRURI) blieben nach der Behandlung mit 17,1 ( SD 15, 5) gering. In der Biopsie 12 Monate post-op wiesen 19,4 % der Patienten (n = 7) ein Lokalrezidiv auf und bei 13,8 % der Patienten (n = 5) wurde eine Progression zu einem höheren Gleason-Score festgestellt. Diese Gruppe zeigte tendenziell ein höheres Maß an Entscheidungsreue (p = 0,3309). Schlussfolgerungen: Die Lebensqualität war nach fokaler Therapie mit VTP stabil. 12 Monate nach VTP bereuten nur 24 % der Patienten (n = 7) die Behandlung. Eine längere Nachbeobachtung dieser Patienten ist erforderlich, um die langfristigen Auswirkungen der Therapie auf die QoL und Behandlungszufriedenheit nach VTP zu untersuchen.

Quality of life after laparoscopic and robotic-assisted radical prostatectomy: Results of a multicentre patientblinded, randomised controlled trial ( LAP-01) Objectives: To date, no multicentre randomised trial has compared robotic-assisted ( RARP) and laparoscopic radical prostatectomy ( LRP) in terms of quality of life ( QoL) . This study provides high-quality data on healthand prostate cancer-related QoL for both surgical techniques. Materials and methods: 782 patients were recruited at four German hospitals and randomly assigned to either RARP or LRP in a 3:1 ratio. Patient-reported outcomes were prospectively collected before and 1, 3, 6, 12 months after radical prostatectomy using validated questionnaires to assess general ( EORTC QLQ-C30) and prostate-specific ( QLQ-PR25) QoL. Cross-sectional and longitudinal contrasts were analysed by linear modelling. Results: In terms of general QoL, cross-sectional analysis showed only minimal differences between study arms, whereas longitudinal comparison indicated an advantage of RARP on recovery: RARP patients reported an earlier return to baseline in global health status (3 vs. 6 months) and social functioning (6 vs. 12 months) . Only the RARP arm regained baseline scores in role functioning, whilst cognitive functioning only returned to baseline in the LRP arm. With regard to prostate-specific QoL, LRP patients experienced more urinary symptoms. Mean scores of the LRP arm were 3.2 points (95% CI 0.4, 6; p = 0.024) higher at 1-month follow-up and 2.9 points (0.1, 5; p = 0.042) higher at 3-month follow-up than for RARP. There were no other significant differences between treatment groups. Urinary symptoms, sexual activity and sexual function remained significantly worse at all timepoints in both arms. Conclusion: Compared to LRP, robotic assistance led to an earlier return to baseline in several domains of general health-related QoL and a better short-term recovery of urinary symptoms. Fragestellung: Im vorliegenden Projekt werden die Prävalenz und Prädiktoren für eine symptomatische Lymphozele nach offener retropubischer radikaler Prostatektomie ( RRP) und nach robotisch-assistierter radikaler Prostatektomie ( RARP) untersucht. Methoden: In dieser retrospektiven, monozentrischen Studie wurden 472 Patienten evaluiert, die nach RRP (n = 241) und RARP (n = 231) für zwei Jahre nachgesorgt wurden. Demographische und histopathologische Parameter wurden verglichen und mittels univariater und multivariater logistischer Regression wurde nach Prädiktoren für das Auftreten einer symptomatischen Lymphozele gescreent. Ergebnisse: Nach RRP wurden insgesamt signifikant weniger Lymphozelen beobachtet als nach RARP (8,2 % vs. 16,7 %; p = 0,049) , wobei für symptomatische Verläufe kein relevanter Unterschied festgestellt wurde (7,4 % vs. 11,7 %, p = 0,315) . Obwohl die Lymphadenektomie häufiger für die RARP erfolgte (70,1 % vs. 50,6 %; p < 0,001), zeigte sich ein L1 Status häufiger nach RRP (18 % vs. 6,2 %, p = 0,002). Die mediane Lymphknotenzahl betrug 11 für die RRP und 10 für die RARP (p = 0,381). In der multivariaten Regression erwiesen sich die Lymphknotenzahl (mind. 11) ( OR 1,1; 95 % Cl 1,055-1,147; p = 0,001), der Gleason-Score ≥8 ( OR 4, 7; 95 % Cl 2, 363 ; p = 0,001) und der präoperative PSA-Wert ≥ 10 ng/ml ( OR 1,05; 95 % Cl 1,02-1,074; p = 0,001) als unabhängige Prädiktoren für das Auftreten von symptomatischen Lymphozele. Schlussfolgerung: Das Ausmaß der Lymphadenektomie und das Vorliegen einer high-grade Disease sind unabhängig vom technischen OP-Verfahren mit einem erhöhten Risiko für symptomatische Lymphozelen assoziiert. Dies ist eine wichtige Information für die Evaluation und Beratung von Patienten vor einer operativen Behandlung des Prostatakarzinoms. 16.09.2021, C5.2, 13:30-14:30 V06.1 KIM-1 shows potential to be predictive of re-perfusion damage in porcine kidneys during normothermic whole-blood machine perfusion C. Steinhauser 1* , J. Putz 1 , A. E. Yakac 1 , S. Füssel 1 , S. Kromnik 2 , W. Markgraf 2 , R. Mühle 2 , P. Talhofer 2 , W. Löffler 2 , H. Malberg 2 , C. Thiele 2 , C. Thomas 1 1 Technische Universität Dresden, Department of Urology, Dresden, Germany; 2 Technische Universität Dresden, Institute of Biomedical Engineering, Dresden, Germany Introduction: Normothermic machine perfusion ( NMP) using oxygenated whole-blood is a currently investigated tool to combat the scarcity of usable kidneys for transplantation by assessing marginal organs under physiological conditions. Establishing markers predicting the transplantability of those organs during NMP is necessary. Kidney injury marker 1 ( KIM-1), a marker for tubule damage, mediates phagocytosis of necrotic/apoptotic debris. Materials and methods: Kidneys obtained from slaughterhouse pigs were perfused for 4 h. They were grouped based on their morphology (hemorrhagic infarction) after NMP into "good" n = 7 and "injured" n = 3. Tissue samples were taken before and after NMP; urine and plasma samples were taken at the start and after 1 h, 2 h and 4 h. KIM-1 was assessed in tissue using qPCR and IHC; liquid samples were analyzed with ELISA. Results: Good Kidneys experienced no change in relative KIM-1-mRNA levels over the course of 4 h NMP (1,7·10 -4 ± 6,9·10 -5 vs 1,6·10 -4 ± 7,5·10 -5 ; ns), injured kidneys showed a slight decrease (1,5·10 -4 ± 3,3·10 -5 vs 0,7·10 -4 ± 3,5·10 -5 ; ns). Staining intensity and distribution of KIM-1-protein was slightly increased in good kidneys after NMP. No change was observed in injured kidneys. Relative KIM-1 levels in plasma increased in injured kidneys but remained stable in good kidneys, but did not differ significantly after 4 h (p = 0,067). Urinary KIM-1 increased in both groups to similar levels. Conclusion: Injured kidneys shed higher levels of KIM-1 into the bloodstream than uninjured ones, although KIM-1 is increased within tissues of good kidneys to help clear cell debris. As plasma levels rise within 1 h of NMP, KIM-1 has, in conjunction with further markers, the potential to predict the outcome of NMP. Introduction: The UROSOFT® Tumor Stent is a reinforced ureteral stent available for treatment of chronic ureteral obstruction. According to the manufacturer, it has a maximal dwell time of 6 months. Under certain conditions, stent failure may negatively impact on this theoretical maximal dwell time. Aim of this study was to evaluate predictors of stent failure. Material and methods: All patients undergoing Tumor Stent insertion in our institution between 2010 and 2018 were analyzed. Exclusion criteria were planned temporary stent dwell time or refusal to participate in the study. Primary endpoint was time to stent failure after first-time Tumor Stent insertion. Only the first 5 months after insertion were considered for analysis, since planned Tumor Stent exchange was usually undertaken within 1 month prior to maximal dwell time. Results: 182 patients were available for analysis. Failure free survival estimates at 1, 2, 3, 4 and 5 months were 89%, 83%, 76%, 65% and 52%, respectively. We found bilateral insertion, intrinsic ureteral obstruction, and prolonged postoperative antibiotic therapy to be significant and independent predictors of stent failure (p < 0.04). Patients with stent failure had significantly higher grade of hydronephrosis, higher urinary culture bacterial growth, higher serum WBC, higher CRP and lower eGFR at the time of re-intervention, compared to patients with timely stent exchange.

The Tumor Stent has a high operation success rate in the presence of chronic ureteral obstruction. Predictors of stent failure are bilateral insertion, intrinsic ureteral obstruction, and the need of prolonged postoperative antibiotic therapy. Patients should be closely monitored for infectious signs or impaired kidney function, which may suggest stent failure. 16.09.2021, C7.2, 13:30-14:30 V07.2 CTLA4 promoter hypomethylation correlates with lymphocyte infiltration and predicts response to anti-PD-1 based immunotherapy in metastatic renal cell carcinoma Introduction: In advanced and metastatic clear cell renal cell carcinoma (ccRCC), different combination therapies, each including anti-PD-1 immune checkpoint blockade ( ICB), are applied as the first-line treatment. Robust predictive biomarkers for rational upfront therapy decisions are still pending, although they are urgently needed. Recently, we showed that CTLA4 promoter methylation (mCTLA4) predicts response to ICB in melanoma. Here, we aimed to investigate the epigenetic regulation of CTLA4 in ccRCC and its utility as a predictive biomarker in a multicenter ICB-treated RCC cohort. Materials and methods: mCTLA4 was analyzed with regard to transcriptional gene activity, intratumoral immune cell composition, and clinical course in two ccRCC cohorts obtained from The Cancer Genome Atlas ( TCGA, N = 533) and the University Medical Center Bonn ( UKB, N = 116). In addition, mCTLA4 was evaluated in pre-treatment samples from a multicenter ICB-RCC cohort (N = 36) treated with anti-PD-1 monotherapy or anti-PD-1/ CTLA-4 combination therapy with regard to treatment response according to RECIST and progression-free survival ( PFS) following treatment initiation. Results: mCTLA4 was significantly correlated with CTLA4 mRNA expression (Spearman's ρ = -0.54, P < 0.001), lymphocyte infiltration (ρ = -0.56, P < 0.001), and poor overall survival in both cohorts ( TCGA: P < 0.001; UKB: P = 0.043). Of note, CTLA4 promoter was significantly hypomethylated in ICB-responders compared to non-responders (P < 0.001)and associated with prolonged PFS after ICB-treatment initiation (P = 0.008). Introduction: Recently, our group showed that Vim3 is overexpressed in tissue samples of renal oncocytomas and Mxi-2 in clear cell renal carcinoma (ccRCCs). The mechanism leading to the truncation of both proteins is known and involves with two miRs, both detectable in urine. Since the analysis of miRs is time consuming, our aim was to identify the truncated proteins in urine instead. Furthermore, urine samples from small renal cancers ( SRM) (n = 45, < 4 cm) were analyzed to get a pre-surgical differentiation of the cancer subtypes. Methods: Urines were accessed from the urological biobank (n = 350). Proteins were isolated from urine samples, and Western blots were performed. Each sample was analyzed with ELISA for the expression of Vim3 and Mxi-2. A lateral flow assay was established. For the detection of SRMs, the miRs were isolated and qRT-PCR was performed. Results: A significant increase of Vim3 in urines from patients with oncocytoma (n = 20) was detectable with ELISA compared to all other subtypes of RCCs (chromophobe (n = 50), papillary (n = 40), ccRCC (n = 200), and controls (n = 40) (***p < 0.0001)). Mxi-2 was predominantly overexpressed in ccRCCs (***p < 0.0001). Lateral flow assay of Vim3 and Mxi-2 shows two bands in the case of oncocytoma and ccRCC indicating the specificity of this test. For SRMs, an overexpression of miR-15a/Mxi2 was detectable in urine samples from ccRCC and chromoRCC patients. In contrast to that miR-498/Vim3 were predominantly overexpressed in oncocytoma patients. Conclusion: Both proteins (Vim3 and Mxi-2) were detectable in patients' urines and can be used for the non-invasive differentiation of kidney cancers.

Association of DNA methylation of P-Cadherin (CDH3) with adverse histopathology and shortened survival in renal cell carcinoma 4, 7 mm ( IQR 3, [3] [4] [5] 6 mm) . Die Abgangsrate bei einem Durchmesser von 0 bis 2,9 mm, 3 bis 4,9 mm, 5 bis 6,9 mm, 7 bis 8,9 mm Gerichtsmedizin in Deutschland dar. Seit der Gründung der Zeitschrift wurden Fragen der Kastration und "Entmannung" in der Zeitschrift thematisiert, welche auf Grund des betroffenen organischen Bereichs -insb. beim Mann -einen engen Zusammenhang zur Urologie, Andrologie, Sexualmedizin und Sexualwissenschaft aufweisen. Material und Methode: Die Deutsche Zeitschrift für die gesamte gerichtliche Medizin (heute: International Journal of Legal Medicine) wurde auf die Stichworte "Kastration", "Castration" und "Entmannung" untersucht. Die Treffer wurden elektronisch gesichert, in Orginalia und Rezensionen kategorisiert und inhaltlich ausgewertet. Ergebnisse: Zwischen 1922 und 1943 finden sich 291 Beiträge in der Zeitschrift, in denen mindestens eines der gesuchten Stichworte vorkommt. Eine zentrale Frage stellt hierbei die "Entmannung" von Sittlichkeitsverbrechern dar, die bereits seit den 1920er Jahren als Therapie in Betracht gezogen und ab 1934 durch das nationalsozialistische "Gesetz gegen gefährliche Gewohnheitsverbrecher und über Maßregeln der Sicherung und Besserung" legalisiert wurde. Schlussfolgerung: Fragen der Kastration und "Entmannung" spielen in der Deutschen Zeitschrift für die gesamte gerichtliche Medizin eine wichtige Rolle. Aus der disziplinären und geographischen Breite der Rezensionen lässt sich ablesen, dass die Frage nach dem Zusammenhang von Keimdrüsen, Sexualität und Verhalten im Untersuchungszeitraum intensiv diskutiert wurde. Durch die nationalsozialistische Gesetzgebung in den 1930er Jahren erhielt das Thema eine noch größere Bedeutung. V09.5 Samuel Jessner (1859 -1929 aus der Datenbank "Familiäres Prostatakarzinom" mit einem LR (Gleason Grade Group ( GG) 1, cT1c-2a, Prostata-spezifisches Antigen ( PSA) < 10 ng/ml (n = 2607)), Gleason GG 1 FIR ( GG 1, cT1c-2a, PSA 10-20 ng/ml (n = 630)) und Gleason GG 2 FIR ( GG 2, cT1c-T2a, PSA < 10 ng/ml (n = 854)) PCa eingeschlossen. In multiplen Regressionsmodellen wurde der Einfluss der FA auf das Upgrading (Gleason GG ≥3) bzw. Upstaging (≥pT3/pN1) untersucht. Ergebnisse: In der LR Gruppe hatten 7,2 % ein Upgrading, 12,0 % ein Upstaging. Prädiktoren für ein Upgrading waren ein höheres Alter bei RP ( OR 1,06 [1, 08] ) und ein höherer PSA-Wert ( OR 1,14 [1, 23] ), für ein Upstaging ein höherer PSA-Wert ( OR 1,18 [1, 26] Einleitung: Spleißvarianten des Androgenrezeptors, insbesondere AR-V7, haben einen bedeutenden Einfluss auf die Tumorbiologie. Die klinische Anwendung ist aktuell fokussiert auf den Nachweis von AR-V7 mRNA oder Protein in zirkulierenden Tumorzellen. Die prognostische Aussagekraft von AR und AR-V7 in primärem Tumorgewebe ist hingegen noch nicht ausrteichend geklärt. Patienten und Methoden: Wir verwendeten einen tissue microarray mit Gewebeproben von 410 radikalen Prostatektomiepräparaten aus dem Zeitraum von 1999-2010. Der immunhistochemische Nachweis erfolgte für AR (AR411, Dako) und für AR-V7 (AG10008, A&G). Ein immunoreaktiver score ( AR, AR-V7) sowie ein Prozentsatz positiver Tumorzellen ( AR-V7 granulär) kam zum Einsatz. Ergebnisse: Mehr als 80 % der Gewebeproben zeigten einen positiven Nachweis von zytoplasmatischem AR-V7. Sowohl ein positiver Nachweis von AR als auch AR-V7 ( IRS>2) in den Tumorzellen ist korreliert mit einem höherem Tumorstadium, einem höheren Gleason score und der Anwesenheit von Perineuralscheidenkarzinose. Die Färbemuster von AR waren ohne Assoziation zum Gesamtüberleben, dem tumorspezifischen Überleben oder dem rezidivfreien Überleben ( RFS). AR-V7 hingegen zeigte eine Assoziation mit RFS. Hierbei erwies sich der AR-V7 Nachweis im Zytoplasma als negativer Prädiktor für das RFS, wohingegen ein vermehrtes Auftreten von AR-V7 in granulären Strukturen (≥5 % der Tumorzellen) ein positiver Prädiktor für ein längeres RFS war. Schlussfolgerung: Es besteht keine Assoziation zwischen AR-V7 im Primärtumor und dem Gesamtüberleben oder dem tumorspezifischen Überleben. Für das rezidivfreie Überleben erscheint die Lokalisation von AR-V7 relevant zu sein. AR-V7 im Zytoplasma ist assoziiert mit einem kürzeren, in granulären Strukturen mit einem längeren RFS. Background: To test the effect of urological primary cancers (bladder, kidney, testis, upper tract, penile, urethral) on overall mortality ( OM) after secondary prostate cancer (PCa). Material and methods: Within the Surveillance, Epidemiology and End Results ( SEER) database, patients with urological primary cancers and concomitant secondary PCa (diagnosed 2004 PCa (diagnosed -2016 were identified and were matched in 1:4 fashion with primary PCa controls. OM was compared between secondary and primary PCa patients and stratified according to primary urological cancer type, as well as to time interval between primary urological cancer vs. secondary PCa diagnoses. Results: We identified 5987 patients with primary urological and secondary PCa (bladder, n = 3287; kidney, n = 2127; testis, n = 391; upper tract, n = 125; penile, n = 47; urethral, n = 10) vs. 531,732 primary PCa patients. Except for small proportions of Gleason grade group and age at diagnosis, PCa characteristics between secondary and primary PCa were comparable. Conversely, proportions of secondary PCa patients which received radical prostatectomy were smaller (29.0 vs. 33.5%), while no local treatment rates were higher (34.2 vs. 26.3%). After 1:4 matching, secondary PCa patients exhibited worse OM than primary PCa patients, except for primary testis cancer. Here, no OM differences were recorded. Finally, subgroup analyses showed that the survival disadvantage of secondary PCa patients decreased with longer time interval since primary cancer diagnosis. Conclusion: After detailed matching for PCa characteristics, secondary PCa patients exhibit worse survival, except for testis cancer patients. The survival disadvantage is attenuated, when secondary PCa diagnosis is made after longer time interval, since primary urological cancer diagnosis. Background: Proclarix® is based on novel biomarkers, PSA and age. An algorithm returns a risk score to identify clinically significant prostate can-Abstracts cer (csPCa GG≥2). Prostate Health Index (phi) is a formula that provides a probability of prostate cancer (PCa), combining PSA, free PSA, p2PSA. We performed a head-to-head comparison of Proclarix versus phi to predict any and significant PCa on biopsy. Methods: We evaluated Proclarix and phi performance in 185 patients undergoing TRUS-guided prostate biopsy. Among those, 90 men with PCa on biopsy underwent radical prostatectomy (rP). All men had a PSA 2-10 ng/mL, normal DRE and an enlarged prostate (≥35 mL). Comparison of AUC and performance at predefined cut-offs was performed to predict PCa and csPCa. Results: Proclarix was more accurate than phi for predicting PCa ( AUC 0.79 vs 0.62, p < 0.01) and csPCa ( AUC 0.73 vs 0.66, p = 0.31) based on TRUS-biopsy. Taking Gleason GG derived from rP from biopsy positive men into account, Proclarix was significantly more accurate than phi for predicting PCa ( AUC 0.79 vs 0.61, p < 0.01) and csPCa ( AUC 0.81 vs 0.63, p < 0.01). At predefined cut-offs, Proclarix outperformed phi with specificity and positive predictive value (p < 0.01), which results in avoiding a higher number of unneeded biopsies. On decision curve analysis the highest net benefit was observed with Proclarix. Conclusions: Proclarix outperformed phi in terms of AUC, specificity and clinical net benefit. Limitations of the study include the retrospective design, the use of biobanked samples and the exclusion of men with small prostate volume, which may negatively impact the analytical validity of PSA und PSA derived subfractions included in phi. Prospective studies are warranted to substantiate our findings. Funding: Sponsored by Proteomedix V10.9 Identifikation pathogener Mutationen durch die mpMRT beim lokalisierten Hoch-Risiko Prostatakarzinom A. Borkowetz 1* , U. Sommer 2 , F. Fahlteich 2 , S. Zeugner 2 , I. Platzek 3 , S. Füssel 1 , K. Erdmann 1 , T. Todenhöfer 4 , H. Erb 1 , C. Thomas 1 Fragestellung: Spezifische Alterationen in tumor-assoziierten Genen sind mit der Aggressivität und der Prognose beim Prostatakarzinom (PCa) assoziiert. Es sollen Gensignaturen, die das Progressionsrisiko beim lokalbegrenzten Hoch-Risiko PCa (hr-PCa) hervorsagen können, identifiziert und mit der multiparametrischen MRT (mpMRT) verglichen werden. Material und Methoden: 17 Patienten mit hr-PCa (≥pT3, ≥pN1, Gleason Score ( GS)≥8), die mit einer Prostatektomie ( RP) behandelt wurden, wurden untersucht. RP-Präparate wurden direkt mit der mpMRT verglichen, wobei der Index-Tumor (Tumor mit dem höchsten GS oder größter Durchmesser) und Index-Läsion (Läsion mit dem höchsten PI-RADS oder größten Durchmesser) identifiziert wurden. Mittels eines Genpanels, welches 328 Gene inkludiert (QIAseq Targeted DNA V3 Panel, Qiagen), erfolgten gezielte DNA-Sequenzierungen. Die Varianten-Evaluierung erfolgte mittels Varsome. Ergebnisse: Tumor-assoziierte Mutationen wurden in 32 unterschiedlichen Genen bei 88 % der Patienten identifiziert. 16 pathogene Mutationen (37 Allele), 14 Mutationen unsicherer Signifikanz (24 Allele) und 6 wahrscheinlich benigne Mutationen (7 Allele) wurden identifiziert. 54 %, 77 % bzw. 23 % der pathogenen Mutationen waren mit einem GS≥8, einer PI-RADS 4 bzw. 5 Läsion assoziiert. Neben Mutationen in BRCA2, PTEN oder CK12 wurden auch weniger bekannte Mutationen beim PCa wie IDH1 oderNTRK3 nachgewiesen. Patienten mit Nachweis mehrerer pathogener Mutationen (≥1) zeigten ein tendenziell kürzeres Rezidiv-freies Überleben (75Mo (95 %-KI 64-84 Mo) vs. 49Mo (95 %-KI 31-67Mo); p = 0,172)). Schlussfolgerung: Die frühe Identifikation pathogener Mutationen in aggressiven PCa ist ein Marker für die Prognose. Über die mpMRT können Regionen, die diese pathogenen Mutationen aufweisen, identifiziert werden. Einleitung: Gibt es Unterschiede im Schmerzscore und in der Bevorzugung der OnabotulinumtoxinA Detrusorinjektion bei Anwendung unter Lokalanästhesie ( LA) vs Vollnarkose ( VN)? Material und Methoden: PatientInnen, die zu einer OnabotA-DI anstanden, entschieden selbst das Anästhesieverfahren. Zur Evaluation der Unterschiede bzgl. anästhesiologischem Vorgehen und Ergebnissen der Therapie kamen zur Anwendung: der Amsterdam Preoperative Anxiety and Information Scale ( APAIS), ein Schmerzscore, der UDI-6,der IIQ-7, der Symptom Severity Index SSI, der Symptom Impact Index SII sowie ein postoperativer Zufriedenheitsfragebogen. Ergebnisse: 50 PatientInnen (46w, 4 m; Alter ∅ 64 (34-80) Median 66,5 Jahre) konnten ausgewertet werden. Die OnabotA-DI wurde bei 36 PatientInnen in LA und bei 14 in VN durchgeführt. Jeweils Vergleich der LA-mit der VN Gruppe: Der präoperative Angstscore ( APAIS) wies keine signifikanten Unterschiede aus (5,91 vs. 5,07, p = 0,383) . Indes zeigte sich im Schmerzscore während des Eingriffs ein signifikanter Unterschied: 3,55 vs. 1,08, P < 0,001). Die Inkontinenzfragebögen 4 Wochen nach dem Eingriff zeigten alle hochsignifikante (p < 0,001) Verbesserungen, jedoch ohne signifikante Unterschiede zwischen den beiden Gruppen. 80,0 % vs. 92,3 % (p = 1,00) der PatientInnen gaben an, dass sie sich erneut für diese Therapie ihrer Blasenfunktionsstörungen entscheiden würden. Von PatientInnen, die angaben, den Eingriff in der Vergangenheit mit beiden Anästhesieverfahren durchgeführt haben zu lassen, gaben 17 an, die LA der VN vorzuziehen, 6 würden hingegen der VN vor der LA den Vorzug geben. Schlussfolgerung: Die Therapiequalität der OnabotA-DI scheint unabhängig vom Anästhesieverfahren zu sein. Trotz höherer Schmerzbelastung wird der LA der VN der Vorzug gegeben. Introduction: Sacral neuromodulation ( SNM) is often applied for Patients with idiopathic overactive bladder ( OAB), refractory to conservative treatment. The effect of SNM on nocturia is unknown. The aim of our Multicenter study was to study the effect of SNM on nocturia episodes retrospectively. Materials and methods: Sensation-related bladder diaries ( SR-BDs) were assessed in all our patients who underwent SNM for idiopathic OAB between January 2014 and July 2020. SNM was performed following a two-phased tined lead procedure under local or general anesthesia. The SR-BDs were collected prospectively. Patients filled out a SR-BD, for 3 con-secutive days at baseline and after 2 weeks, during a 4-week test phase. Bedtime and times of voiding, as well as intake and output were noted. Results: A total of 84 (males and females) patients with OAB, with and without incontinence (95 and 5% respectively), were included. 5340 voids were analyzed. 61 patients had a successful test phase (>50% reduction of OAB symptoms). In patients with a successful test phase (T+), the number of nocturia episodes changed significantly from 3.03 (±2.4) to 1.55 (±1.4) P = 0.000. Also, the mean volume voided at night was significantly fewer (P = 0.000). The total number of voids frequency over 3 days was significantly reduced between baseline and during the test-phase (12 +/-5 vs 9+/-3, P = 0.000). There was no significant difference in fluid in intake prior versus during SNM test phase. There was no significant decrease in nocturia episodes in patients with a negative tined lead test, 2.8.1 ± 1.2 vs 2.7 ± 1.5 P = 0.109. (< 50% reduction in OAB symptoms). V11.4 The role of partially absorbable midurethral slings for the treatment of stress urinary incontinence in a realworld study T. Hüsch 1* , C. Fünfgeld 2 , N. Ng-Stollmann 2 1 Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany; 2 Klinikum Tettnang GmbH, Tettnang, Germany Introduction: To evaluate the performance of retropubic midurethral sling procedure for female stress urinary incontinence ( SUI) in a real-world setting and to identify risk factors for sling failure in this cohort. Methods: This was a single center cohort study including women who underwent retropubic midurethral sling procedure for stress or mixed urinary incontinence between 2012 and 2019 with a follow-up of 12 months. Primary endpoint was cure of SUI assessed by the severity categorization of the International Consultation of Incontinence Questionnaire-Urinary Incontinence-Short Form ( ICIQ-UI-SF). Univariate and multivariate analysis was applied to identify risk factors for failure. Wilcoxon signed-rank tests were used as paired samples tests. The significance level was set at 5%. Results: A total of 662 women with a median age of 65 ( IQR 19) were included in the investigation. 79.0% presented with complicated SUI. Cure was reported by 32.2% and cure or improvement ( COI) by 76.3% of patients. Independent predictors for decreased odds for cure or COI were obesity, pharmacotherapy for overactive bladder ( OAB), postoperative sling tailing and the utilization of partially absorbable mesh. The utilization of partially absorbable mesh was correlated with a 56% and 46% decrease in the odds for achieving cure or COI respectively. Conclusions: The current investigation emphasizes the impact of the patient heterogeneity on the success of midurethral sling procedure in clinical daily practice. Furthermore, amongst several risk factors for failure, partially absorbable mesh and the pharmacotherapy of OAB were associated with decreased success rates. The role of partially absorbable mesh for SUI treatment should be evaluated in further prospective trials. V11 Introduction: Cell based therapies are a promising tool for the treatment of Stress urinary incontinence ( SUI). Cell injection by needle may cause misplacement of cells. Therefore, a novel WaterJet ( WJ) technology was developed to deliver cells precisely into the urethral sphincter. Methods: Porcine muscle-derived cells (pMDC) were expanded and characterized by expression of marker genes, labeled and injected by William's needle ( WN) or WJ (Erbe) in porcine urethral cadaveric samples ( CS) (n ≥ 24) and in living animals ( LA)(n = 24). From CS, cells were retrieved and expanded in vitro. The distribution of cells in tissues targeted including their distributions in X-depth, Y-width, Z-height (3D) and areas of cell clusters were analyzed. Results: The pMDC expressed specific markers on transcript and protein levels. Upon CS, viable cells were retrieved in all samples investigated injection by WJ (n = 8) and by WN (n = 5). Due to channels generated by the WN, the distribution of cells was significantly higher in the Z-axis (p < 0.002) when compared to WJ injections. After transurethral WJ injection of cells in pigs, in 95.83% of injections labelled, intact appearing cells were detected. There was a significant difference for the X-depth (p < 0.0001) and Z-height (p < 0.0002) between WJ injections in CS vs. LA with a wider MDCs distribution in LA urethra samples. Conclusion: In vitro tests confirmed that WN injection punched visible channel in the tissue while WJ injections resulted in no visible tissue defects in cryosections. The novel WJ is a way to inject living cells in tissues with wider and diffuse distribution and less disintegration of the tissue targeted. Supported by grants from BMBF, DFG, EU V11.9 Intermittierender Selbstkatheterismus bei Personen mit Querschnittlähmung -Gold-Standard für alle? -Eine retrospektive Kohortenstudie Objectives: Post chemotherapy residual tumor resection ( PC-RTR) is a crucial part of treatment in patients (pts) with metastatic non-seminomatous germ cell tumor ( NSGCT). In case of retroperitoneal and thoracic metastases, multiple surgeries are necessary. This study compares histologies after abdominal and thoracic PC-RTR in order to predict thoracic histology. Material and methods: From 2008 to 2020, 537 retroperitoneal RTRs have been performed at a single center. We identified 54 pts who had under-gone retroperitoneal and thoracic PC-RTR after first line or salvage chemotherapy (CTx). Results: All pts presented with stage III NSGCT. 42 (78%) and 12 (22%) pts had first line and salvage CTx, respectively. Pts were classified as good, intermediate and poor prognosis according to IGCCCG in 17%, 22%, and 61%. 49 (91%) pts received retroperitoneal RTR first, followed by thoracic RTR. 3 (5%) pts had thoracic before retroperitoneal RTR and 2 (4%) pts underwent simultaneous surgery. Overall, histology of retroperitoneal and thoracic RTR matched in 35 (65%) pts. In 19 (35%) pts histology was discordant. Discordant histologies showed retroperitoneal necrosis in 7 (37 %), teratoma in 9 (47 %) and vital tumor other than teratoma in 3 (16 %) pts. Of 21 pts with retroperitoneal necrosis 7 (33 %) showed vital cancer or teratoma in the thorax. After first line CTx discordance of histology was 29% (12/42), after salvage CTx 58% (7/12) (not significant, p = 0.087). Conclusion: This data underlines that sequential PC-RTR in all locations is mandatory, since discordance of histology is up to 35%. Comparing findings after first line and salvage CTx, discordance increase from 29 to 58%. Thus, thoracic surgery should be performed in all pts after salvage CTx independent on tumor volume. Objectives: The benefit of post-chemotherapy residual tumor resection ( PC-RTR) in patients with germ cell tumors and elevated serum tumor markers ( STM) remains undefined. This retrospective analysis aims to define patients who benefit from surgery in this setting. Patients and methods: Of 575 PC-RTR (07/2008-07/2019) 153 were performed in patients with elevated STM (ß-HCG > 2 mIU/ml, AFP > 7 µg/l), 55 patients after first-and 98 after salvage chemotherapy. Analysis was performed to determine predictors for RTR histology and oncological outcome. Results: Viable cancer was more frequent in the salvage group than in the first-line group, 48.98% vs. 16.36% (p = 0.00019) and was a predictor for survival. AFP ≥ 30 µg/l was a predictor for viable cancer in first-line and salvage setting, 55.56% (p = 0.0157) and 66.67% (p = 0.0017), respectively. In the salvage group compared to the first-line, the relapse-free rate (22.7% and 50%, p = 0.00032) and survival rate (37.8% and 65%, p = 0.0058) were significantly poorer. AFP ≥ 30 µg/l and HCG ≥ 20 mU/ml were significant factors for survival in the first-line group. Conclusion: If preoperative AFP is ≥ 30 µg/l after first-line chemotherapy, chances for viable GCT are high and survival is poor. For these patients PC-RTR is probably not beneficial and salvage chemotherapy should be the preferred treatment. In turn, for patients with AFP < 30 µg/l and HCG < 20 mIU/ml after first-line chemotherapy, PC-RTR yields favorable results and should be the primary treatment. After salvage chemotherapy prognosis is poor regardless of STM status. In this group, AFP ≥ 30 µg/l is associated with a higher risk for viable GCT. So called "desperation surgery" in this situation is justified if complete resection is possible since two-year survival approaches 40%. V12.4 Skeletal surgery during postchemotherapy retroperitoneal lymphadenectomy ( PC-RPLA): management and outcome K. Zimmermann 1* , P. Paffenholz 1 , D. Pfister 1 , T. Nestler 1 , A. Hiester 2 , Y. Che 2 , P. Albers 2 , A. Heidenreich 1 1 Uniklinik Köln, Köln, Germany; 2 Uniklinik Düsseldorf, Düsseldorf, Germany Objective: to report oncological and functional outcomes of skeletal surgery during PC-RPLA and to identify patient characteristics, surgical approaches and diagnostic algorithms associated with an increased risk of skeletal surgery. Patients and methods: 29 pts underwent RPLA plus resection of 1-2 vertebral bodies. In 25 and in 4 pts, primary and redo-PC-RPLND was performed, resp. All pts were marker negative or had plateauing markers; 3 pts. had late relapse. We assessed progression-free and overall survival. We assessed surgery related complications according to the Clavien-Dindo classification. Results: Mean age was 24.5 (18-52) years. All pts had primary nonseminomas. 6 and 23 pts underwent thoracoabdominal or retroperitoneal approach, resp.. In 22 pts complete resection of the vertebra with replacement was performed. 7 patients were managed with partial resection of the vertebral body. Mean surgical time was 8.7 (7) (8) (9) (10) (11) hours, mean intraoperative blood loss was 950 (600-2500) ml. Vascular, renal, or hepatic surgery was necessary in 10 (34.5%) pts. Mean hospitalization was 12 days. Pathohistology revealed teratoma in 15, embryonal carcinoma in 3, yolk sac tumor in 2, malignant somatic transformation in 2, and necrosis in 7 patients. Mean follow-up is 27 (12-43) months, overall survival and progression-free survival is 83% and 66.6%, respectively. Teratoma had the best long-term prognosis and only patients with vital cancer relapsed. Conclusion: Combined resection of vertebral bodies and residual tumor masses is feasible with a low rate of treatment related complications. Only Teratoma patients will benefit from this procedure. Preoperative biopsy should be performed to exclude viable cancer. V12 Purpose: 10-15% of patients with mTGCT will develop chemorefractory disease of which about 50% will die. We report on the integration of next generation sequencing in daily clinical practice to identify druggable mutations. Patients and methods: 3 consecutive patients with chemorefractory mT-GCT (n = 1 extragonadal YST, n = 1 seminoma and n = 1 nonseminoma with retroperitoneal and pulmonary metastases) were included. All patients underwent CT-guided biopsies of progressing metastatic lesions. Biopsy samples were immediately shipped to the molecular biology lab, processed and analyzed. 40 ng DNA was quantified with the Qubit dsDNA HS Assay on the Qubit 2.0 Fluorometer and sheared on the Covaris E220 Focused-ultrasonicator using the 8 microTUBE-50 Strip AFA Fiber V2. For DNA library preparation and enrichment the TruSight Oncology 500 Kit was used. Post-enriched libraries were quantified, pooled and sequenced on a NextSeq 500. Sequencing data are analyzed with the TruSight Oncology 500 Local App Version 1.3.0.39. Besides mutational data, microsatellite status and tumor mutational load can be analyzed from sequencing data. Differential expression of targetable genes on mRNA level is determined using a customized NanoString Panel. Results: Mutational analysis revealed KIT D820G, TP53, and NPM1 mutations as well as MMR deficiency with loss of MSH2 and MSH6 proteins so that targeted therapy with sunitinib (n = 2) or pembrolizumab (n = 1) was initiated. Targeted therapy resulted in remarkable partial remissions for a duration of 9, 12+, and 15 months. Conclusion: Although rare, identification of druggable mutations might be an option in chemorefractory TGCT following all sequences of approved treatment options. Introduction: Cisplatin resistance remains a major obstacle in the standard chemotherapeutic approach in late-stage and metastatic testicular germ cell tumour patients. MiRNA-371a-3p (miR-371), the novel serum biomarker of TGCTs, shows significantly increased expression in cisplatin-resistant TGCT cell lines compared to the parental cell lines. However, the influence of miR-371 on cisplatin-sensitivity has not yet been investigated. Materials and methods: In three non-seminomatous TGCT cell lines and their respective cisplatin-resistant subclones, the expression of miR-371 was determined by qPCR. By using two different antagomirs, we inhibited miR-371, leading to a decreased miR-371 expression (>95%). To measure cytotoxic impacts of chemotherapeutic drugs, miR-371-inhibited and control cells were exposed to different concentrations of cisplatin for 24-72 h.

Afterwards, changes in viability were measured by crystal violet assay. Additionally, the effects on cell cycle phase distribution and apoptosis rates were measured by flow cytometry ( PI, AnnexinV/ PI). Results: In the cisplatin-resistant and corresponding parental TGCT cell lines, cisplatin-sensitivity was significantly raised after the miR-371 inhibition, indicated by a strongly reduced viability and increased apoptosis after cisplatin application in miR371-inhibited cells as compared to controls. These data suggest that miR-371 might contribute to the acquisition of cisplatin-resistance. Conclusion: In summary, our results show that the miR-371 has a decisive influence on the development of cisplatin-resistance in TGCT, i. e. interfering with the miR-371-expression can increase the cisplatin-sensitivity of the tumours cells. This may represent a promising approach for the treatment of patients with cisplatin-resistant TGCTs. Ergebnisse: Aufgrund ihres stark zytotoxischen Effekts wurden sieben "epi-drugs" ausgewählt. Alle Agenzien induzierten Apoptose und/oder Zellzyklusarrest in den KZT-Zelllinien inklusive Cisplatin-resistenter Subklone, jedoch nicht in den Kontrollzellen. Außerdem führte die Inhibition einzelner PTM zu weitreichenden Veränderungen der epigenetischen Landschaft (auf DNA-und Histon-Ebene), jenseits des erwarteten Wirkspektrums. Des Weiteren zeigten sich deutliche Veränderungen im Transkriptom. Fazit: In dieser Studie konnte gezeigt werden, dass sich die Modulation von PTM aufgrund des zytotoxischen Effekts eine vielversprechende Therapieoption für (Cisplatin-)resistente KZTs darstellt. Als wirksamster Kandidat zeigte sich dabei der Histondeacetylase-Inhibitor Quisinostat, welcher bereits in Phase-II-Studien bei Ovarialkarzinomen eingesetzt wird. Objectives: About 65% of infertile men are still diagnosed with unexplained infertility, lacking major factors sufficient to explain the fertility status. The aim was to identify subgroups of similar patients in a cohort of unexplained infertile men by an unbiased clustering approach. Patients and methods: We retrospectively (2008-2018) selected patients with unexplained male infertility from our database Androbase® (exclusion: obstructive, genetic, other known causative factors; inclusion: total sperm count ≥1 mill./ejac., FSH ≥ 1 IU/ l, Testosterone ≥ 8 nmol/l). For the 2422 patients somatic, semen, and hormonal parameters as well as testicular volumes ( TV) were included, supplemented by genotyping of the FSHB c.-211G>T (rs10835638) single nucleotide polymorphism. For the cluster analysis, partitioning around medoids method was employed for 2 to 20 medoids based on Gower distance between patients. Quality of clustering was evaluated by average silhouette widths. Results: Separation of patients into two clusters resulted in the best average silhouette width (~0.12); sign. different distributions were evident for: total sperm count, sperm motility, TV, FSH, and FSHB genotype. The clusters each contained the majority of either men carrying the Wildtype ( GG) or men carrying a T-allele in the FSHB (>98% Cluster 1, >92%, Cluster 2). Conclusion: In this unbiased approach an evident separation by genotype in the FSHB was most prominent. Consequently, genotyping should be implemented as diagnostic routine in these men. Potential therapeutic consequences have to be investigated. Still, a large fraction remains unexplained infertile, showing the necessity of new assays and genetic markers for further classification. schungszwecken zur Verfügung. Zur Beurteilung der Qualität der Spermien nach dem Einfriervorgang wird 3 Tage später ein Aliquot der Probe aufgetaut und die Motilität und die Vitalität der Spermien bestimmt. Im Rahmen unserer Studie wurde von allen zur Verfügung stehenden Forschungsproben wiederum ein Aliquot zur erneuten Beurteilung der Spermien analysiert. Zum Zeitpunkt der Auswertung waren die Proben im Mittel 9,4 ± 3,6 Jahre eingefroren. Nach Unterteilung der Einfrierdauer in drei Gruppen (1: ≤5 Jahre, 2: 6-14 Jahre, 3: ≥15 Jahre) zeigte sich kein signifikanter Einfluss der Einfrierdauer auf Motilität oder Vitalität. Es zeigte sich ein signifikanter Zusammenhang zwischen Vitalität in der Kontrolle drei Tage nach Kryokonservierung und der Spermienvitalität nach der Langzeitlagerung (p = 0,001). Den selben Effekt zeigte sich für die Spermienmotilität (p < 0,001). Die Kryokonservierung stellt ein sicheres Verfahren zur langfristigen Fertilitätsprotektion vor gonadenschädigender Therapie dar. Patienten, die nach langer Lagerungsdauer ihr Kryospermadepot verwenden wollen, müssen nicht mit Qualitätseinschränkungen rechnen. Wochen vor Befragung mindestens 4-mal PM, während 93,5 % der weiblichen MS in diesem Zeitraum 0-4-mal PM konsumierten. 93,6 % der männlichen MS masturbierte meistens oder immer während des Konsums von PM. 43,5 % der weiblichen MS berichtete solch ein Verhalten. Männliche und weibliche MS, die angaben durch Pornos inspiriert worden zu sein (74,6 %) und die schon einmal Analverkehr hatten (33,7 %) konsumierten häufiger PM. Weibliche MS die bereits Erfahrungen mit einem "Dreier" hatten (9,0 %), die erotische Bilder von sich selbst verschickt haben (33,5 %) und die schon einmal eine Geschlechtskrankheit hatten (14,7 %) , konsumierten häufiger PM. (alles p < 0,05) Schlussfolgerung: Der Konsum von pornografischem Material ( PM) unter Medizinstudierenden, insbesondere männlichen, ist weit verbreitet. PM ist für viele junge Erwachsene eine Inspiration für ihre eigene Sexualität, so dass sich Assoziationen zwischen vermehrten Konsum von PM und einem ausgefalleneren Sexualleben zeigen. Der Umgang mit Pornographie und die Einordnung der dargestellten Sexualität sollte Jugendlichen und jungen Erwachsenen frühzeitig beigebracht werden. V13.4 Less mortality and less major adverse cardiovascular events ( MACE) under long-term testosterone therapy (TTh): 15-year data from a prospective controlled registry study M. Alwani 1* , M. Salman 2 , K. Haider 2 , A. Al-Qudimat 3 , R. M. Al-Zoubi 3 , F. Saad 4 , A. Yassin 3, 4 Introduction: We have previously demonstrated improvements in cardiometabolic risk factors in hypogonadal men on long-term TTh. Methods: Cumulative registry study to investigate long-term effectiveness and safety of 3-monthly TU to treat hypogonadism was established in 2004 in a urological setting. Of 805 hypogonadal men, 412 received parenteral TU 1000 mg/12 weeks (T-group) for up to 12 years. 393 men opted against TTh and served as controls ( CTRL). 10-year data are reported. Confounders including age, BMI, smoking, alcohol, total and HDL cholesterol, systolic blood pressure, and type 2 diabetes were assessed and considered in statistical modeling. Results: Baseline age was 57.7 ± 7.4 in the T-group and 63.7 ± 4.8 years in CTRL (p < 0.001). The absolute follow-up time comprised approximately 6500 patient-years. The mean Framingham risk score at baseline was 15.5 in the T-group and 15.8 in CTRL (p < 0.05). The mean 10-year risk was 22.7% in the T-group and 23.5% in CTRL (p = 0.11). Mean and median observation time in the T-group was 8 years. There were 16 deaths (3.9 %) but no myocardial infarctions or strokes. Mean observation time in CTRL was 8, median 9 years. There were 74 deaths (18.8 %), 70 MIs (17.8 %) and 59 strokes (15 %). All classical cardiovascular risk factors including obesity, glycaemic control, lipid pattern, and C-reactive protein improved in the T-group and worsened in CTRL. The reduction of cardiovascular events by TTh after applying a linear mixed effect model was 24.7 % and 15.5 % after applying a random effect longitudinal model. Conclusions: In hypogonadal men, long-term TTh reduces cardiovascular events and mortality. IPSS sank um 5,1 ± 0,1 (T-Gruppe) und stieg um 4,1 ± 0,1 ( KTRL). Geschätzte adjustierte Differenz zw. Gruppen (adj. Diff.): -9,2. Prostatavolumen stieg um 3,1 ± 0,2 (T-Gruppe) bzw. 3,9 ± 0,2 ml ( KTRL), adj. Diff.: 0,8 ml (p < 0,01). PSA stieg um 0,06 ± 0,1 (T-Gruppe) bzw. 1,1 ± 0,1 ng/ml ( KTRL), adj. Diff. 1,0 (p < 0,0001). Bei 12 Patienten (3, 1 %) in der T-Gruppe und 50 (12,7 %) Objectives: To evaluate mixed approach between the trials to 6 or 8 injection achieve the most possible outcomes and patient satisfaction. Methods: Prospective registry study for PD patients who underwent Collagenase Clostridium Histolyticum ( CCH) treatment. Inclusion Criteria were any Peyronie's disease patient with penile curvature >30o and < 90o. Exclusion criteria were any ventral curvature and calcified plaque. Data with follow up to 2 years. International Index of Erectile Function ( IIEF), and Penile ultrasound with induced erection for plaque size and curvature determination pre and post-treatment. Group 1 (G1) was patients who received 6 injections while Group 2 (G2) was patients who received 8 injections. A Pearson Chi-Square and T-test (P < 0.05) was used to figure out the statistical significance. Results: 80 patients (G1 n = 31 and G2 n = 49) suffer from PD underwent 0.58 mg CCH injections, Age (mean ± standard deviation) 56. 7 ± 8.4 years for G1, and 55.3 ± 10 years for G2. The mean size of the plaque was 1.7 ± 0.6 cm for each group. Baseline mean curvature degree was 47.3o±10.2o and 48.6o±11.7o for G1 and G2, respectively (p > 0.05). The mean change in degree after treatment was 21.6o±12.1o and 17.3o±13.4o for each G1 and G2 (p > 0.05). Almost, 83.9% and 81% have more than or equal to 20% reduction in curvature for G1 and G2, sequentially (p > 0.05). A mean improvement in IIEF score after treatment by 3.25 points and 1.59 points for G1 and G2, respectively. Conclusion: No significant difference between the two groups (6 and 8 injections) . Ccustomizing the treatment plan for PD patients greatly advised by considering the number of injections in relation to curvature reduction and patient satisfaction, reducing inessential costs and ensuring a satisfactory outcomes. V13.9 Ist es möglich, die erektile Funktion nach nervenschonender radikaler Prostatektomie durch Verdoppelung der Dosis von täglichen PDE5-Hemmern zu verbessern? -2 Jahre Follow-up Einleitung: Verschiedene Behandlungsschemata zur Rehabilitation der erektilen Funktion ( EF) nach nervenschonender radikaler Prostatektomie (nsRP) werden derzeit diskutiert. Die "optimale" Dosis von PDE5-Hemmern zur Rehabilitation der EF ist jedoch nicht bekannt. Material und Methoden: Bei 36 Patienten führten wir eine nsRP durch. Die EF wurde bei allen Patienten mittels IIEF-5 Fragebogen evaluiert. Gruppe 1 (n = 12 Patienten) erhielt täglich Vardenafil 5 mg/d, im Vergleich zu Gruppe 2 (n = 12), die Vardenafil 10 mg/d zur Nacht erhielten. Eine Kontrolle von 12 Patienten wurde ohne PDE-5-Hemmer weiterverfolgt. Die Evaluierung der EF mittels IIEF-5 erfolgte präoperativ sowie 3, 6, 12, 18 und 24 Monate nach nsRP. Ergebnisse: In der Gruppe mit 5 mg Vardenafil (Gruppe 1) verringerte sich der IIEF-5-Score von präoperativ 22,4 auf 4,2 nach 3 Monaten, 8,9 nach 6 Mo., 13,4 nach 12 Mo., 15,2 nach 18 Mo. und 18,3 nach 24 Mo. nach nsRP. In Gruppe 2 zeigte der IIEF-5-Score präoperative 22,8 sowie 4,1 nach 3 Mo., 7, 9 nach 6 Mo., 12, 8 nach 12 Mo., 14, 9 nach 18 Mo. und 18,4 nach 24 Mo. Der präoperative IIEF-5-Score in der Kontrollgruppe von 21,9 sank auf 3,8 nach 3 Mo., 6,1 nach 6 Mo., 8,9 nach 12 Mo., 10,2 nach 18 Mo. und 11,3 nach 24 Mo. Die statistische Auswertung ergab signifikante Unterschiede im IIEF-5 im zeitlichen Verlauf der EF zwischen den Gruppen 1 und 3 und zwischen den Gruppen 2 und 3 (p < 0,05). Es wurden keine Unterschiede zwischen den Gruppen 1 und 2 festgestellt. Schlussfolgerung: Täglich niedrig dosierte PDE-5-Inhibitoren führen zu einer signifikanten Verbesserung der Wiederherstellung der EF nach nsRP. In dieser Studie konnte gezeigt werden, dass die Verdoppelung der täglichen Dosis nicht zu einer weiteren Verbesserung der EF nach 2 Jahren führt. Introduction: Urooncological guidelines highlight the need for patient involvement in medical decision making. Little is known about patients' desire for autonomy specifically in urooncological decisions. Therefore, we introduce the API-Uro, a tool to measure participation preference in patients with urological cancers. Methods: We recruited 460 urological outpatients (42% urooncological) at a university hospital. Participation preference was assessed with the Autonomy Preference Index ( API), its generic case vignettes, and six novel urooncological case vignettes describing 12 medical decisions of varying severity ( API-Uro). A polychoric principal component analysis ( PCA) was used to reduce items. Results: PCA revealed two components for the API-Uro: diagnostic and treatment decisions. Internal consistency was good for both components (αs ≥ 0.8). Two vignettes were removed due to substantial cross-loadings. Convergent validity of the API-Uro is documented in high correlations with the API (r = 0.45) and the generic API case vignettes (r = 0.64). The combined sumscore for the API-Uro was in the moderate range (M = 35, SD = 13, Range = [0-100]). More patients desired active participation for treatment decisions (78%) then for diagnostic decisions (22%), χ 2 (1) = 20.8, p ≤ 0.001. Oncological patients did not differ in their participation preference from non-oncological patients in any measure (all ps ≥ 0.14). Conclusion: The API-Uro is an efficient and valid instrument to assess participation preference in patients facing medical decisions for urological cancers. We found considerable differences in the desired involvement in treatment vs. diagnostic decisions. This highlights the importance of assessing participation preference with a specific rather than a generic measures.

V14 Research Questions: Patient-centered care and shared decision making ( SDM) are recognized as the gold-standard for medical consultations, especially for preference-sensitive decisions. While medical conditions that influence the choice of urinary diversion ( UD) are well known, the impact of psychological patient factors on this decision remains unclear. We set out to explore the role of anxiety and personality in the choice of UD after radical cystectomy and determine if anxiety predicts patients' participation preferences. Methods: We recruited a multi-center sample of bladder cancer patients (N = 143, primarily male, retired) before their medical consultation regarding radical cystectomy. Patients filled in a set of self-report questionnaires, including preferred UD, personality, anxiety, and participation preference (generic and uro-oncological case vignettes), as well as socio-demographic characteristics. Results: More patients preferred continent UD (43%) than incontinent UD (32%). A quarter of patients did not indicate a preference. Patients who preferred incontinent UD were significantly older than patients who preferred continent UD. Their personality profile showed lower conscientiousness and less openness to new experiences. Most patients expressed a low participation preference. Almost a third of patients (29%) reported clinically relevant anxiety (scores ≥ 55). Anxiety predicted higher uro-oncological participation preference. Conclusion: Our findings provide insight into the role of psychological patient characteristics for SDM. Patients who reported less openness and conscientiousness were more likely to prefer less invasive treatment methods. Moreover, anxiety may drive the motivation to be more involved in consultations. Introduction: Medical treatment for LUTS/ BPO includes reduction of smooth muscle tone in the prostate. Recently we could show that thalidomide inhibits prostate smooth muscle contraction and that lenalidomide reduces prostate stromal cell growth and modulates cytoskeletal actin organization. Here, we addressed effects of thalidomide-analogue lenalidomide on adrenergic and non-adrenergic contractions of human prostate smooth muscle. Methods: Prostate tissues were obtained from patients undergoing radical prostatectomy for prostate cancer (n = 33 patients). Contractility of prostate strips was then assessed in an organ bath. Results: Noradrenaline-induced adrenergic contractions were decreased up to over 51% with lenalidomide (20 µM) for concentrations of 1-100 µM (p < 0.03 at 100 µM for lenalidomide vs. control), up to 67% for 1-100 µM of methoxamine-induced contractions (p < 0.01 at 1 µM, 3 µM, 10 µM, 30 µM, 100 µM for lenalidomide vs. control), and up to 33% for 1-100 µM of phenylephrine-induced contractions (p < 0.02 at 3 and 10 µM for lenalidomide vs. control). Lenalidomide inhibited non-adrenergic contraction with endothelin-1 up to 88% (p < 0.05 at 0. Introduction: Male lower urinary tract symptoms ( LUTS) include obstructive symptoms attributed to benign prostatic hyperplasia and storage symptoms due to overactive bladder. Mirabegron is a β 3 -adrenoceptor agonist and available for treatment of storage symptoms. Despite its clinical use in LUTS, effects in the prostate are hardly characterized. Off-target effects may include antagonism of α 1 -adrenoceptors, which are an important target in obstructive symptoms. However, improvements by mirabegron did not become unequivocally obvious during clinical application.

Here, we examined mirabegron effects on contractions of human prostate tissues and proliferation of prostate stromal cells. Methods: Prostate tissues were obtained from radical prostatectomy. Contractions were studied in an organ bath, and effects on WPMY-1 cells in cell culture. Results: 5 µM and 10 µM mirabegron, but not 1 µM inhibited neurogenic contractions of human prostate tissues. 5 µM and 10 µM mirabegron, but not 1 µM shifted concentration response curves for noradrenaline-, methoxamine-and phenylephrine-induced contractions to the right, including recovery of contractions at high agonist concentrations, increased EC 50 values, and unchanged E max values. Endothelin-1-induced contractions were not affected. U46619-induced contractions were slighly inhibited. Effects of mirabegron on proliferation and viability of stromal cells were neglectable or small (maximum decreases: 8% proliferation, 17% viability). Conclusions: Mirabegron inhibits neurogenic and α 1 -adrenergic human prostate smooth muscle contractions. Effects are based on antagonism of α 1 -adrenoceptors, but do not include β 3 -adrenoceptors and require concentrations ranging 50-100fold higher than plasma concentrations during normal dosing. Introduction: The presumed ARF6 inhibitor NAV2729 inhibits human prostate smooth muscle contraction and proliferation of stromal cells, which are driving factors of voiding symptoms in benign prostatic hyperplasia ( BPH). However, its specificity and a confirmed role of ARF6 for smooth muscle contraction are pending. Here, we created Arf6 knockout clones of human prostate stromal cells, and characterized phenotypes of contractility, proliferation, and susceptibility to NAV2729. Methods: Monoclonal Arf6 knockouts were generated in human prostate stromal cells ( WPMY-1). Phenotypes were characterized by comparison to ARF6-expressing control clones. Effects of NAV2729 were assessed in knockout and control clones. Results: ARF6 knockout was verified by Western blot. Knockout resulted in reduced contraction, breakdown of actin organization, reduced proliferation rate ( EdU), reduced expression of the proliferation marker Ki-67, reduced viability, and increased apoptosis and cell death. In ARF6-expressing control clones, NAV2729 (5 µM) reduced contraction, caused actin breakdown (2.5-5 µM) , reduced proliferation ( EdU, Ki-67, both 5 µM), increased apoptosis and cell death (5 µM), and reduced viability (EC 50 ~2.5 µM). In ARF6 knockouts, effects of NAV2729 were widely reduced, represented by lacking effects on contractions (5 µM NAV2729), actin (2.5-5 µM) and proliferation in EdU assays (2.5-5 µM) , only slight decreases of Ki-67 mRNA (5 µM Methods: Human prostate tissues were obtained from radical prostatectomy. Contractions were studied in an organ bath, and effects on WPMY-1 cells in cell culture. Results: Neurogenic contractions of human prostate tissues were inhibited by WNK463 (500 nM) (~50%) and HTH01-015 (500 nM) (~30%). Contractions by a thromboxane A 2 analog were inhibited by WNK463 (~50%) and HTH01-015 (40-50%). Endothelin-1-induced contractions were inhibited by WNK463 (35-50%), but not HTH01-015. Both inhibitors reduced viability of stromal cells at concentrations >1 µM by, but not < 1 µM. Proliferation ( EdU assays) was reduced by 13% and 57% by 1 µM and 10 µM WNK463, and by 52% by 10 µM HTH01-015 (not by 2.5 µM). Growth of stromal cells (colony formation assays) was reduced by 39% and 66% by 1 µM and 10 µM WNK463, and by 30% and 78% by 2.5 µM and 10 µM HTH01-015. Conclusions: WNK463 and HTH01-015 inhibit neurogenic and non-adrenergic contractions in the human prostate, and stromal cell growth in vitro.

The translational value may be higher for WNK463, as the spectrum of inhibited non-adrenergic contractions was higher, and growth occurred at lower concentrations. Background: Radical surgery ± cisplatin (C)-based neoadjuvant chemotherapy (chemo) is the standard of care ( SOC) for pts with MIUC, but many pts are C-ineligible. There is no conclusive evidence supporting adjuvant chemo in pts who did not receive neoadjuvant chemo and in those with residual disease after neoadjuvant C.

Methods: CM 274 is a phase 3, randomized, double-blind trial in pts with high-risk MIUC after radical surgery receiving N 240 mg Q2 W or P for ≤1 year of adjuvant treatment. Pts had radical surgery within 120 days ± neoadjuvant C or were ineligible/declined C-based chemo, evidence of highrisk UC, were disease-free by imaging after surgery, and ECOG PS ≤1. Primary endpoints: disease-free survival ( DFS) in all randomized pts ( ITT population) and in pts with tumor PD-L1 expression ≥1%. Non-urothelial tract recurrence-free survival ( NUTRFS) in ITT pts and in pts with PD-L ≥ 1% is a secondary and safety an exploratory endpoint. Results: 353 pts were randomized to N ( PD-L1 ≥1%, n = 140) and 356 pts to P ( PD-L1 ≥1%, n = 142). DFS was met in ITT pts and in pts with PD-L1 ≥1%. DFS and NUTRFS were improved with N v P in both populations. DFS improvement with N was generally consistent across subgroups. Objective: To compare the efficacy of multiparametric magnetic resonance imaging (mpMRI) directed and micro-ultrasound (micro-US) directed biopsy for detecting clinically significant (Grade Group >1) prostate cancer (csPCa). Materials and methods: 203 patients were prospectively enrolled at 3 institutions across Germany and Austria in the period from January 2019 to December 2019. During each biopsy, the urologist was blinded to the mp-MRI report until after micro-US targets had been assessed. After unblinding, targets were then sampled using software-assisted fusion, followed by systematic samples. The primary outcome measure was non-inferiority of micro-US to detect csPCa with a detection ratio of at least 80% of mp-MRI. Introduction: Multiparametric magnetic resonance imaging (mpMRI) and targeted biopsies ( TB) facilitate accurate detection of significant prostate cancer (sPC). However, it remains unclear how many cores should be applied per target. The main objective of this study was to assess sPC detection rates of TB and TS in prospectively randomized men. Material and methods: Using a noninferiority margin of 5% and a onesided alpha level of 5%, the randomization of 170 men (n = 85 in each group) provides the trial with 80% power. All men underwent either TB or TS in addition to 24 systematic cores. Cancer and sPC (International Society of Urological Pathology grade group > = 2) detection rates were analysed. Cancer detection rates were calculated for TS, TB, and SB at both lesion and patient level. Combination of SB + TB or TS served as reference. With a median follow-up of 16 years the ERSPC trial shows a relative reduction of prostate cancer (PCa) specific mortality ( PCSM) of 20% in favor of PSA based screening. Despite screening 520 men died from PCa. This multicentre population-based randomised screening trial has included a total of 182,160 men. We provide descriptive analyses and visualizations of the screening history and outcome data of men who died of PCa in the ERSPC. A total of 1313 men died of PCa in the ERSPC. 793 (60%) men had been randomised to the control arm and 520 (40%) to the screening arm. 137/520 (26%) participants randomised to screening never attended (Group A). 218/520 (42%) participants had an initial positive screening (i. e., recommendation for biopsy) (Group B). 117/520 (23%) participants had at least one negative screening and did not follow up or had a positive screen (Group C) and 48/520 (9%) participants completed the screening with negative screening and were diagnosed with PCa later in time (Group D). Median ( IQR) age at death for the groups A-D was 72 years (69-77), 73 years (69-77), 74 years (70-78) and 75.5 years (70-80), respectively. The rate of M+ disease at diagnosis was 5% for Group A, 12% for Group B, 29% for Group C, and 52% for Group D. This study analyses all cases of PCSM in a large population and describes scenarios in which screening failed. Adherence to screening was identified as most important contributing factors for success or failure of a screening protocol, reflected by the percentage of M+ disease. In addition, men who completed screening with negative screenings in all rounds and died of prostate cancer should be classified as failure of screening protocol. These data should help in development and refinement of the future screening policy for PCa. Purpose: The present study evaluates the potential role of 68 Ga-PSMA PET/ CT to detect pelvic LNM in newly diagnosed, treatment-naïve high risk PCa patients prior to RP and EPLND. Methods: 165 men with newly diagnosed high risk PCa ( ISUP grade 4/5, PSA > 20 ng/ml or ≥cT3a) were included in the retrospective study. All men underwent transperineal MR fusion biopsy, all men underwent RPE with epLND. Patients with neoadjuvant ADT, TRUS guided biopsies, previous radiation or surgery in the small pelvis were excluded. Imaging and pathohistological findings were correlated and sensitivity, specificity, positive and negative predictive values were calculated. Results: Median PSA was 24.5 (6.7-185) ng/ml, median number of dissected lymph nodes was 21-5 . 68/165 (41,2%) pts had lymph node metastases ( LNM) of which 43 (63.2%) were positive on PSMA-PET/ CT, 25 (36.8%) LNM were negative. 97/165 (58.8%) pts had pN0 disease of whom 93 (95.9%) and 3 (4.1%) demonstrated negative and positive PSMA PET/ CT findings, resp. n = 47 had positive PSMA PET/ CT and 40 (85.1%) demonstrated LNM, 7 (14.9%) had pN0 disease. N = 118 had negative PSMA PET/ CT of which 93 (78.8%) and 25 (21.2%) were true and false negative, resp. Sensitivity was 63.2%, specificity was 97.0%, and positive and negative predictive values were 93.5% and 78,8%, resp. 3564 lymph nodes were resected, 149 (4.2%) had LNM. 88/149 (59.1%) were detected on PSMA PET/ CT and 61 (40.9%) were undetected. On a per lymph node base, sensitivity and specificity were 40.4% and 94.5%, resp; positive and negative predictive values were 59.1% and 97.3%. Conclusions: PSMA-PET/ CT has a high reliability to identify LNM in high risk PCA. If a positive lesion is detected, epLND is mandatory due to high frequency of undetected small LNM. Ziel: Die Bestimmung der wahrgenommenen Beteiligung an der Partizipativen Entscheidungsfindung ( PEF) urologischer Patienten und die Identifikation möglicher Einflussfaktoren. Methoden: Es wurden 372 urologische Patienten einer universitären Ambulanz prospektiv in die Studie eingeschlossen. Vor der ärztlichen Konsultation wurden klinische und soziodemographische Parameter erhoben. Nach der Konsultation gaben die Patienten Auskunft über das Ausmaß ihrer wahrgenommenen Beteiligung, erfasst mittels des "Partizipative Entscheidungsfindung" Fragebogen ( PEF-FB-9). Ein hohes Maß an Beteiligung war definiert als PEF-FB-9 Gesamtwert > 66. Relevante Einflussfaktoren der wahrgenommenen Beteiligung wurden mit einer logistischen Regressionsanalyse identifiziert. Fragestellung: Vergleich zwischen den G8-und ISAR-Screening-Fragebögen für die Einschätzung der geriatrischen Risikofaktoren bei urogeriatrischen Patienten. Material und Methoden: Wir untersuchten retrospektiv 100 Patienten im Alter von 75 und darüber, die wegen verschiedener urologischer Erkrankung behandelt wurden. Alle Patienten wurden bei der Aufnahme sowohl einem G8-als auch einem ISAR-Screening unterzogen. Ein G8-Score ≤14 und ISAR-Screening Score > 2 wurden als positiv bewertet. Die Ergebnisse wurden zwischen beiden Tests verglichen und mit den Merkmalen des Patienten in Beziehung gesetzt. Ergebnisse: Das Durchschnittsalter der Patienten betrug 83 Jahre (min. 75-max. 101). 78 der Patienten waren Männer und 22 Frauen. 24 waren Notfall Patienten und 76 geplante Aufnahmen. 56 der Patienten waren wegen urologischer Malignitäten und 44 wegen gutartiger urologischer Erkrankungen behandelt worden. 58 der Patienten waren G8-positiv und 42 G8-negativ. 24 waren ISAR-positiv und 76 ISAR-negativ. Alle ISAR positive Patienten waren auch G8-positiv. 34 der Patienten waren G8-positiv und ISAR-negativ. Es gab eine signifikante und starke negative Korrelation zwischen dem G8 und ISAR Score(r = -0,77, p < 0,001). Beide Tests korre-lierten signifikant mit dem Charlson-Komorbiditätsindex, der Verweildauer, der Anzahl der codierten Diagnosen und dem Braden-Score. Schlussfolgerungen: Beide Tests korrelieren gleichermaßen mit klinischen Daten, die sich auf geriatrische Gebrechlichkeit beziehen. Im Vergleich weist der G8-Score eine viel höhere Rate an positiven Tests auf. Dies schränkt die Verwendung des G8-Score ein und begünstigt den ISAR-Score. Für geriatrische "Fitte"-Patienten ist ein negativer G8-Score für die weitere onkologische Entscheidungsfindung von großem Nutzen sein. Background: In order to contain the COVID-19 pandemic, Germany has implemented drastic restrictions on public or social life, while health institutions are invoked to postpone elective procedures. Although urologists are less involved in the direct treatment of COVID-19 patients, the current situation strongly affects the urological work routine. The objective was to analyze the impact of the COVID-19 pandemic on aspects of work and personal life among urologists in Germany. Material and methods: 589 urologists in Germany participated in an online survey between March 18th and April 11th 2020. Participants were stratified into subgroups according to professional characteristics. Results: Most urologists rated Germany as "well prepared" and the increasing restrictions of social life as "very positive". Routine operation was more restricted in hospitals compared to the outpatient sector (p = 0.046). Moreover, urologists from the outpatient sector felt significantly less prepared for the COVID-19 pandemic (p = 0.001), reported a higher shortage of protective medical equipment (p < 0.001) and described a tendency towards a higher level of threat (p = 0.054). Although restrictions regarding telemedicine approaches were reported by 60% of participants, the outpatient sector used telehealth more frequently compared to hospitals (25.5% vs. 17.0%, p < 0.001). Conclusions: This survey systematically evaluates the impact of the COVID-19 pandemic on private and professional aspects among German urologists. We identified several issues such as a higher shortage of medical protective equipment in the outpatient sector that could trigger specific measures to further improve the quality of urological care in Germany.

Einfluss der COVID-Pandemie auf die klinische Versorgung in der Urologie -eine weltweite Umfrage R. Dotzauer * , K. Böhm vs. 52,5 Jahre), ebenso wenig der Case-Mix-Index (0,605 -Range 0,175-1,288 vs. 0,597 -Range 0,175-1,33). Die mittlere Verweildauer der Patienten stieg jedoch von 2,29 ± 2,3 Tagen in der Vor-Pandemie-Periode auf 3,1 ± 6,1 Tagen in der Lockdown-Periode, wobei ein signifikant höherer Patientenanteil länger als einen Tag stationär aufgenommen wurde (p < 0,05). Auch der Anteil an Langliegern mit einer Aufenthaltsdauer über der oberen Grenzverweildauer am Patientengut stieg von 3,5 % auf 6,3 %. (2) = 8,31, p = 0,016). Ein hoher GS zum ZP Entlassung zeigte sich als unabhängiger Prädiktor für eine hohe QoL 8 Wochen postoperativ ( OR = 5, 26, 37, p = 0, 013 Hintergrund: Die Aktivierung des Plasmamembran-assoziierten P2X7 Rezeptor (P2X7R) zeigt je nach extrazellulärer ATP-Konzentration proliferative oder pro-apoptotische Effekte. Die mutierte Variante (nfP2X7) konnte als spezifisch für das Urothelkarzinom ( UC) nachgewiesen werden. NFATc1 als Downstreamparapeter des nfP2X7 wird ein proliferativer Effekt zugeschrieben. In der vorliegenden Arbeit wurden die differentielle Expressi-Abstracts on von PX2X7R, nfP2X7R und NFATc1 sowie deren prognostische Relevanz beim invasiven UC untersucht. Methode: An einem Kollektiv von 103 UC-Patienten nach Zystektomie und 46 benignen Urothelgewebeproben wurde immunhistochemisch die Expression und zelluläre Lokalisation des P2X7-Rezeptors, des nfP2X7 und dem NFATc1 ermittelt und diese mit klinischen Daten korreliert. Ergebnisse: Der P2X7R zeigt sich nur zytoplasmatisch exprimiert ( CP). Der nfP2X7 kann zusätzlich membranständig ( MEM) abgegrenzt werden. P2X7 und vor allem MEM nfP2X7 zeigen sich in den UC signifikant stärker exprimiert als in benignem Gewebe (beide p < 0,0001). NFATc1 wird in benignem Urothel nicht exprimiert (p < 0,0001), auch nicht bei hoher CP nfP2X7 Expression (p < 0,0001). pT>2 BC exprimieren mehr NFATc1 (p = 0,0003). Hohe Expressionslevel von MEM nfP2X7 korrelieren mit einem verlängerten Gesamt-(p = 0,0434) und tumorspezifischen Überleben (p = 0,043). Schlussfolgerung: Die MEM nfP2X7 und CP P2X7 Expression zeigen sich charakteristisch für das UC. Eine hohe nfP2X7 Expression zeigt einen prognostischen Effekt für das Überleben. Da die NFATc1 Überexpression mit hohen T-Stadien korreliert, könnte dies zudem als Progressionsmarker dienen. Zielgerichtete Therapien gegen nfP2X7 befinden sich aktuell in der präklinischen Evaluation. Objective: To assess the feasibility of near-infrared fluorescence sentinel node mapping ( NIRF-SNM) in open radical cystectomy ( CE) for muscle invasive bladder cancer ( MIBC) using a novel hand-held device and to compare this technique with standard bilateral extended lymphadenectomy. Material and methods: Monocentric analysis of 17 patients who underwent CE for MIBC with NIRF-SNM. Intraoperatively, a cystoscopic injection of indocyanine green was performed before cystectomy. Prior to lymphadenectomy, the pelvis was scanned for sentinel areas using the novel Hamamatsu Ò system. After dissection, specimens were transferred to a standardized template for a second ex vivo analysis. Detection rate and false negative rate was calculated. Results: Median age was 64 (33-78) with 14 (82.35%) male patients. Bladder specimens showed ypT0-pT3 cancers except for one pT4 tumor. Sentinel nodes were in 14 cases detected bilaterally, in 3 cases unilaterally. A total of 144 template-based lymph node areas were harvested, of which 56 showed a positive NIRF signal. 6 NIRF positive areas showed metastatic involvement, whereas no lymph node metastasis was detected in NIRFnegative template-regions, corresponding to a false-negative rate of 0% and a detection rate of 100%. Of 34 lymphadenectomized hemipelves, 31 (91.18%) showed a NIRF signal, of which 6 (17.65%) were histologically proven to be metastatic. Sentinel lymphnode mapping and resection was non-inferior to standard extended lymphadenectomy in this series. Objectives: To evaluate the concordance of preoperative staging with postoperative pathology as well as follow-up data with emphasis on upper tract urothelial recurrences in high-grade ureteral cancer undergoing kidney-sparing surgery ( KSS). Methods: Retrospective, single center analysis with blinded radiological (contrast CT) reinterpretation of 16 high-grade ureteral cancer patients with KSS and complete upper tract tumor resection between 5/2010 and 6/2020. Results: Ureteral tumors of all stages were visible on CT with an association of contrast enhancement in all tumors ≥pT1. Non organ-confined tumors (≥pT3) were correctly staged by CT in 5 of 6 (83%) patients. Only 1 of 4 (25%) patients with regional lymph node metastases ( LNM) showed suspicious regional lymph nodes (>8 mm) in preoperative imaging, while one case was falsely classified as cN+. Postoperative upgrading occurred in 4 of 13 (31%) cases. All surgical specimens had negative margins in the upper tract. In one patient there was residual CIS in the bladder cuff. Within a median follow up of 26 months recurrence occurred in 8 of 14 (57%) patients (ipsilateral upper tract: 1, LNM: 4, distant metastasis: 5) with a median time to recurrence of 16 months. Therefore urothelial recurrence in the ipsilateral upper tract developed in only 1 of 14 (7%) cases. Muscle-invasive tumors (≥pT2) had a very high likelihood of tumor recurrence (6/9, 67%). Conclusion: While showing a good sensitivity for detecting non organconfined tumors, preoperative assessment in high-grade ureteral cancer remains a challenge with high proportions of understaged LNM and upgrading. The low rate of recurrences in the ipsilateral upper tract may justify KSS even in high-grade ureteral cancers to allow for an eventual cisplatin-based chemotherapy. Patienten [Durchschnittalter: 65, 8 ± 8, 9] waren 61,9 % Männer und 8,1 % Frauen. Als HA wurde ein Ileum conduit in 57,1 %, ein orthotoper Pouch in 35,7 % und ein kontinenter heterotoper Pouch in 7,2 % der Fälle konstruiert. Als assoziierte Komplikation wurde bei 33,3 % (n = 14) eine Harntransportstörung postoperativ nachgewiesen. Sie löste sich mehrheitlich spontan auf. 2 Introduction: Connexins are a family of membrane proteins that form gap junctions between neighbouring cells. They play important roles in regulation of cell proliferation, differentiation, apoptosis and tissue development. We have previously identified connexin31 (GJB3) in a RNAi genomic screen as a ploidy-control gene. Since bladder cancer ( BC) displays an increase in aneuploidy during tumor progression, we suggest that GJB3 may be involved in the progression of BC. Materials und Methods: The expression of GJB3 was analysed in normal human and murine urothelial cells and tissues as well as in BC cells and tissues using immunohistochemistry, RT-qPCR and Western blot. Wound healing assay, Boyden chamber and porcine bladder organ culture were applied to evaluate the impact of GJB3 on the migratory and invasive capacity of BC cells in response to shRNA-mediated GJB3 knockdown and ectopic GJB3 expression. Immunofluorescence was used to investigate the mitotic dysregulation, aneuploidy, invadopodia formation and colocalization experiments. Results: GJB3 is downregulated in BC cells with higher invasive capacity and in advanced tumour stages in vivo. The knockdown of GJB3 induced Abstracts chromosomal instability by dysregulation of the accurate mitosis in normal urothelial cells. While the shRNA-mediated depletion of GJB3 improved migration and invasion capacities of BC cells, ectopic expression of GJB3 in cells impaired their migration and invasion through regulating invadopodia formation. Interestingly, GJB3 was found to be colocalized with cytoskeleton proteins F-actin and α-tubulin.

The data indicate that the loss of GJB3 promotes the initiation and progression of BC by regulating cell division and invasion via interaction with cell cytoskeleton proteins. Introduction: Proteinase-activated receptor-1 (PAR1), encoded by the F2R gene, belongs to a subfamily of the G-protein-coupled receptors. The wide distribution of PARs in a variety of cells supports the idea that they are involved in many processes, including coagulation, proliferation and adhesion. Materials and methods: F2R/PAR1 expression was determined by RT-qPCR and Western blot in primary human urothelial cells, immortalized urothelial cell strains (e. g. UROtsa and HBLAK) and bladder cancer ( BC) cell lines (RT4, UMUC3 and T24). Stable ectopic PAR1 expression was used to elucidate the role of PAR1 in BC cells (UMUC3 and T24). MTT assay, Boyden chamber assay and Scratch assay experiments were used for functional experiments. Results: PAR1 is readily detectable in immortalized Y235T and HBLAK cells, established from normal urothelial cells, while its expression was lower in bladder cancer cell lines RT4, T24, UMUC3. Overexpression of PAR1 inhibited proliferation, migration and invasion of T24 cells and impaired the proliferation and invasion of UMUC3 cells. At the molecular level, ectopic PAR1 expression resulted in increased LATS1 and p-YAP levels in both cell lines. Interestingly, PAR1 expression reduced PTEN expression and resulted in increased levels of p-AKT Ser473 , p-AKT Thr308 in T24 cells. Conversely, expression of PAR1 resulted in reduced p-AKT Ser473 , p-AKT Thr308 levels in PTEN null UMUC3 cells. Conclusions: This study shows for the first time potential role of PAR1 in BC and indicates that PAR1 may impair proliferation, migration and invasion of BC cells via AKT and Hippo-YAP signaling pathways. It also remains ambiguous whether the PAR1-induced contradictory AKT phosphorylation results in T24 and UMUC3 cells are due to PTEN expression in these cells. Introduction: The molecular mechanism of the progression of BCa is not fully understood. DNA sequencing of progressive NMIBC and their corresponding MIBC identified frequent gene mutations, including BCL9L to be associated with β-catenin signalling. BCL9L, a coactivator of β-catenin, plays a crucial role in the carcinogenesis of various tumour entities. We analyzed the functional role of BCL9L and the influence on Wnt/β-catenin signalling. Material and methods: Knockdown of BCL9L using siRNA and the manipulation of Wnt/β-catenin signalling using SKL2001 and iCRT3 were per-formed. Growth was assessed by spheroid formation and proliferation by crystal violet staining. Migration and invasion were analyzed in real-time using xCelligence RTCA system. The localization of BCL9L in bladder cancer cells was investigated by immunofluorescence. For pathway analysis, mRNA expression of wnt/β-catenin target genes were analyzed by qRT-PCR. Results: Knockdown of BCL9L and inhibition of β-catenin significantly repress the growth of bladder cancer cells in monolayer and 3D spheroid models as well as inhibit the migration and invasion of bladder cancer cells. Interestingly, immunofluorescence data shows that BCL9L is mainly localized in the nucleus of Cal29 cells and mainly in the cytoplasm of T24 cells. Knockdown of BCL9L reduces mRNA level of Wnt/β-catenin target genes in Cal29 but not in T24 cells. Conclusion: BCL9L has an oncogenic role. Our data indicate the existence of the BCL9L/β-catenin axis in bladder cancer cells, which is cell line dependent, suggesting that BCL9L could act dependently and independently from β-catenin. Our data provide new insights into the understanding of molecular mechanisms of carcinogenesis in bladder cancer, which might provide new therapeutic targets.

Validation of the association of high androgen receptor mRNA expression with improved prognosis in high-risk non-muscle-invasive bladder cancer Introduction: The role of the androgen receptor ( AR) in bladder cancer remains controversial. Methods: We retrospectively analyzed 95 patients with high-risk nonmuscle-invasive bladder cancer ( NMIBC) treated with transurethral resection of the bladder. The mRNA expression of AR and the keratins KRT5 and KRT20 used as surrogate markers for basal and luminal subtypes, respectively, was measured by RT-qPCR and correlated with clinical data and recurrence-free ( RFS), cancer-specific ( CSS), and overall survival ( OS). Results: AR mRNA expression was positively correlated with KRT5 (r s = 0.456; p < 0.001). High AR (p = 0.050) and KRT5 (p = 0.030) were associated with lower tumor grade. Kaplan-Meier analysis indicated significantly prolonged CSS (p = 0.020) and OS (p = 0.015) and a trend towards longer RFS (p = 0.051) in patients with high AR expression. High KRT5 mRNA expression showed significantly longer RFS (p = 0.033), CSS (p = 0.029) and OS (p = 0.030), while high KRT20 was associated with reduced RFS (p = 0.042). In multivariable analysis, none of the markers was an independent prognostic factor. When substratificating with regard to molecular subtypes, age, gender and instillation therapy, high expression of KRT20 and AR showed improved OS (p = 0.041) compared to patients with high KRT20 and low AR expression. Women and younger patients had significantly longer RFS (p = 0.034 and p = 0.009) and OS (p = 0.011 and p = 0.007) in cases with high AR expression. High AR expression was associated with longer CSS in patients with instillation therapy (p = 0.040), while RFS and OS was improved regardless of instillation therapy. Conclusions: High AR mRNA expression is associated with KRT5 and improved outcome in high-risk NMIBC. The role of androgen deprivation therapies needs to be explored in future studies.

Absence of telomerase delays onset and progression of BBN-induced bladder cancer in mice S. Meessen 1* , A. Azoitei 1 , X. Zheng 1 , M. Eckstein 2 , A. Hartmann 2 , F. Zengerling 1 , C. Bolenz 1 , C. Günes 1 Purpose: Telomerase activity is observed in 99% of human bladder cancers ( BC), indicating an essential role for telomerase for survival and sustained replicative capacity of BC cells. Thus, telomerase inhibition could be a useful target for tumor therapy. The N-butyl-N-(4-hydroxybutyl)nitrosamine ( BBN)-induced bladder cancer mouse model recapitulates the muscle-invasive human bladder cancer. The impact of telomerase deletion on tumor development was evaluated in vivo using the BBN-mouse model in combination with wildtype and telomerase deficient (Terc-KO) mice. Method: WT C57/BL6 and Terc-KO mice (male/female) were treated ad libitum with 0,1% BBN from 8 weeks of age on. The mice were sacrificed at different time-points post treatment (2, 4, 6, and 8 months) . The resected bladders were evaluated histologically for tumor progression. Based on previous reports from in vitro experiments showing that telomerase can promote tumor formation by alleviating replication stress-induced senescence, the bladder samples were analyzed by phospho-RPA2 (pRPA2) immunohistochemistry to evaluate the accumulation of replication stress during tumor progression. Results: The histological evaluation of the bladders showed that the onset of BBN-induced tumor development is significantly delayed in Terc-KO mice, as well as a significant increase in survival compared to telomerase positive WT mice. The evaluation of the replication stress levels revealed an increase in Terc-KO mice, conforming the results from in vitro experiments.

The results of this study suggest that telomerase is a potential target for tumor therapy in BC and that the BBN-induced BC mouse model represents a useful experimental tool to test efficacy of potential telomerase inhibiting therapeutics.

Shorter peripheral blood telomere length is associated with worse survival of patients with bladder and kidney tumours X. Zheng * , F. Wezel, A. Azoitei, S. Meessen, W. Wang, G. Najjar, A. John, F. Zengerling, C. Bolenz, C. Günes Department of Urology, Ulm University Hospital, Ulm, Germany Background: Telomeres are protein-DNA complexes at the tip of linear chromosomes. It is well established that telomere shortening results in genome instability and promotes tumor formation. Recent data indicated that telomere length of PB cells may serve as a prognostic biomarker for patients with solid cancers. Although the molecular basis of this relationship is yet unknown, telomere length measurement in PB cells could be a prognostic marker for the survival in patients with bladder cancer ( BC) and kidney cancer ( KC). Methods: Relative telomere length ( RTL) was measured by qPCR using genomic DNA prepared from the PB cells of normal control population without malignant disease ( NC, n = 73), patients with BC (n = 144) or with KC (n = 144). Chi square test, Kaplan-Meier analysis and Cox regression analysis were performed to investigate the correlation of RTL with patients' clinical and pathological parameters and overall survival ( OS). Results: RTL was significantly shorter in PB of patients with BC (p < 0.0001) or with KC (p < 0.0001), compared to the age-matched control group. The cancer patients were divided into long and short RTL subgroups with the median RTL value. Both BC and KC patients with shorter RTL had significantly worse OS ( BC: p = 0.029; KC: p = 0.012) during the 83 months' follow-up period. The multivariate analysis revealed that short RTL ( BC: p = 0.039; KC: p = 0.046) was an independent prognostic factor for OS in BC and KC compared to long RTL. Conclusions: A reduced RTL is associated with the presence of BC and KC. It may serve as a prognostic biomarker for the prediction of reduced survival in BC and KC patients. Further prospective studies with larger sample numbers are needed for more accurate validation and for better understanding of the potential mechanisms.

3K04.10 Einfluss der präoperativen Plasmaspiegel des Urokinasetyp-Plasminogenaktivator (uPA), seines löslichen Rezeptors ( SuPAR) und seines Inhibitors ( PAI-1) auf den Krankheitsverlauf nach radikaler Zystektomie beim Urothelkarzinom der Blase , p < 0,001) nach NAC assoziiert. Die Addition des NLR zu prädiktiven Modellen verbesserte die Diskriminationsfähigkeit bezüglich CR und PR ( AUC +5,7, p = 0,012 bzw. AUC +4,1, p = 0,04). In der präoperativen Cox-Analyse war ein erhöhter NLR mit schlechteren Überlebenserwartung (Tumor-freies Überleben, Krebs-spezifisches Überleben und Gesamtüberleben) assoziiert, ermöglichte aber keine relevante Verbesserung des C-Index (Änderung < 2 %). Diskussion: Der NLR ist mit dem Ansprechen auf NAC und der Überlebenserwartung bei UCB-Patienten assoziiert, welche mit NAC + RC behandelt werden. Der NLR verbesserte die Diskriminationsfähigkeit etablierter Modelle zur Prädiktion von CR und PR signifikant und kann so individuelle Therapieentscheidungen ermöglichen.

Introduction: Epigenetic inhibitors of DNA methyltransferases (DNMTi) and histone deacetylases (HDACi) show broad gene induction making them potential combination partners for immune-oncological approaches. We therefore investigated whether pretreatment of bladder cancer cell lines with DNMTi decitabine ( DEC) or HDACi romidepsin ( ROM) might improve the lytic capacity of CAR T-cells. Materials and methods: Several bladder cancer cell lines and HBLAK pretreated with 3 nM ROM or 100 nM DEC were co-incubated with CAR Tcells directed against EGFR or CD44v6 and subsequent cytotoxicity assays were performed. Surface expression of target antigens and T-cell ligands was assessed by flow cytometry. For further analysis, we performed next generation RNA sequencing and siRNA mediated knockdown of potential regulators of CAR T-cells lysis. Results: Pretreatment with DEC, but not with ROM enhanced CAR-T cell lysis towards all bladder cancer cell lines, but not towards benign HBLAK. Differential effects could not be attributed to target antigen induction nor to changes in T-cell interaction molecules. Alternately, regulators of cell survival and apoptosis were differentially modulated by the two treatments. DEC shifted the balance between survival and apoptosis towards a state prone to apoptosis associated with increased CAR T-cell lysis, ROM altered this balance to the opposite. Subsequent siRNA experiments supported BID and BCL2L1 as two important factors in this context. Conclusion: We propose DEC pretreatment in combination with CAR T-cell therapy as a new therapeutic option for treatment of bladder cancer. Beyond, targeting of BID and BCL2L1 as key factors of CAR T-cell lysis might be suitable for combination with immune-oncological approaches in other malignancies as well.

3K04.14 Establishing of a new nanoparticle-based immunotherapy for treatment of high-grade nonmuscle invasive bladder cancer B. Kind 1* , S. Tietze 2 , D. Nahhas 1 , N. Wetterling 2 , D. Appelhans 3 , A. Temme 2 , C. Thomas 1 , S. Füssel 1 1 Uniklinikum Dresden, Department of Urology, Dresden, Germany; 2 Uniklinikum Dresden, Department of Neurosurgery, Section Experimental Neurosurgery/Tumor Immunology, Dresden, Germany; 3 Leibniz Institute of Polymer Research Dresden, Dresden, Germany Purpose: BCG therapy reduces the risk of recurrence and progression in patients with high-grade non-muscle invasive bladder cancer (BCa) after transurethral resection and is in use for long-term therapy. There are common adverse effects including cystitis and fever after admission of BCG and ~30% of non-responders. To overcome these problems, we evaluate a new nanoparticle-based immunotherapy (Nano:BICs) for BCa. Materials and methods: The Nano:BICs used in this study contain short single-stranded DNA molecules ( ODN) as specific Toll-like receptor 9 (TLR9) ligands and antibodies targeting prostate stem cell antigen ( PSCA) on the surface of BCa cells as functional components. Both are shielded by transfection-incompetent polypropylenimine dendrimers (PPIs) to prevent unspecific cellular uptake. After developing a successful assembly protocol, activation of endosomal TLR9 was proven using mTLR9 + / PSCA + HEK-Blue reporter cells co-expressing murine TLR9 and an inducible alkaline phosphatase ( AP) reporter gene for colorimetric assay. Furthermore, cytokine production was analyzed by cytometric bead array. Results: Nano:BICs designed in this study activated mTLR9 + / PSCA + HEK-Blue cells specifically. Nano:BICs containing 1 equivalent anti-PSCA-antibody, 2 equivalents PPI containing 18% Maltose and 1 µM ODN1668 (partly phosphorothioate-modified) induced a 2.9 ± 0.07 fold induction of AP activity. Furthermore, 1.07 ± 0.07 ng/ml of the cytokine IL-8 were secreted to the medium in vitro. Conclusion: Our Nano:BICs are suited to induce a proinflammatory cytokine response specifically in reporter cells. Further studies using a syngeneic orthotopic immunocompetent BCa mouse model are ongoing to prove if this cytokine induction results in an appropriate immune response causing tumor shrinkage in vivo. Funding: This project is funded by the European Union and the European Regional Development Fund ( EFRE) and the Free State of Saxony ( SAB; project no. 100379619).

Evaluation of immunostimulatory nucleic acids in a reporter cell model for the potential therapy of NMIBC D. Nahhas 1* , B. Kind 1 , S. Tietze 2 , A. Temme 2 , C. Thomas 1 , S. Füssel 1 1 Uniklinikum Dresden, Department of Urology, Dresden, Germany; 2 Uniklinikum Dresden, Department of Neurosurgery, Section Experimental Neurosurgery/Tumor Immunology, Dresden, Germany Purpose: Alternatives for BCG-refractory cases of non-muscle invasive bladder cancer ( NMIBC) are lacking as high-risk NMIBC frequently recurs despite guideline-based therapy. Toll-like receptor 9 (TLR9), a pattern recognition receptor of the innate immune system, is under investigation as an anti-tumour immune response mediator. Here, we examined TLR9 and different agonists ( CpG ODNs) in vitro. Material and methods: Expression analysis (qPCR) was performed in human bladder cancer (BCa) cell lines. HEKBlue reporter cells expressing human or murine TLR9 secrete an alkaline phosphatase for photometric assessment (QUANTIBlue assay) after stimulation of TLR9. They were treated by CpG ODNs 1668, 2006 or 2395 (0.01-1 µM). Secreted cytokines were analysed by cytometric bead array ( CBA). Results: In 5 out of 14 BCa cell lines (Cal29, KU1919, RT112, SW780, UMUC-16), hTLR9 mRNA was detected. In h/mTLR9 + HEKBlue reporter cells, TLR9 was activated in a concentration-dependent and species-specific manner. ODN 2006 specifically activated hTLR9 with a 1.8-fold induction over unstimulated control. The ODNs 1668, 2006 and 2395 activated mTLR9 with a 4.9, 2.6 or 3.5-fold induction, respectively. After stimulation of HEKBlue h/mTLR9 + reporter cells, the proinflammatory cytokines IL-8 (70 ± 8/2907 ± 182 pg/ml) and IP-10 (22 ± 0.1/89 ± 8 pg/ml) were increased in CBA.

The proof of hTLR9 expression in several BCa cell lines revealed TLR9 to be a beneficial target for immunotherapies. ODN 2006 potently stimulates hTLR9 and, therefore, is a candidate for a cancer immunotherapy. ODN 1668 might be helpful to evaluate the therapy in a mouse BCa model. The specific secretion of proinflammatory cytokines in vitro suggests TLR9 to be a potential mediator of anti-tumour immune response. Funding: This project is funded by the European Union and the Europe- Objectives: Epigenetic regulators like class I histone deacetylases (HDAC1, 2, 3, 8) are frequently deregulated in urothelial cancers ( UC) and may thus represent promising targets for new therapy approaches. In this study, we characterized the cytotoxic effect of three class I HDAC targeting inhibitors (HDACi) with different isoenzyme specificity, namely romidepsin (HDAC1/2), entinostat (HDAC1/3) and RGFP966 (HDAC3). Since HDACi, as a mono-treatment, do not sufficiently induce apoptosis in UC cells ( UCC), but promote accumulation in the G2/M-phase, we also analysed the combination of romidepsin with the G2/M checkpoint inhibitor MK-1775 for synergistic action. Material and methods: The UCC VM-CUB1 and UMUC-3 were treated with HDACi for 24 h and 48 h. Cell cycle changes and apoptosis induction were analysed by flow cytometry. HDACi induced expression changes of cell cycle-and DNA damage response-proteins were evaluated by western blot. The Chou-Talalay method was used to assess synergism for the combination of romidepsin with MK-1775 in UCC and normal HBLAK cells. Results: Inhibition of HDAC1/2, but not of HDAC3 impeded transition of UCC into M phase. Likewise, HDACi targeting HDAC1 or HDAC2, but not HDAC3 induced DNA damage. At the same time these compounds impaired DNA damage response by downregulation of checkpoint control proteins like CHK1. Since HDAC1/2 inhibition also downregulated G2/M checkpoint regulators like CDK1, CDC25C, WEE1, AURKB and CCNB1, the WEE1 inhibitor MK-1775 could not overcome G2-arrest and did not synergize with romidepsin. Conclusion: Targeting HDAC1 and HDAC2, but not HDAC3 is the most promising approach for HDACi based therapy in UC. Since they induce DNA damage, we suggest their combination with DNA damage inhibitors. Background: In muscle-invasive bladder cancer ( MIBC) mTOR inhibition has proven to be less effective in previous clinical trials. Aim of this study was to evaluate hypotheses for the failure and to find a possible new therapeutic approach. Methods: The study comprised a tissue microarray of 103 patients (79 m/24f, median age 69y, 31 × pT2, 72x>pT2) who underwent radical cystectomy due to MIBC. Of 46 patients, corresponding normal urothelium of the bladder was included. Samples were immunohistochemically stained for mTOR, phosphorylated (p-)mTOR and 4E-BP1 as downstream effector. Results were determined histologically and correlated to clinical data and outcome. Results: MIBC tissue showed clearly higher mTOR (medians 184/140, p = 0.02), lower %mTOR (0.78/1.00, 0.0009) and higher 4E-BP1 (104/35, < 0.0001) than urothelium. T > 2 BC showed lower mTOR and p-mTOR (157/200, 0.032 and 104/135, 0.010), G > 2 BC showed higher 4E-BP1 (119/100, 0.048). P-mTOR correlated strongly positive with mTOR in MIBC as well as in normal urothelium (both < 0.0001, r 2 = 0.25 and 0.39). Only in MIBC downstream 4E-BP1 correlated positively with mTOR (p = 0.0011, r 2 = 0.11) and p-mTOR (0.007, 0.07). Survival analysis showed clear tendencies for worse outcome in case of lower mTOR, lower p-mTOR, higher %-mTOR and higher 4E-BP1, whereby overall survival was significantly shorter in case of lower p-mTOR (p < 0.05).

The activation of the mTOR system seems to be an event which decreases at a certain stage of BC progression and may be replaced by other oncologic mechanisms. Hence, these results may indicate the relevance of mTOR inhibition in early tumor stages. Introduction: Tumor endothelial cells ( TEC) are essential components of the tumor microenvironment ( TME). We isolated for the first time TEC from prostate cancer (PCa) patients to identify novel targets. Methods: Normal endothelial cells ( NEC) and TEC were isolated from 65 fresh prostatectomy specimens, selected by the endothelial cell ( EC) marker CD31 and surveyed for EC characteristics using Immunofluorescence ( IF) and FACS. Functional properties were analyzed by 3H-thymidine and scratch assays. To identify molecular differences between TEC and NEC, we performed bulk RNA-sequencing. For validation, immunohistochemistry ( IHC) was performed on human and murine samples, IF was used for cultured NEC/ TEC. Results: Compared to NEC, cultured TEC have an increased cell and nucleus area, more abundant discontinuous cell junctions and show increased migration and proliferation. Differential gene expression analyses revealed an upregulation of genes associated with tumor vasculature and cytokine signaling. Complementary, we confirmed an increased protein expression of transcriptionally upregulated genes, such as VDR and CXCL12 in cultured TECs. Increased expression of the novel prostate TEC markers PTGIR, PLAC9, CXCL12 and VDR was validated in an independent cohort of primary and metastatic PCa samples. For first in vivo validation of CXCL12 as a potentially actionable TEC marker, a subcutaneous xenograft mouse model of human PCa was used. Indeed, targeting CXCR4 by AMD3100 decreases vessel number and density in the TME when compared to solvent-exposed mice. Conclusion: We identified and validated novel prostate-specific TEC markers. In addition, in vivo validation suggest that blockade of the CXCL12/ CXCR4 interaction is a novel promising vasculature targeting therapeutic option. Ergebnisse: Zwei vielversprechende Derivate mit IC50s im niedrigen mikro-und nanomolaren Bereich wurden identifiziert. Eine Glukose-Reduktion im Medium führte zu erhöhter Zytotoxizität und eine simultane Behandlung mit einem GLUT1-Inhibitor zu antagonistischen Effekten, ein Indiz für eine konkurrierende Aufnahme mit Glukose und damit eine erfolgreiche Nutzung des Warburg-Effekts. Beide Derivate zeigten eine hohe zytotoxische Aktivität in PCa-Zellen mit unterschiedlichem Resistenzprofil. Dabei wurde die Wirkung vermittelt über einen Verlust des mitochondrialen Membranpotentials, eine Freisetzung von Cytochrom C und AIF in das Zytosol sowie eine Hochregulation von Caspase-9, Caspase-3 und gespaltenem PARP und somit einer Aktivierung der intrinsischen Apoptose. Frühe intrazelluläre Effekte umfassten eine gesteigerte ROS-Produktion und zytosolische Kalziumfreisetzung als Indikatoren für ER-Stress. Eine vielversprechende Aktivität konnte in einem 22Rv1-Xenograft-Maus-Modell beobachtet werden. Zusammenfassung: Glukose-konjugierte 1,4-Naphthochinone zeigen eine hohe in vitro und in vivo Effektivität und Selektivität in humanen PCa unter Nutzung des Warburg-Effekts.

Introduction & Objectives: A deeper characterization of the non-epithelial factors involved in prostate cancer became critical for the development of novel therapies. It has been stated that the tumor microenvironment ( TME) plays a central role in the prostate cancer progression and resistance to therapies. We recently showed that the overexpression of CDCP1 in the Pten-null background induces metastatic prostate cancer. We hypothesized that CDCP1+/Pten-null tumors could be associated with protumoral macrophages. Our objective is to establish a novel organoid exvivo model to study the interaction between tumor cells and the TME.

We performed immunohistochemistry ( IHC) analyses in metastatic CDCP1+/Pten-null compared to non-metastatic Pten-null mouse prostate tumors to assess their TME. We set up an ex-vivo organoid model from the tumors of CDCP1+/Pten-null and Pten-null mice to study the interaction between macrophages and tumor cells. Conditioned media was collected from organoids and used to stimulate murine bone marrow derived macrophages (BMDMs). Flow cytometry analyses for CD206 were performed. Results: The IHC analyses performed on CDCP1+/Pten-null tumors reported a higher level of macrophages when compared to Pten-null tumors. We observed an enrichment of CD206+ pro-tumoral macrophages among BMDMs harvested with conditioned media from our established CDCP1+/ Pten-null organoid model. Conclusions: Our results show that CDCP1+/Pten-null advanced prostate tumors are infiltrated by pro-tumoral macrophages associated with prostate cancer progression. These results were confirmed through an ex-vivo organoid model from mice prostate tumors, where the interactions between tumor cells and the TME can be further investigated.

Prostate cancer-specific transcripts isolated from urinary exosomes show diagnostic potential in patients scheduled for prostate biopsy K. Erdmann 1*,2,3 , A. Borkowetz 2,3 , A. Lohse-Fischer 2 , C. Thomas 1, 2 Objective: The diagnostic potential of selected messenger RNAs (mRNAs) and long non-coding RNAs (lncRNAs) in comparison to serum PSA levels was explored by using urinary exosomes from patients scheduled for prostate biopsy. Materials and methods: After digital-rectal examination, urine samples from 88 patients with suspected prostate cancer (PCa) were collected prebiopsy. Urinary exosomes were obtained by centrifugation following precipitation. After RNA isolation, multiplexed reverse transcription followed by a preamplification step was conducted. Twenty PCa-associated mRNAs and lncRNAs as well as KLK2 as reference were quantified by qPCR and then evaluated for their diagnostic ability by receiver operating characteristic ( ROC) curve analyses and determination of the area under the curve ( AUC) value. Results: PCa was detected in 42 patients (47.8%) by prostate biopsy. Using 4 ng/ml as cutoff value, serum PSA showed an insufficient diagnostic ability ( AUC = 0.569, p = 0.267) in the present cohort with a sensitivity, speci-ficity and accuracy of 81.0%, 15.2% and 46.6%, respectively. ROC curve analyses revealed a potential for non-invasive urine-based PCa detection for AMACR, DLX1, ERG, HOXC6, PCA3, PCAT14 and PSGR with AUC values ranging from 0.632 to 0.756 (p < 0.05). The combination of the five best performing transcript markers ( AMACR, DLX1, ERG, PCA3, PCAT14) resulted in an AUC of 0.834 (p < 0.001) as well as a sensitivity, specificity and accuracy of 76.2%, 78.3% and 77.3%, respectively, and thus, surpassed the diagnostic power of serum PSA and individual markers. Conclusion: These findings highlight the potential of urinary exosomal mRNAs and lncRNAs as molecular markers with high clinical performance. Overall, these results need to be validated in an independent patient cohort.

3K05.5 Therapeutic resistance of prostate cancer cells in vitro to second-and third-generation antiandrogens depends on androgen receptor splicing, is regulated by H3K27me3, and can be affected by modifying the lysine demethylase UTX Background: Androgen deprivation therapy ( ADT) is the foundation of prostate cancer ( PCA) treatment in advanced stages. Therapeutic resistance is an emerging problem and the sequence of drugs to be used for optimal outcome remains unclear. Here, we assessed the role of the trimethylated lysine 27 residue of histone 3 (H3K27me3) in therapeutic resistance. Methods: VCaP and LNCaP cells were cultivated with increasing concentrations of different anti-androgens. Resistance was verified using imagebased cytometry. Global H3K27me3 levels were assessed and their impact was measured by RNA sequencing (RNAseq) as well as by qRT-PCR and Western blot. Its regulators were manipulated using siRNA knockdown and small molecule inhibitors. We analyzed Androgen Receptor ( AR) splicing by Western blot and qRT-PCR. Chromatin immunoprecipitation ( ChIP) of H3K27me3 was performed to identify a possible direct impact on AR expression. The public Stand Up To Cancer (SU2C) data set was used to validate our findings in a large patient cohort. Results: Significant decrease of H3K27me3 levels occurred in cells resistant to abiraterone but not to other drugs. RNAseq confirmed several H3K27me3 dependent gene sets to be differentially regulated. Knockdown as well as overexpression of H3K27me3 demethylase UTX and treatment with its inhibitor GSK-J4 lead to changes both in AR levels and in the expression of its constitutively active variant AR-V7. Treatment with GSK-J4 affected cellular proliferation. ChIP assay showed different binding patterns of H3K27me3 in resistant and wildtype cells. The SU2C dataset confirmed UTX amplification to be correlated with abiraterone resistance. Conclusions: H3K27me3 could serve as a predictive biomarker as well as a therapeutic target in castration resistant PCA. Background: The ExoDx Prostate test ( EPI) is a non-invasive urine exosomal RNA test for risk assessment prior to prostate biopsy and has been available in the US as a laboratory developed test ( LDT) for several years. Here we present the clinical validation of an CE-IVD version of the EPI test ( EPI CE), developed as a distributed test for clinical laboratories, in compliance with in-vitro diagnostic devices ( IVD) requirements and required to make the test available to patients and clinicians in Europe. Methods: Subjects, ≥50 years with PSA 2-10 ng/mL, scheduled for systematic prostate biopsy due to suspicion of prostate cancer were enrolled in the study after informed consent at 11 sites in EU and US. First catch urine < 50 mL was collected without prior digital rectal examination ( DRE) analyzed at Exosome Diagnostics according to the Instructions For Use ( IFU) of the EPI test. EPI test score performance around the 15.6 EPI cutpoint was compared to the previously published performance characteristics of the EPI LDT assay. Results: A total of N = 109 patients, with median ( IQR) age of 66 (62-71) years, median PSA 5.88 (4.8-7.5 ) ng/mL, 80% Caucasian, and 54% positive biopsy rate (36% Gleason Grade ( GG)1, 34% GG2, and 30%≥GG3) was included. Using the EPI score cut-point 15.6 would avoid 34% (95% CI: 23-46%) of unnecessary prostate biopsies and 25% (95% CI: 17-34%) of all biopsies, with negative predictive value ( NPV) 89% (95% CI: 71-98%) and missing 8% (95% CI: 2-21%) of ≥GG2 PCa.

The EPI CE is a non-invasive urine exosomal RNA CE-IVD test validated for predicting high grade prostate cancer(≥GG2) in patients with suspected prostate cancer.The clinical performance of EPI CE is equivalent to previously published results of the US CLIA laboratory developed test. Background: 68 Ga-PSMA CLI is a novel imaging modality for the assessment of resection margins in radical prostatectomy ( RP). 18 F has a lower light yield and minimum detection limit ( MDL), but a significantly longer half-life. Does a flexible scintillator improve the imaging of 18 F by using ARI? Methods: A total of 10 mice bearing subcutaneous RM1-PGLS tumors ( PC) were examined. First, CLI and ARI were performed in the LightPath System. Afterwards, repeat imaging of PC was performed ex vivo. Due to strong renal PSMA expression, imaging of the kidneys was performed for correlation to activity levels. Median time to imaging of PC was 5.7 h (4.7; 7.1). Imaging was performed with acquisition times of 300 and 120 s. Based on the PET data, respective tracer concentration was decay corrected to the time of CLI and ARI. Activity levels at imaging are stated as kBq/mL. Results: A median of 4.3 MBq (4.1; 4.7 MBq) 68 Ga and 2.6 MBq (2.3; 2.9 MBq) of 18 F were injected into 5 mice each. At time of CLI, median activity levels of 68 Ga was 0.9 (0.6; 1.3) in PC and 8.7 (7.3; 10.5) in kidneys. Median activity levels of 18 F was 9.02 (8.2; 10.2) in PC and 106.7 (95; 121.8) in kidneys. For both 68 Ga and 18 F, tracer activity showed a significant Pearson correlation for contrast-to-noise ratio (68Ga: r = 0.55, p < 0.001 and 18F: r = 0.68, p < 0.001). In CLI, MDL for 68 Ga was 1.4 and 73.8 for 18 F. ARI significantly improved the representation of low activity levels for 18 F (p < 0.001). The lowest imaged activity present was 7.3. Conclusion: Using ARI, it is possible to detect low signals that are not visible by CLI. AR significantly improves the use of 18 F, lowering the MDL to levels comparable, but still higher than 68Ga. Intraoperatively, this may provide an advantage of 18 F over 68 Ga due to a longer half-life.

High fibroblast-activation-protein ( FAP) expression in castration resistant prostate cancer supports the use of FAPI-molecular theranostics Several different mutations of the AR are already known, nevertheless, we identified a novel truncated AR, called AR/ TC. It was possible to identify a hypothetical miR/ DNA binding site. Method: We isolated the cfRNA from blood (n = 40) and performed SNP PCR and qRT-PCR for the identification of the novel truncated AR. We analyzed our collective on the presences and distribution of heterozygotes vs homozygotes (n = 45). Therefore, we isolated the cfDNA from blood samples and established a SNP PCR. Since the hypothesized truncation of the AR is only present on RNA level, we isolated the RNA form blood and performed qRT-PCR. Results: The distribution of heterozygotes to homozygotes was 50%. Even in our group of castration-resistant PCa there was a distribution of 50%. Furthermore, the novel truncated AR was present in all patients in the group of castration-resistance. Significant differences were detectable by comparing the group of castration-resistance patients with patients who were diagnosed with high risk or intermediate prostate cancer. Conclusion: It seems to be of great importance to screen all patients regarding the HSD3B1 mutation. According to the identification of a novel truncated AR further experiments needed. Whether the newly identified AR/ TC is responsible for castration-resistance or whether the ADT increases the miR and therefore leads to an overproduction of the AR/ TC needs to be proven in detail.

Glutamine deprivation as a potential therapy in docetaxel resistant prostate cancer Introduction: Docetaxel is one therapy option for metastatic prostate cancer (PCa). Although initial remission, acquired docetaxel-resistance is inevitable. The mechanisms behind docetaxel-resistance are not clarified yet; however, a cancer stem cell phenotype with altered metabolic features is associated with docetaxel-resistance. Metabolic analysis revealed that docetaxel-resistant ( DR) cell lines obtain most ATP production by oxidative phosphorylation, powered substantially by glutamine (Gln). Likewise, Gln is indispensable in redox homeostasis. Thus, we investigated the influence of Gln deprivation on PCa cell models and determined its therapeutic value in DR cells. Methods: Docetaxel sensitive and DR PC3 and DU145 cells were screened regarding their Gln dependency. Proliferation and migration were examined using an InCucyte live-cell imager. siRNA transfection was used for Glutaminase ( GLS) 1/2 knock-down. Clonogenic assays were carried out as published by Franken et al. 2006 . Reactive oxygen species ( ROS) induction was determined using the ROS indicator CM-H 2 DCFDA. Results: In general, lower Gln concentrations significantly decreased cell proliferation, clonogenic potential, and migratory behaviour of the selected PCa cell models. Especially DR cell sub-lines were susceptible to Gln deprivation. GLS 1/2 knock-down experiments revealed that observed effects are mainly mediated by GLS1. In addition, only DU145 DR exhibited in formation of ROS. Conclusion: Gln availability highly influences PCa cell proliferation, clonogenic potential, and migration. These findings highlight the potential of blocking the Gln metabolism as a therapeutic strategy to target DR cells and thereby delay accelerated tumor progression and metastatic spread. Introduction: Androgen-regulated gene expression is a highly coordinated dynamic process mediated by androgen receptor ( AR) ligand binding by specific AR protein-protein interactions. The constitutively active androgen receptor splice variant 7 ( AR-V7) lacking the ligand-binding domain has been implicated in the pathogenesis of castration-resistant prostate cancer and in mediating resistance to newer drugs that target the androgen axis. The purpose of the present project is to investigate the kinetics of the androgen receptor dimerization with its androgen receptor splice variant 7. Methods: NanoLuc Binary Technology (NanoBiT) is a system based on two small subunits, Large BiT and Small BiT, of the very bright NanoLuc luciferase, allowing to detect protein interactions using structural complementation. HEK-293 cells were transfected with generated AR-FL and AR-V7 NanoBiT constructs and luminescence readings were obtained with a microplate reader. To investigate co-localization, cells were transfected with the indicated plasmids on Poly-D-Lysine-coated coverslips. Confocal images were obtained by using a Leica SP5 II system. Results: We found that AR-V7 homodimerizes in a ligand independent manner with nuclear co-localization. Homodimerization of AR-V7 cannot be androgen-stimulated nor inhibit with enzalutamide. As expected, AR-FL homodimirizes in the cytoplasm upon dehydrotestosterone ( DHT) stimulation and translocates into the nucleus. AR-FL-AR-V7 heterodimerization occurs in the nucleus only upon DHT stimulation. Conclusions: Our results elucidate important steps in the mechanism by which AR-V7 and AR-FL heterodimers mediate gene regulation and provide a pivotal pathway for rational drug design for the effective treatment of advanced prostate cancer. Hintergrund: Die unterschiedlich hohe Insulinrezeptor( IR)-Expression sowie das veränderte Verhältnis der IR-substrat( IRS)-isoformen im Prostatakarzinom (PCa) legen eine Beteiligung an der Tumorentstehung und Progression durch Veränderungen im down-stream signaling nahe. In dieser Studie wurde normales und PCa Gewebe auf IR-und IGFR1-Expression, IRS1, IRS2 sowie deren Einfluss auf den proonkogenen PI3K-AKT Signalweg untersucht. Material und Methoden: PCa und normales Prostata-Gewebe aus Operationspräparaten von Patienten mit nmPCa (n = 53) und benigner ( BEN) Prostatahyperplasie (n = 26) wurden mittels Tissue Microarray Technik aufgearbeitet und immunhistochemisch die Proteinexpressionen des IRß und IGFR1 sowie IRS1 und IRS2 denen von Akt gegenübergestellt. Mittels multivariater Analysen wurde der Einfluss des IRß und IGFR1 auf IRS1, IRS2 und Akt untersucht. Ergebnisse: IRß und IGFR1 exprimieren beide im PC höher als im BEN Gewebe. IRS1 und IRS2 korrelieren beide mit der Akt-Expression. Sowohl im BEN als auch PCa ist multivariat der Einfluss von IRß sowohl auf IRS1 und IRS2 als auch auf Akt dabei erhalten und der Einfluss von IGFR1 nicht Einleitung: Das inzidentelle Prostatakarzinom (iPCA) wird entweder via radikaler Zystektomie oder TUR-P diagnostiziert. Ziel dieser Studie war es, Unterschiede in miRNA-Profilen zu bestimmen. Material und Methoden: Wir untersuchten 86 miRNAs (miR) in 25 Patienten davon 5 Patienten, bei denen ein iPCa via radikaler Zystektomie entdeckt wurde (iPCa-Cyst) und 10 Patienten, bei denen ein iPCA via TUR-P gefunden wurde (iPCa-TUR). Als Kontrollgruppe zogen wir 10 Patienten heran, die sich einer radikalen Prostatektomie ( RPE) wegen eines stanzbioptisch gesicherteten Prostatakarzinoms unterzogen. Das Pca-Gewebe wurde makrodisseziert, die miRNA mit dem miScript PCR Array Prostate Cancer (Qiagen) quantifiziert. Ergebnisse: Insgesamt wurden 13 miR identifiziert, die bei iPCa-Cyst überexprimiert sind, nicht aber bei iPCA-TUR. Das Expressionsniveau in der Hochrisikogruppe wurde als Kontrolle verwendet. Die Niedrigrisikogruppe diente als Normalisierungskohorte. Das Expressionsniveau der beiden miR-92a-3p und miR-223-3p war signifikant erhöht bei iPCa-Cyst gegenüber sowohl iPCa-TUR als auch gegenüber dem der Kontrolle ( RPE). Die miR-7-5p, miR-142-3p und miR-374a-5p zeigten einen signifikanten Unterschied gegenüber iPCa-TUR und nicht jedoch gegenüber der Kontrolle ( RPE). Zusätzlich fanden wir acht weitere miRs, die bei iPCa-Cyst signifikant überexprimiert sind, die allerdings auch mit einem Urothelkarzinom assoziiert sein können: miR-21-5p, miR-27b-3p, miR-29b-3p, miR-32-5p, miR-101-3p, miR-142-5p, miR-150-5p und miR-155-5p. Schlussfolgerung: Es fanden sich unterschiedliche Expressionsmuster für miR im iPCA je nach Detektionsmethode TUR-P versus radikaler Zystektomie. Weitere Studien werden notwendig sein, um ihre Rolle als Tumorsuppressoren oder Onkogene zu bestimmen.

3K05.14 Non-virale Etablierung primärer Prostatalinien als uroonkologisches Forschungsobjekt präklinischer Stadien Assays zum Migration-und Invasionspotential sowie in-vivo-Studien zum Tumorbildungspotential. Ergebnisse: Von drei aus vier ausgewählten RPE-Patienten konnten immortalisierte Linien abgeleitet und dauerhaft kultiviert werden. Trotz fehlender PCa-Marker sind einige der Linien in der Lage sowohl in-vitro in 3D-Matrices als auch in-vivo zu proliferieren und Tumore auszubilden. Die tumorbildenden Linien zeigen in beiden Fällen ein heterogenes Bild aus p40 + Basalzellen und p40 -Zellen, die im Tumor das gestreifte Plattenepithel der Prostata abbilden. Schlussfolgerung: Wir präsentieren hier die erste Immortalisierung humaner Primärkulturen durch Einsatz der SBT. Auch ohne die Expression der klassischen Prostatamarker sind die isolierten Linien in der Lage, in Kultur dauerhaft zu proliferieren und prostata-ähnliche Strukturen in Mäusen zu entwickeln. Der Einsatz von RNA-Sequenzierung und in-vitro-Differenzierung wird das weitreichende Potenzial dieser Zelllinien für Grundlagenforschung und pharmazeutische Entwicklung zeigen. Einleitung: In der vorliegenden Studie wurde der Einfluss von Shikonin ( SHI) aus der Traditionellen Chinesischen Medizin auf das Wachstumsverhalten Docetaxel ( DX)-resistenter Prostatakarzinom (PCa)-Zellen untersucht. Material und Methoden: DX-resistente PCa-Zellen, PC3, DU145, LNCaP und 22Rv1, wurden für 12-72 h mit SHI [0,1-1,5 µM] behandelt. Therapiesensitive (parentale) und SHI-unbehandelte PCa-Zellen dienten als Kontrollen. Evaluiert wurden das Tumorzellwachstum, die Proliferation, die Zellzyklusphasen, apoptotische, nekrotische und nekroptotische Ereignisse, der Glutathion-Gehalt sowie die metabolische Aktivität. Weiterhin wurde die Expression der entsprechenden regulatorischen Proteine analysiert. Ergebnisse: Die Behandlung mit SHI resultierte zeit-und dosisabhängig in einer signifikanten Inhibition des Wachstums und der Proliferation parentaler und DX-resistenter PCa-Zellen. Die Wachstumshemmung war mit einem Zellzyklusarrest in der G2/M-oder S-Phase und Veränderungen zellzyklusregulierender Proteine assoziiert. Die SHI-Gabe führte weiterhin zum Zelltod parentaler und DX-resistenter PCa-Zellen. In allen parentalen und DX-resistenten PCa-Zellen vermochte SHI dabei signifikant die Nekroptose zu induzieren. Diese ging mit einer Hemmung von Caspase-8 und erhöhter Aktivität von pRIP1 und pRIP3 einher. Parallel rief SHI eine Reduktion des Glutathion-Gehalts hervor, kennzeichnend für einen Anstieg reaktiver Sauerstoffspezies. Die metabolische Aktivität der PCa-Zellen wurde durch die SHI-Behandlung hingegen nicht beeinflusst. Schlussfolgerungen: Aufgrund unserer Daten postulieren wir, dass SHI ein vielversprechendes Additivum in der Therapie fortgeschrittenerauch Therapie-resistenter -PCa darstellen könnte. Weiterführende Studien sollen dies verifizieren. Introduction: Immune evasion is one of the hallmarks of cancer and one of the most important strategies for tumor survival. One mediator, which can induce immune evasion and therefore tumor survival, are extracellular vesicles (EVs). The question was if EVs derived from tumor cells with different TP53 status can have an impact on macrophage activation and therefore on phagocytosis of tumor cells. Materials and methods: EVs isolated from prostate cancers (PC3 and LN-Cap), bladder carcinoma ( HTB-9) and seminoma (TCam2) were investigated. These cell lines differ in their TP53 status. Impact of EVs on phagocytosis was analyzed by an antibody dependent cellular phagocytosis ( ADCP). EVs were checked for the expression of PD-L1 and CD47. In order to understand the role of PD-L1 and CD47 in this mechanism, EVs were pretreated with Anti-PD-L1 and Anti-CD47 and further investigated in an ADCP. To proof the principle CRISPR-KO of PD-L1 and RAB27A in PC3 cells were established and isolated EVs analyzed via an ADCP.

Results: EVs from cells with different TP53 status can have an impact on macrophage activation and therefore on phagocytosis of tumor cells. EVs derived from TP53 null cell line cause a significant decrease of phagocytosis, compared to TP53 wild type and to the control. In the case of blockage of PD-L1 on PC3 derived EVs cause significant increase on phagocytosis performed by macrophages. Furthermore, the blockage of PD-L1 and Rab27A in PC3 cells cause a significant increase in macrophage activation. Conclusion: Therefore it could be concluded that EVs derived from tumor cells with different TP53 status can have an impact on macrophage activation in the presence of exosomal PD-L1 and therefore on the therapy response 98 (1990-1994) auf 335 (2015-2019) . 21 % der Tumore waren benigne, bei Frauen häufiger als bei Männern. (30 % vs. 16,6 %, p < 0,001). Der Anteil maligner Tumore stieg mit der Tumorgröße von 52 %(0,1-1 cm) auf 81 % (3,1-4 cm, p < 0,001) . Klarzellige (67,4 %), papilläre (15,2 %) und chromophobe (5,3 %) Nierenzellkarzinome stellten die häufigsten malignen, Onkozytome (61,3 %) und Angiomylipome (19,6 %) die häufigsten benignen Tumore dar. pT3 Tumore (7 %) waren mit höherer Tumorgröße assoziiert (p = 0,018). 27 (2,6 %) Patienten hatten synchrone (n = 12) oder metachrone Metastasen (n = 15). Der Anteil an pT3-Tumoren war bei metastasierten Patienten signifikant höher (22, 2 % vs. 6, 4 %, p = 0, 006) . Das Gesamtüberleben (Nachbeobachtung: 64 Monate (1-278)) unterschied sich zwischen benignen und malignen Tumoren nicht, und war in den malignen Tumoren bei Frauen besser als Männer (p = 0,037 Niere 367 14,2 (8,7) 55 48,9 (13,4) 21 43,9 (7,6) Tab . Einleitung: Bis heute liegen keine prädiktiven Biomarker für die Therapie metastasierter Nierenzellkarzinome (mNZK) vor. Im Rahmen der prospektiven multizentrischen MARC-2 Studie wurden potenzielle Biomarker aus Blutproben für das Therapieansprechen auf Everolimus in der Zweitlinie untersucht. Material und Methoden: Blutproben von 54 Patienten wurden vor Beginn der Therapie und nach 15 Tagen asserviert. 55 Angiogenese-assoziierte Proteine wurden mit Antikörper-Arrays analysiert und ausgewählte Proteine sowie metabolische Moleküle ( LDH, SOD1, ENO2) mittels ELISA quantifiziert. Polymorphismen im mTOR Gen wurden mittels Pyrosequenzierung untersucht.

Ergebnisse: Thrombospondin-2 ( TSP-2) vor Therapiebeginn war bei Langansprechern signifikant niedriger und für ein längeres progressionsfreies Überleben prädiktiv ( PFS, ≤665 parts per billion, 6, 9 vs. 1, 8 Monate, p = 0, 005 ). An Tag 15 war eine erhöhte Serum-LDH (>27,14 nmol/l) mit längerem PFS (3, 8 vs. 2, 2 Monate, p = 0, 013) und Gesamtüberleben ( OS, 31,0 vs. 14,0 Monate, p < 0,001) verbunden. In der multiplen Cox Regression war das baseline TSP-2 ein stärkerer unabhängiger Prädiktor für das PFS ( HR 0,22, p = 0,001) als klinische Patientencharakteristika, wie auch die LDH an Tag 15 für das OS ( HR 0, 15, p < 0, 001 Ergebnisse: Nur für PD-L1 zeigte sich unabhängig von der Lokalisation eine höhere Proteinexpression im Metastasen-vs. korrespondierendem Primärtumorgewebe (p < 0,01). BTLA war am höchsten in Lokalrezidiven (n = 12), Lymphknoten (n = 23) und der Nebenniere (n = 14) exprimiert. In Lunge (n = 37) und Knochen (n = 24) zeigte sich eine signifikant niedrigere Expression. Eine hohe PD-L1 Expression im Primärtumor war mit einem schlechteren Überleben ( CSS HR 6, 3, 95 % CI: 2, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] 3, p = 0, 004 & OS HR 5, 6, 95 % CI: 2, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] 3, p < 0, 001) Background: Immune checkpoint blockade combining aPD-1 and aCT-LA-4 ( IO+IO) vs. aPD-1 in combination with VEGFR-targeting tyrosine-kinase inhibitors ( IO+TKI) are considered equivalent first line therapies for metastatic renal cell carcinoma (mRCC). Unfortunately, there is sparse data on direct comparison of these therapies and precise biomarkers for outcome prediction have yet to be defined. Methods: 100 mRCC from 6 different German tertiary referral centers receiving either first-line IO+IO (nivolumab + ipililumab, n = 64) or IO+TKI Der Urologe · Suppl 1 · 2021 S81 (pembrolizumab + axinitb, n = 36) were included in this retrospective study by reviewing all relevant clinical and therapy outcome parameters. Results: At comparable baseline patient characteristics and a median follow-up of 9 months (range 0-37 months), patients receiving IO+IO combination experienced significantly less adverse events (AEs, 64% vs. 86%, p = 0.021). However, overall survival (mean 26.9 vs. 20.2 months) and progression-free survival (median 11.0 months for both groups) did not differ between IO+IO vs. IO+TKI patients. Of note, patients with a decrease of CRP ( CRP ratio < 1) during the first 3 months after treatment initiation showed better therapy responses with regard to target lesion change (-31.1% vs. +5.6%, p = 0.0003), irrespective of the applied IO combination, and favorable outcome. Conclusion: In one of the largest German multicenter cohorts comparing IO+IO vs. IO+TKI in mRCC to date, we highlight the potential role of early CRP dynamics to predict oncological outcomes, which were comparable between the two groups despite different AE profiles. Since CRP is collected in many hospitals as a standard laboratory parameter, early CRP dynamics could be an interesting and easy-to-implement predictive biomarker for therapy success.

Final results and response pattern of the randomized phase II trial comparing switch-maintenance from TKI to nivolumab in metastatic renal cell carcinoma (mRCC) patients ( NIVOSWITCH) Background: Combinations of tyrosine kinase inhibitors ( TKI) and checkpoint inhibitors ( CPI) are considered standard options in mRCC patients (pts.). Our study investigated a maintenance switch approach in 1st line mRCC. Methods: Pts. with measurable clear cell mRCC, ECOG 0-2, adequate organ function and partial remission or stable disease to TKI therapy were eligible. 49 patients were randomized to early study termination between December 2016 and August 2018. After 12 weeks, 1:1 randomization to TKI continuation (24 pts.) or nivolumab ( NIVO; 25 pts.; 240 or 480 mg IV q2-4wk) was performed. With MSKCC risk, type of TKI (sunitinib, pazopanib) and response as strata. Objective response rate ( ORR) was assessed according to RECIST 1.1. KM/log-Rank analyses were used for survival analyses. Results: Median age was 65 years (range 35-79), 82% were male and 4% had ECOG PS 2. With metastases predominantly in lung (47%), lymph nodes (27%) and liver (24%). 55% received sunitinib. ORR for NIVO vs. TKI differed when assessed from start of induction therapy (64 vs. 70%, P = 0.76) or from randomization (16 vs. 48%; P = 0.03). Accordingly, progression free survival ( PFS) from randomization was 3.0 vs. 11.9 mo. ) in favor for TKI continuation. With a 2-year OS of 64% for NIVO vs. 66% for TKI ; P = 0.82). All grades adverse events ( AE) for NIVO vs. TKI occurred in 96% vs. 100%, grade 3-5: 48% vs. 71% and serious AE ( SAE): 40% and 46%, respectively. Conclusion: Continuation of TKI is more efficacious than early switch to NIVO. The major limitation of our trial is the premature closure and its limited sample size. Authoring Group Name: IAG-N of the German Cancer Society Sponsor, funding source: AIO-Studien-gGmbH, financial support BMS 3K06.14 Nephrotoxizität unter Immuncheckpoint-Inhibitor-Therapie: eine Arzneimittelüberwachungsstudie Einleitung: Die Immuncheckpoint-Inhibitor ( ICI) Therapie weist beeindruckende klinische Ergebnisse in einer Vielzahl von Krebserkrankungen auf. Jedoch kann es, häufig aufgrund Autoimmunsyndromen, zu unerwünschten Arzneimittelwirkungen ( UAW) kommen. Ziel der Studie war es, eine Assoziation zwischen ICI Therapie und Nephrotoxizität mithilfe einer Arzneimittelüberwachungs-Datenbank zu untersuchen. Material und Methoden: VigiBase, die Arzneimittelüberwachungs-Datenbank der WHO, wurde analysiert, um renale UAW (rUAW; Nephritis, Nephropathie, vaskuläre Störungen), die unter laufender ICI Therapie auftraten, zu filtern. Wir führten eine Disproportionalitätsanalyse durch, um zu untersuchen, ob rUAW in anderer Häufigkeit -verglichen mit der gesamten Datenbank -unter ICI Therapie angegeben wurden. Hierzu wurde eine empirische Bayes Signifikanz-Screeningmethode und eine reporting odds ratio ( ROR) zur Definition der Effektgröße angegeben. Ergebnisse: Unter 2341 rUAW für alle untersuchten ICI Medikamente zeigte sich lediglich für die Nephritis ein Disproportionalitätssignal ( ROR 3, 67, 95 % CI: 3, 04) . Untersucht man die Medikamente separat, weisen Pembrolizumab, Nivolumab und Kombination aus Ipilimumab+Nivolumab signifikant höhere ROR für Nephritis auf als die anderen ICI Medikamente ( ROR 4, 54, 95 % CI: 3, 4; ROR 3, 94, 95 % CI: 3, 56; ROR 3, 59, 95 % CI: 2, 76; respektive 3K06.16 Patient-reported outcomes ( PRO) of patients (pts) with advanced renal cell carcinoma (aRCC) treated with first-line (1L) nivolumab (N) plus cabozantinib (C) versus sunitinib (S): the CheckMate ( CM) 9ER trial Background: In the phase 3, open-label CM 9ER trial (NCT03141177), aRCC pts were randomized 1:1 to N 240 mg IV Q2 W + C 40 mg PO QD (N+C; n = 323) or S 50 mg PO (4 weeks of 6-week cycles; n = 328) for 1L treatment until disease progression/unacceptable toxicity. N+C met primary and secondary efficacy endpoints by significantly improving progression-free survival, overall survival ( OS), and objective response rate vs S. We present in-depth health-related quality of life ( HRQoL) PRO results. Methods: PROs in all randomized pts were an exploratory endpoint assessed using FKSI-19 and EQ-5D-3L instruments at baseline, on-treatment and follow-up visits. Changes from baseline were assessed using mixedmodel repeated measures. Time to confirmed deterioration ( TCD) was calculated from Kaplan-Meier estimates and Cox proportional hazards models.

Results: Median follow-up for OS was 18.1 months. PRO completion rates were ≥80% at all on-treatment assessments (≥10 pts) through week 91 in both arms. The overall least squares mean difference in change from baseline favored N+C vs S in FKSI-19 (all domains) and in EQ-5D-3L. Pts treated with N+C experienced less treatment burden, with improved TCD across most measurements vs S, including FKSI-19 (in all domains except treatment side effects), and EQ-5D-3L visual analog scale scores. Conclusions: Pts reported statistically significant HRQoL benefits with N+C vs S. N+C treatment significantly reduced the risk of deterioration in HRQoL scores. These results suggest that the superior efficacy of N+C vs S comes with the additional benefit of improved HRQoL. (Reused with permission from ASCO-GU 2021, Abstract 285, Cella D et al.) 3K06.17 The natural history of sarcomatoid renal-cell carcinoma-a stage-by-stage analysis Introduction & objectives: Sarcomatoid differentiation in renal cell carcinoma imply aggressive behavior and often metastatic disease at the time of the diagnosis. We aim to evaluate the impact of the sarcomatoid differentiation on the overall survival ( OS) using the National Cancer Database ( NCDB). Material and methods: We identified patients diagnosed with sRCC using the NCDB for the period 2010-2015. We employed Kaplan-Meier curves and multivariable Cox proportional hazards regression models to examine the impact of sarcomatoid differentiation on OS. Results: In total, 8582 patients with renal cancer were found to have sarcomatoid differentiation at the time of surgery. The median OS was 8.3 months ( IQR 3.3, 22.7 months) . Compared to patients who did not undergo surgery, OS was significantly longer in patients undergoing partial or total nephrectomy across all stages. This result remained consistent on multivariable Cox proportional hazards regression adjusting for patient and tumor characteristics (Surgery: Hazard ratio 0.61 95%Confidence interval 0.43-0.88, p = 0.008). Conclusion: In our cohort of patients diagnosed with sRCC, nephrectomy followed by systemic therapy was associated with favorable OS across all stages. This study supports the notion surgical therapy provides a survival benefit in patients with sRCC. Aim: A major breakthrough in cell culture technologies facilitates drug response analyses in 3D organoid systems when compared to previous standard 2D cultures thus mimicking the 3D situation in tissues. Materials: Organoids were established from upper tract urothelial carcinoma ( UTUC) and bladder cancer ( BC). For cytotoxicity testing [cis-platin ( CIS; 1-30 µM), venetoclax ( VTX; 0.6-10 µM), S63845 (S63; 0.6-10 µM)] were used over 24, 48 and 72 h of incubation. Cell viability was determined GloMax and 2D/3D-specific chemistry. Untreated cells or solvent only samples ( DMSO) served as controls. Normal urothelial cells and bladder cancer lines RT4 and HT1197 were included. Data obtained were processed by Two-way ANOVA statistical tests. Results: Normal urothelial cells were sensitive to CIS (p < 0.5, IC50 d3 3.5 µM), VTX (p < 0.5, IC50 d3 0.6 µM), and S63 (p < 0.5, IC50 d2 2.1 µM) dose/ time dependently. RT4 ( CIS: p < 0.5, IC50 d3 12.1 µM; VTX: p < 0.5, IC50 d3 12.8 µM) and HT1197 ( CIS: p < 0.5, IC50 d3 12 µM); VTX: p < 0.5, IC50 d3 ∼ 10.7 µM; S63; p < 0.5, IC50 d3 ∼ 11.5 µM) were less sensitive. UTUC organoids were sensitive to CIS (p < 0.5, IC50 d3 15.5 µM) and S63 (p < 0.5, IC50 d3 ∼ 10 µM) dose/time dependently. The BC organoids were sensitive to CIS (p < 0.5, IC50 d3 2 µM) and VTX (p < 0.5, IC50 d3 9.3 µM). Preliminary data suggest that VTX yielded with UTUCO an IC50 d3 of about 10 µM. Introduction: Organoids consisting of several different cell types better mimic solid tumors in terms of 3D structure, proliferation, cell-cell interaction and ECM deposition. We developed five organoids aiming to find models for bladder cancer (BCa) research and anti-cancer drug development. Material and methods: We generated organoids from RT4, RT112, T24 and CAL29 cell lines or non-malignant HBLAK with human bladder fibroblasts and bladder smooth muscle cells in ultra-low attachment 96-well plates. Paraffin sections were stained for cytokeratins (panCK, CK7, CK13, CK20), Ki67, and fibronectin. Immunoreactivity ( IR) was analyzed using ImageJ. Results: After 96 h, the organoids were 650-1000 µm in diameter mimicking the structure of an inverse bladder wall with outside urothelial cells and a core of supportive cells. HBLAK were smaller than BCa organoids, which formed lumina and were negatively size correlated with cell line grading. In line with the progenitor status of HBLAK panCK, CK7, CK13 and CK20-IR was significant lower. CK-IR was higher in RT4 and RT112 than in T24. RT112 showed a stratified layering: CK7/CK13-IR in basal and intermediate cells; CK20-IR in superficial cells. The proliferation rate was 7-8% in HBLAK and 2% in the low-grade RT4 compared to 35-50% in higher grade BCa. Fibronectin-IR was highest in G3/G4 organoids. Conclusion: Bladder organoids can be generated in large numbers using the ULA plate method. They form a bladder-like structure and reproduce in-vivo features as stratified urothelium and fibronectin deposition. Thus, they can be useful tools in cancer biology research and anti-cancer drug evaluation.

genes, particularly FANCD2, NHEJ1, PARP2 and POLE2 was altered by the combination which may explain its synergistic action. Conclusions: Synergistic treatment with PLX51107 and Olaparib strongly reduced viability of cisplatin-resistant LTTs but spared normal cells. Thus, this combination could be a promising therapeutic option for UC, also in the second line after chemotherapy.

Cisplatin-resistant urothelial carcinoma cells are dependent on upregulation of chromatin regulators HDAC9 and HAT1

Objective: Aberrant gene expression due to alterations in histone acetylation mediated by histone acetyl transferases (HATs) and histone deacetylases (HDACs) plays an important role in cancer. Transcriptome analysis of long-term cisplatin resistant sublines ( LTT) of three different urothelial carcinoma cell lines ( UCC) revealed that genes encoding for HDAC9 and HAT1 were upregulated in LTTs as compared to their parental UCCs. Thus, we analyzed the function of these epigenetic enzymes in cisplatin resistance. Material and methods: We investigated expression of HDAC9 and HAT1 in four UCC (RT112, J82, 253J, T24) and their respective LTT sublines by qRT-PCR and western blotting. Modulation of their expression by siRNA knockdown as well as treatment with enzyme inhibitors was analyzed regarding the effect on cell proliferation (clonogenic assays), cell cycle and apoptosis induction (flow cytometry) and cisplatin sensitivity. Results: Knockdown of HDAC9 or HAT1 resulted in inhibited proliferation and increased apoptosis for HDAC9. We performed dose-response curve analysis with the HAT-inhibitors L-Moses and A-485 and the HDAC9-inhibitor BRD43543. While LTTs were less sensitive to BRD4354 compared to parental UCCs (1.25 to 2-fold), they were more sensitive to L-Moses. However, combined treatment of LTTs with BRD4354 (IC 50 range 20-50 µM) and cisplatin reduced viability of LTTs more efficiently than mono-treatment with cisplatin and allowed an IC 50 reduction of up to 30%. Further, induction of apoptosis was stronger (e. g., 2-fold in T-24 LTT). Objective: Urothelial carcinoma ( UC) has one of the highest prevalence of alterations in epigenetic enzymes. Therefore, the use of epigenetic inhibitors (Epi-I) is considered as a new therapeutic approach. We investigated the cytotoxic impact of the second-generation Bromodomain protein inhibitor (BETi) PLX51107 ( PLX) on UC cells ( UCC). We also analyzed, how the treatment with BETi could be applied to episensitize UCC towards approved treatments. Material and methods: UCCs VM-CUB1 and UM-UC-3 and normal HBLAK control cells were treated with Epi-I PLX and PARP inhibitor (PARPi) Talazoparib or the chemotherapy drug Cisplatin. Effects on proliferation, cell cycle and apoptosis induction were analyzed by viability and colony formation assays and flow cytometry. Effects on DNA damage signaling were investigated by qPCR, Western Blot and immunocytochemistry. Synergy of combination treatment was evaluated by the Chou-Talalay method. Results: Treatment with PLX induced DNA damage, reduced cell proliferation in UCC, disturbed the cell cycle regulation and induced apoptosis. PLX altered gene expression contributing to DNA repair deficiency. Thus, combination treatment of PLX and Cisplatin acted strongly synergistic in UCC, especially in PLX-resistant UM-UC-3 cells, but not in normal HBLAK cells. Even better synergism was obtained in UCC by combining PLX with Talazoparib. Concurringly, cell death induction was 6-fold more increased compared to mono-treatment. Ergebnisse: Es konnten 92 Patienten in die Auswertung eingeschlossen werden, von denen 65 BCG erhielten. Tumorbudding korrelierte statistisch signifikant mit multifokalen Tumoren in der Chi 2 -Analyse (p = 0,003) sowie mit dem EORTC recurrence risk (ρ: 0,262, p = 0,012) und progression risk score (ρ: 0,264, p = 0,011) in der Spearman-Analyse. In der Kaplan-Meier-Analyse war ein medianer bud-count von ≥0,9 statistisch signifikant mit schlechterem RFS (p = 0,005), PFS (p = 0,017) und CSS (p = 0,002) assoziiert. In der multivariablen Cox-Regressions-Analyse war ein medianer bud-count von ≥0,9 der beste prädiktive Parameter für ein Rezidiv ( HR: 2,94, 95 %-CI: 1,15-7,52; p = 0,025). Bei den BCG-therapierten Patienten war ein medianer bud-count von ≥0,9 ebenfalls mit schlechterem RFS (p = 0,012), PFS (p = 0,011) und CSS (p = 0,022) assoziiert. Schlussfolgerungen: Die Implementierung des einfach zu erhebenden Tumorbuddings in die pathologische Aufarbeitung des TUR-Gewebes könnte helfen, pT1 Hochrisikopatienten zu identifizieren, die von einer Frühzystektomie profitieren.

3K07.14 Validierung zweier Subklassifikationen des T1 Urothelkarzinoms der Blase und Evaluation der prognostischen Wertigkeit Einleitung: Prostatic artery embolisation ( PAE) for the treatment of lower urinary tract symptoms secondary to benign prostatic obstruction ( LUTS/ BPO) still remains under investigation. This study compares efficacy and safety of PAE and TURP in the treatment of LUTS/ BPO at 2 yr of follow-up.

A randomised, open-label trial randomized 103 participants aged ≥40 yr with refractory LUTS/ BPO to PAE or TURP. Outcomes included IPSS and other questionnaires, functional measures, prostate volume, and adverse events. Changes from baseline to 2 yr were tested for differences between the two interventions with standard twosided tests. Ergebnisse: The mean reduction in IPSS after 2 yr was 9,21 points after PAE and 12,09 points after TURP (difference of 2,88 [95 % confidence interval 0,04-5,72]; p = 0,047). Superiority of TURP was also found for most other patient-reported outcomes except for erectile function. PAE was less effective than TURP regarding the improvement of maximum urinary flow rate (3,9 vs 10,23 ml/s, difference of -6,33 [-10,12 to -2,54] ; p < 0,001), reduction of postvoid residual urine (62,1 vs 204,0 ml; 141,91 [43,31-240,51] ; p = 0,005), and reduction of prostate volume (10,66 vs 30,20 ml; 19,54 [7,70-31,38] ; p = 0,005). Adverse events were less frequent after PAE than after TURP (total occurrence n = 43 vs 78, p = 0,005). Ten patients (21 %) who initially underwent PAE required TURP within 2 yr due to unsatisfying clinical outcomes. Schlussfolgerung: Inferior improvements in LUTS/ BPO and a relevant retreatment rate are found 2 yr after PAE compared with TURP. PAE is associated with fewer complications than TURP. The disadvantages of PAE regarding functional outcomes should be considered for patient selection and counselling. Introduction: REZUM Water Vapor Therapy has recently become available in Switzerland. This study evaluates efficacy and safety of this therapy 1 year after its introduction at the University Hospital Zurich. Methods: All patients undergoing REZUM therapy since June 2019 were included. Primary outcome was time to catheter withdrawal. Secondary outcomes were anesthesia-related complications, hospital stay length, continuous bladder irrigation ( CBI) >24 h, postoperative urinary tract in-fection ( UTI), maximal urinary flow (Qmax), post-void residual volume ( PVR) and continence at 3 months after surgery. Results: A total of 47 patients were included. Median age was 78 years (range 54-92). ASA-score was ≥3 in 29/47 (62%) patients. Before surgery, 16/47 (34%) patients had a permanent indwelling catheter. Median prostate volume was 50 ml (range 30-160). Median operative time was 8 min (range . A median 5 water vapor injections (range 3-18) were applied. Prostate volume significantly correlated with injections count (R 2 = 0.57; p < 0.001), and operative time (R 2 = 0.38; p < 0.001). Postoperative delirium occurred in 1 patient (2%). Anaphylactic shock occurred in 1 patient (2%). Median hospital stay was 2 days (range 0-7). CBI >24 h was necessary in 3 (6%) patients. UTI occurred in 4 (9%) patients. Bladder tamponade occurred in 1 (2%) patient. Median time to catheter withdrawal was 9 days (range 5-67). A significant improvement of Qmax (median 2.8 ml/s higher; p = 0.036) and PVR (median 26 ml lower; p < 0.008) was found, and continence was preserved. Conclusions: REZUM water vapor therapy under intravenous sedation is applicable to patients with severe comorbidities. Complications occur seldom, but require close monitoring of patients after surgery. Objective: To report 3 year safety and efficacy outcomes of the Aquablation procedure for the treatment of men with symptomatic BPH and largevolume prostates. Methods: 101 men with moderate-to-severe BPH symptoms and prostate volumes of 80-150cc underwent a robotic-assisted Aquablation procedure in a prospective multicenter international clinical trial with scheduled follow-up at 6, 12, 24 and 36 months. Results: Mean prostate volume was 107cc (range 80-150). Mean operative time was 37 min and mean Aquablation resection time was 8 min. IPSS scores improved from 23.2 at baseline to 5.2 at 36 months (change of -16.7 points, p < 0,0001). Qmax improved from 8.7 cc/sec at baseline to 19.0 cc/sec at 36 months. Improvements in both IPSS, IPSS Quality of Life, Qmax, and PVR were immediate and sustained throughout follow-up. Three subjects (3%) have required surgical retreatment over the course of three years post-Aquablation. Conclusions: In 3-year prospective follow-up, the Aquablation procedure was shown to be safe and effective in men with large prostates (80-150cc 3K08.5 Routine use of focal bladder neck cautery in 1116 consecutive Aquablation controls postoperative bleeding Introduction and Objective: To determine if focal bladder neck cautery effectively prevents blood transfusions across various prostate volumes following prostate tissue resection for benign prostatic hyperplasia using Aquablation. Methods: Consecutive patients between late 2019 and August 2020 undergoing Aquablation followed by focal bladder neck cautery from 11 countries from Asia, Europe, and North America were evaluated for transfusions. Results: 1,116 Aquablation cases were performed using focal bladder neck cautery with a mean prostate size of 81 cc (range 20 to 300cc). The average time spent after removing the handpiece to inserting the urinary catheter was 18 min. This segment of the procedure includes flushing, transitioning to the resectoscope, and cauterizing at the bladder neck. Postoperative bleeding requiring transfusion occurred in seven cases (0.6%, 95% CI 0.3-1.3%). This result compares favorably (p < 0,0001) to the previously published hemostasis aggregate transfusion rate of 31/801 (3.9%) using methods performed in the years 2014 to 2019. Conclusions: Routine use of additional focal bladder neck cautery subsequent to aquablation will bring down the risk of postoperative bleeding to a level known from TURP or HoLEP while preserving the main strategic goals of aquablation: reliable desobstruction of the prostatic urethra, high safety profile for protection of the urinary sphincter, high efficacy in preserving antegrade ejaculation, minimizing and standardizing the ablative procedure.

In-hospital cost analysis of aquablation compared with transurethral resection of the prostate in the treatment of benign prostatic enlargement Objectives: To compare in-hospital treatment costs of aquablation and transurethral resection of the prostate ( TURP) in the treatment of benign prostatic enlargement. Patients and methods: Patient data and procedural details were derived from a prospective database. In-hospital costs were calculated using detailed expenditure reports provided by the hospital accounts department. Total costs including those arising from surgical procedures, consumables, personnel, and accommodation were analysed for 24 consecutive patients undergoing aquablation and compared to 24 patients undergoing TURP during the same period. Mean total costs and mean costs for individual expense items were compared between treatment groups with t-tests. Results: Mean total costs per patient (± SD) were higher for aquablation at € 10,994 ± 2,478 than for TURP at € 7,445 ± 2,354. The mean difference (md) of € 3,549 was statistically significant (p < 0.001). While the mean procedural costs were significantly higher for aquablation (md € 3,032 (p < 0.001)), costs apart from the procedure were also lower for TURP, but the md of € 1,627 was not significant (p < 0.327). Medical supplies were mainly responsible (md of € 2,057; p < 0.001) for the difference in procedural costs. Conclusions: In-hospital costs are significantly higher for aquablation than for TURP, mainly due to higher costs of medical supplies of the procedure. This difference should be taken into consideration, at least in patients for whom the different side effect profiles of both treatments are irrelevant. Introduction: Robotic assisted prostate adenomectomy ( RASP) was first demonstrated by John et al. 2007 at the AUA. Simple robotic prostatectomy has been modified using different techniques. We propose a new operative technique with extraperitoneal approach, extravesical prostate adenomectomy and reconstruction of the prostatic urethra by running suture of the bladder neck with the intraprostatic urethra ( EE-RASP). Surgical techniques: Extraperitoneal access is performed with placement of a 4-arm daVinci Xi® System. The bladder neck and the proximal prostatic urethra are prepared and dissected. The enucleation of the prostate gland is performed. The urethral tract is reconstructed according to van Velthoven of the bladder neck with the intraprostatic urethral stump excluding the prostatic fossa totally. Suprapubic and transurethral catheters are placed. Results: We performed EE-RASP in 25 patients with a median age of 72 and a prostate size of 120 ml. The operative time of 175 min was observed with a blood loss of 200 ml. The median preoperative residual urine and Q max were 125 ml and 6.7 ml/sec respectively compared to postoperative 0 ml and 19 ml/sec. The transurethral catheter was removed on the first postoperative day, the suprapubic catheter on the eighth. Two months after the operation, no incontinence-pads were used. Conclusion: The EE-RASP is a minimal invasive technique with low complication rate and good functional outcome. The reconstruction of the prostatic urethra, thus excluding the prostatic fossa completely, prevents postoperative complications from the prostatic fossa as postoperative prostate fossa bleeding, urgency, frequency, bladder neck and urethral strictures. In plus, even transurethral irrigation has become obsolete. Purpose: RSP represents a secondary curative approach in the management of rPCA with organ confined disease. Its role in the treatment of rPCA following multiple lines of RT is unclear with regard to oncological and functional outcome and complications. Patients and methods: A case-control study of n = 15 with rPCA following one type of RT (group 1) compared to n = 15 with 3 lines of RT (group 2) was performed. Group 2 received IMRT, LDR-BT and HDR-BT in different sequences. All men underwent PSMA-PET/ CT, mpMRT and transperineal prostate biopsy prior to open retropubic RSP. We compared pathohistology, bNEDl, overall survival and complications according to Clavien Dindo. Results: Median age was 67.5 (42-79) and 59.2 (43-65) years, median PSA at RSP was 4.93 (0,9-41,9) and 4.32 (1.1-23.4 ) ng/ml. In group 1, 46.7% pts exhibited pT2a-c, 20% and 33.9% demonstrated pT3a or pT3b, resp. pN+ was identified in 26.7%, positive surgical margins were present in 26.7%. bNED was 60% for the total cohort and 85.7%, 66.7%, and 60% for pT2, pT3a, pT3b. PFS for pN+ was 25%. In group 2, 40%, 13.3% and 46.7% had pT2a-c, pT3a or pT3b, resp. pN+ was identified in 40%, positive surgical margins were present in 30%. bNED was 40% for the total cohort and 83.3%, 50%, 42.8% for pT2, pT3a, and pT3b. PFS for pN+ was 25%. Median follow-up was 45 (31-67) and 40 (34-62) months, OS was 86.7% for both groups. Grad III & IV complications developed in 13.3% and 26.7%, resp. Complete continence was achieved in 66.7% and 53.3%, resp., severe incontinence developed in 13.3% and 26.7%, resp. Conclusion: RSP following multiple lines RT is technically feasible but with an inferior oncological and functional outcome. These data must be conseidered when counselling the patient for redo-RT or RSP. Introduction: Exploratory analysis to assess the efficacy of ENZA+ADT in patients (pts) from ARCHES (NCT02677896) who progressed to M1 HSPC following initial diagnosis (M0) vs pts who presented with de novo mHSPC at diagnosis (M1). Material and methods: mHSPC pts (n = 1150) were randomized 1:1 to ENZA (160 mg/day)+ ADT or placebo ( PBO)+ ADT, stratified by disease volume and prior docetaxel use. In this post hoc analysis, pts previously centrally categorized as unknown metastasis at initial diagnosis (n = 213) were adjudicated as either M0 or M1 disease following medical profile review; efficacy outcomes were compared according to M0 vs M1 disease at initial diagnosis. Results: 246 pts ( ENZA, n = 117; PBO, n = 129) had M0 and 890 pts ( ENZA, n = 448; PBO, n = 442) had M1 disease at initial diagnosis. At baseline, a greater proportion of M1 pts had high disease volume (68.1% vs 47.2%

[M0]) and prior docetaxel (19.4% vs 11.8% [M0]). ENZA+ADT improved radiographic progression-free survival (rPFS) vs PBO+ADT irrespective of M0 or M1 disease at diagnosis; similar improvements were observed for secondary endpoints including prostate-specific antigen ( PSA) and objective responses, time to PSA progression, time to new antineoplastic therapy (Table) . Safety profiles were generally similar between subgroups and the overall population; exceptions include higher fatigue in M0 ENZA and PBO arms. Conclusions: This post hoc analysis demonstrates clinical benefit of ENZA+ADT vs PBO+ADT based on rPFS and secondary endpoints in men who progressed from M0 to M1 HSPC and those with de novo M1 HSPC.

Analysis of the effect of crossover from placebo ( PBO) to darolutamide ( DARO) on overall survival ( OS) benefit in the ARAMIS Trial 3K09.7 Safety of darolutamide ( DARO) for nonmetastatic castration-resistant prostate cancer (nmCRPC) from extended follow-up in the phase III ARAMIS trial Background: DARO is a structurally distinct androgen receptor inhibitor ( ARI) approved for treating nmCRPC. In ARAMIS, DARO significantly reduced the risk of death by 31% ( HR = 0.69; 95% CI: 0.53-0.88; p = 0.003) and prolonged median metastasis-free survival vs placebo ( PBO; HR = 0.41; 95% CI: 0.34-0.50; p < 0.001). In the final analysis of the doubleblind ( DB) period of the ARAMIS trial, DARO had a favorable safety profile. The incidence of permanent discontinuation due to AEs was also similar between DARO and PBO (8.9% vs 8.7%). Here we present safety data for prolonged treatment with DARO from the final analysis of the DB + openlabel ( OL) period. Methods: Patients (pts) with nmCRPC (N = 1509) were randomized 2:1 to DARO or PBO while continuing ADT. Study unblinding occurred on November 30, 2018, after which pts in the DARO arm continued with OL DARO. The data cut-off for final analysis of the DB+OL period was November 15, 2019. Results: The increase in the incidence of any-grade AEs (85.7% vs 89.8%) and serious AEs (26.1% vs 32.1%) between the DB and DB+OL period was small and only minor changes for ARI-associated AEs were observed. Fatigue remained the only AE of interest that exhibited >10% incidence in the DARO arm during the DB+OL period. The incidence of permanent discontinuation of DARO due to AEs increased slightly from 8.9% during the DB period to 10.5% during the DB+OL period. Conclusions: With longer treatment exposure, DARO remained well-tolerated and no new safety signals were observed. The expected increases in incidence of AEs between the DB and DB+OL periods largely disappeared when adjusted for the longer exposure, confirming the favorable safety profile of DARO with prolonged treatment.

Final analysis results from TITAN: A phase III study of apalutamide ( APA) versus placebo ( PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy ( ADT):

Background: TITAN evaluated APA or PBO added to ADT in pts with mC-SPC (high-and low-volume, prior docetaxel, prior treatment for localized disease, and prior ADT (≤ 6 mos)). At the first interim analysis (22.7 mos median follow-up) APA significantly improved dual primary end points of OS (hazard ratio [ HR] 0.67) and rPFS ( HR 0.48) compared with PBO. Methods: 1052 mCSPC pts were randomized 1:1 to receive APA (240 mg QD) or PBO plus ADT. Time-to-event end points were analyzed by Kaplan-Meier method and Cox proportional hazards model. A preplanned sensitivity analysis for OS, accounting for crossover using inverse probability censoring weighted ( IPCW) log-rank test, was conducted. No formal statistical retesting was performed; nominal p values were reported without multiplicity adjustment. Results: With 44 mos median follow-up, 405 OS events had occurred. After unblinding, 208 PBO pts (39.5%) crossed over to APA. Median treatment duration was 39.3 mos for the APA group, 20.2 mos for the entire PBO group, and 15.4 mos for the PBO→APA crossover group. OS was superior in the APA group compared with the PBO group despite crossover. 48-mo survival rates were 65% ( APA) vs 52% ( PBO). Other end points also favored APA vs PBO. HRQoL, per total FACT-P, was maintained in the APA group and was not different from the PBO group. Safety was consistent with previous reports. Conclusions: With close to 4 yrs of follow-up, the final analysis of TITAN demonstrated that in a broad population of pts with mCSPC, APA plus ADT provides an improvement in OS (35% reduction in risk of death, which increased to 48% after adjusting for pts who crossed over from PBO to APA). There was consistent benefit with APA in other end points. NCT02489318 3K09.9 Impact of time to castration resistance on survival in metastatic hormone sensitive prostate cancer patients in the era of combination therapies Fragestellung: Das biochemische Ansprechen auf 177 Lu-PSMA-617 konnte in mehreren Studien belegt werden. Aus Einigen ging hervor, dass Patienten mit einer höheren PSMA-Expression auch besser auf eine Radioligandentherapie ansprechen. Dies wurde bei Patienten mit niedrigen PSMA-Expression bisher nicht untersucht. Daher analysierten wir in einer kleinen Kohorte das Ansprechen von Patienten mit geringer PSMA-Expression im Vergleich zu Patienten mit hoher Expression. Material und Methoden: Wir behandelten 86 mCRPC Patienten mit 177 Lu-PSMA-617. Verschiedene biochemische Parameterwurden erhoben, retrospektiv analysierten wir PSA, LDH und AP. Anhand der semiautomatisch ausgewerteten 68 Ga-PSMA-11 PET/ CT, wurden die Patienten in eine Lowund High-PSMA Gruppe eingeteilt. Der Einfluss der Dynamik von PSA, AP und LDH unter Therapie wurde für beide Gruppen analysiert. Ergebnisse: Eine PSA-Reduktion ≥50 und ≥90 %, eine LDH-Normalisierung sowie eine AP-Normalisierung unter Therapie waren prognostisch für ein längeres OS. Die High-PSMA Gruppe zeigte ein bemerkenswert besseres Ansprechen des PSA-Wertes, besonders bezüglich der Reduktion ≥ 50 und ≥90 % (jeweils p = 0,01). Auch bei der Normalisierung der AP war ein Unterschied zwischen den Gruppen feststellbar (p = 0,03). Kein signifikanter Unterschied zeigte sich bei LDH-Normalisierung. Dennoch hatten in der Low-PSMA Gruppe 90 % einen Abfall des PSA-Wertes und 27 % einen Abfall über 50 %. In der High-PSMA Gruppe waren es 89 % bzw. 56 %. Schlussfolgerungen: Eine niedrige PSMA-Expression geht mit einem schlechteren PSA-Ansprechen, sowie mit einer schlechteren Reduktion des prognostischen Markers AP, einher. Auf LDH hatte dies keinen Einfluss. Dennoch scheinen einige Patienten mit niedriger Expression auf diese Therapie ausreichend anzusprechen.

Erhöhte PSMA-Expression als positiver Prognostikator des Gesamtüberlebens bei mCRCP Patienten unter 177 Lu-PSMA-617 Radioligandentherapie erodedreservoir, then a cystorrhaphy, and finally insertion of a concealed reservoir between the anterior rectus sheath and rectus muscle at a higher level of theabdominal wall contralaterally due to inflamed retzius space at the contralateral side, as the video demonstrates. Results: Postoperatively, the device was working seamlessly with normal inflating and deflating, recovery was uneventful. At the 10th day, a cystogram wasdone with no contrast extravasation. At the follow-up, the patient was satisfied and used the device efficiently with no observed complications. Conclusions: Eroded Inflatable Penile Prothesis ( IPP) reservoir can be safely replaced in a single procedure with the absence of complications. Nontraditional placement of IPP reservoir is a good alternative especially in case of hostile pelvis or retzius space. Einleitung: VVF ist eine seltene Komplikation nach Beckenchirurgische. Standardtherapie ist eine offene Fistelresektion mit Scheiden-und Blasenverschluss sowie Interponatanlage. Es handelt sich um einen invasiven Eingriff, mit abdominellem Zugang. Methoden: Fall 1: 47jährige Patientin mit Z. n. vaginaler Hysterektomie und Z. n. auswärtigem laparoskopischem Fistelverschluss. Hiernach kam es zu einem rezidiv, welches unter konservativen Maßnahmen nicht abheilte. Es wird ein roboterassistierter Verschluss der Rezidiv-VVF vorgestellt. Nach Blaseneröffnung erfolgen die Mobilisation der Blasenhinterwand, Resektion des Fistelkanals samt Narbengewebe und fortlaufender Verschluss der Scheide mit Vicryl-Naht. Ein Peritoneallappen wird mobilisiert und vor der Scheide platziert. Die Blase wird mit fortlaufender V-Loc-Naht verschlossen. Fall 2: 56jährige Patientin mit Z. n. radikaler Zystektomie und Neoblasenanlage (Urothelkarzinom pT2, pN0, R0, G3) stellte sich mit einer VVF bei uns vor. Die Neoblase wird von der Scheide abpräpariert. Es folgen die Mobilisation der Neoblase, Resektion der Fistel und fortlaufender Verschluss der Neoblase mit einem Stratafix-Faden und der Scheide mit einer Vicryl-0-Naht. Ein Omentumstreifen wird mobilisiert und zwischen der Scheide und der Neoblase fixiert. Ergebnisse: Die OP-Dauer betrug 190 bzw. 183 min ohne signifikanten Blutverlust. Der Blasenkatheter wurde nach 2 bzw. 4 Wochen nach unauffälligem Zystogramm entfernt. Prompte komplette Wiederherstellung der Kontinenz ohne Fistelrezidiv. Schlussfolgerung: Der robotische Fistelverschluss stellt eine sichere OP-Methode auch nach Voroperationen oder in der Rezidivsituation dar. Die Prinzipien der offenen Fisteloperation können bei exzellenter Sicht und minimalinvasivem Vorgehen komplett übernommen werden. Introduction: In this video we present our experience in managing a patient with unusually large prostate measuring of 700 ml diagnosed with prostate carcinoma. Materials and methods: A 75-year-old patient presented with PSA 670 ng/dl. Ultrasound revealed a large prostate measuring 700 ml. Prostate biopsy revealed Adenocarcinoma of prostate with Gleason Score 4 + 4 = 8. Staging CT and PET scan showed no metastasis. Rectoscopy was performed to rule out rectum infiltration. The patient was started on anti-hormone therapy for one month. We demonstrate our robot assisted surgical technique of radical prostatectomy with peritoneal flap fixation. Results: The patient was placed in supine position in a 25 degree trendelenburg position. A typical 6 trocar setup was used. The Retzius space was dissected and pelvic lymphadenectomy was performed on both sides. The ureters were looped on both sides. Inspite the abnormal size of the prostate, the plane between the prostate and rectum was intact and radical prostatectomy was performed successful. A watertight, urethrovesical anastomosis was performed with the single knot technique described as Van Velthoven technique. The peritoneum flap was fixed to the pelvic rim using 2/0 Vicryl. Final histopathology showed Gleason 5 + 5 = 10 tumour without lymph node metastasis. Cystography on the 7th postoperative day and the catheter was removed subsequently. Conclusion: Non-metastatic prostate carcinomas with above-average prostate volume and very high PSA level are rarely described in the available literature. Despite the monstrous size and the advanced tumour stage, we were successfully able to perform radical prostatectomy. The patient recovered normally. Introduction: Recent publications have shown that partial nephrectomy ( PN) can be a safe treatment option even for complex tumours that would otherwise undergo a radical nephrectomy. Careful pre/intra-operative planning is crucial for these complex operations. In this video we present our experience in managing a patient with a central, completely intraparenchymal kidney tumour with the help of cognitive 3D guidance.

A 69 year old male patient presented with newly diagnosed microhematuria. MRT abdomen revealed a 3 cm central kidney tumour on the left side. A 3D model was reconstructed using the MRT images. We demonstrate our robot assisted surgical technique of PN. Results: The patient was placed on a right lateral position. The trocars were placed in a typical manner for transperitoneal PN. The Gerota's fascia was opened and the hilus was dissected. The kidney was completely mobilized following looping of renal vessels. Cognitive fusion based on 3D model and intraoperative ultrasound was used to locate the tumour and mark the resection margins. The tumour was enucleo-resected successfully and the frozen section revealed tumour free margins of a hypernephroma. Haemostasis was achieved by inner layer renorraphy suturing along with placement of haemostatic agents at the end of the procedure. Conclusion: Robot assisted PN is feasible even in case of totally intrarenal tumours. The maneuverability and flexibility of the DaVinci instruments along with ultrasound and 3D cognitive guidance helps the surgeon to perform these fine steps precisely.

Einleitung: Seit der Einführung der PSMA-PET Bildgebung können Lokalrezidive nach radikaler Prostatektomie ( RP) präziser entdeckt werden. Das Ziel der Arbeit war die Auswertung des biochemischen Ansprechens und therapiefreien Intervalls nach Salvage-Operation von Patienten mit Rezidiven in der Samenblasenloge. Material und Methoden: Es wurden 40 Patienten aus zwei Zentren (11/2014-02/2020) analysiert, die eine PSMA-radioguided surgery ( PSMA-RGS) erhielten. Alle Patienten hatten ein biochemisches Rezidiv ( BCR) nach RP sowie ein singuläres Samenblasenlogenrezidiv in der PSMA-PET Bildgebung. 33 (82,5 %) Patienten waren vorbestrahlt. Der Anteil an Patienten mit kompletten biochemischen Ansprechen (cBR, PSA < 0,2 ng/ml) nach 6-16 Wochen wurden erfasst. Das BCR-freie Überleben und das therapiefreie Überleben wurden mittels Kaplan-Meier berechnet. Komplikationen wurden nach Clavien-Dindo ausgewertet. Ergebnisse: Vor PSMA-RGS lag der mediane PSA bei 0,9 ng/ml (Interquartilsabstand [ IQR]: 0,5-1,7 ng/ml). Nach PSMA-RGS war der mediane PSA-Nadir ohne weitere Therapie bei 0,1 ng/ml ( IQR: 0-0,4 ng/ml). Bei 31 Patienten (77,5 %) wurde ein cBR beobachtet. Während des medianen Follow-ups von 24,4 Monaten ( IQR: 11, 9 Monate) erlebten 22 (55,0 %) Patienten ein BCR und 12 (30,0 %) Patienten erhielten eine weiterführende Therapie. Nach einem Jahr lag das BCR-freie Überleben bei 62,2 % und das therapiefreie Überleben bei 88,3 %. Drei (7,5 %) Clavien-Dindo Grad III Komplikationen wurden beobachtet. Hauptlimitation ist das retrospektive Design. Schlussfolgerung: Die Salvage-Operation eines PSMA-PET positiven Samenblasenlogenrezidivs ist mittels PSMA-RGS gut machbar und kann möglicherweise bei hochselektierten Patienten das BCR-freie Überleben und damit das therapiefreie Überleben verlängern.

Step-by-step Video einer penoskrotalen Implantation einer Rigicon Infla10-Penisprothese [3-11d] postoperative day ( POD). Postoperative histology showed pT2a (n = 2), pT2c (n = 6), pT3a (n = 1), pT3b (n = 1). Low and intermediate risk Gleason scores were confirmed in 9 of 10 patients. In 2 cases positive surgical margins (0,5-2 mm, Gleason 3) were found. Early continence was evaluated using pad tests. In the first 24 h after catheter removal the median loss was 5,5 g/24 h [0-25 g/24 h]. At 10th POD and 12 weeks control dry pads were reported. 12 weeks postoperatively a median IIEF-15 of 52,5 points [27-65] was achieved using PDE-5-inhibitors. Conclusion: The Igloo-technique as a complete circumferential nerve sparing with a single lateral approach is feasible, safe but technically demanding. Excellent early continence and midterm erectile function can be achieved. Nevertheless, the Igloo-technique is only to be used for patients with low-risk-profile cancer. 

Der Urologe · Suppl 1 · 2021 S105 Material und Methoden: Eingeschlossen wurden Patienten bei denen im Rahmen der FaST 1 und 2-Studien, prospektiv randomisierte Studien zur Lebensqualität bei postoperativer Harnableitung, nach sekundärer Ureterorenoskopie ein Mono-J-Katheter (Coloplast®, VORTEK® 6 Ch) eingelegt wurde. Ein Dauerkatheter mit Flötenspitze ( UROMED, 18 Ch) wurde über den Mono-J-Katheter aufgefädelt eingelegt. Beide Katheter wurden nach 6 h auf der Station durch eine/ n Krankenpfleger/in entfernt. Endpunkte waren eine Dislokation oder Schwierigkeiten bei der Entfernung. Ergebnisse: Zwischen August 2014 und April 2018 wurden bei 245 randomisierten Patienten bei 121 Patienten nach sekundärer URS ein Mono-J-Katheter eingelegt. Eine Dislokation des Katheters oder Schwierigkeiten bei der Entfernung traten nicht auf. Schlussfolgerungen: Die beschriebene Technik der Befestigung des Mono-J-Katheters ist simpel, erhöht den Patientenkomfort und verbessert die Mobilität, da nur ein Katheterbeutel benötigt wird. Introduction: Symptomatic nephroptosis of a kidney transplant is a rare and potentially fatal complication and requires fast diagnosis and treatment. In this report we describe a case in which intermittent symptomatic urinary obstruction and increased kidney retention parameters were the leading symptoms of nephroptosis. Increasing creatinine necessitated reinstertion of DJ-ureter stent and another removal attempt was unsuccessful. There was no stenosis, but hypermobility of the kidney as the suspected cause. We describe the diagnostic procedures and the successful minimal-invasive treatment. Materials and methods: The operation was performed with the da Vinci Si-Surgical-System® (Intuitive Surgical) in a light Trendelenburg position. We chose a transperitoneal approach and fixed the upper kidney pole to the lateral peritoneum. We further performed an arched incision into the ventral peritoneum and flapped it over the transplant with a cranial fixation. Then we attached this "saftey belt" to the ventral aspect of the kidney transplant. Results: Total surgery time was 86 min and estimated blood loss was 20 ml. The ureteral stent and the bladder catheter were removed on postoperative day 1 and the patient was discharged on postoperative day 3. Eight months later the patient is still asymptomatic with stable renal function. Conclusion: To our knowledge this is the first report of a symptomatic transplant nephroptosis with consecutive intermittent urinary obstruction and without complications of perfusion solved with a minimal-invasive approach. Given the rarity of this event, prophylactic nephropexy could only be discussed in very special constellations. The treatment as described is straight forward, easy to perform and bears little stress for the patient. 

M. Merling 10 , M. Koska 10 , M. Jänicke 10 , N. Marschner 11

Urologische Universitätsklinik

Klinik für Hämatologie, Hämostaseologie und Onkologie

AIO-Studien gGmbH

Chicago, Vereinigte Staaten von Amerika; 3 Dana-Farber Cancer Institute

Hexaminolevurinate (Hexvix®) induced

Switzerland

Deutschland Ziel war Ergebnisse der Thulium-Vapoenukleation der Prostata (ThuVEP) bei Patienten (Pt) mit LUTS und Prostata-Karzinom (PCa) zu evaluieren. Prospektive Multicenter-Analyse von 1256 Pt

Pt mit vollständigen Daten, 708 Pt ohne und 286 (28,8 %) mit PCa

Keine Unterschiede intra-und perioperativ, bei Komplikationen oder Re-OPs. IPSS, QoL, RH und Qmax verbesserten sich in beiden Gruppen (alle p < 0,001). Langzeit-Outcome s. . Tab. 1. Niedrigvs Intermediär-/Hoch-Risiko-Pt: Keine Unterschiede

Jahr: ≤1 Vorlage/Tag; n (%)

Jahr: ≥2 Vorlagen/Tag

≤1 Vorlage/Tag; n (%)

Vereinigte Staaten von Amerika

Instituto do Câncer do Ceará, Fortaleza, Brazil; 16 Hospital Pablo Tobon Uribe, Medellin, Brazil; 17 Pharmaceuticals Division of Bayer

Massachusetts General Hospital Cancer Center

Centro Oncológico do Triângulo, Uberlandia, Brazil; 10 Urology Associates, PC, Nashville, Vereinigte Staaten von Amerika; 11 Setor Leste Universitário, Goiânia, Brazil; 12 Hospital Amaral Carvalho, São Paulo, Brazil; 13 Princess Margaret Cancer Centre

Vancouver, Canada; 2 Guy's, King's and St

Hospitals and Sarah Cannon Research Institute

Liga Norte Riograndense Contra O Cancer, Natal, Brazil; 6 Urology of Virginia

Vereinigte Staaten von Amerika

Vereinigte Staaten von Amerika; 3 Barwon Health

Cabrini Hospital, Malvern, Australia; 5 Mayo Clinic, Phoenix, Vereinigte Staaten von Amerika

Vereinigtes Königreich; 17 Guy's Hospital and Sarah Cannon Research Institute, London, Vereinigtes Königreich; 18 Memorial Sloan Kettering Cancer Center

CTCs und der AR-V7-Status wurden als potenzielle Prognostikatoren (Prog.) diskutiert. Material und Methoden: Wir untersuchten 64 Patienten, die mit Abi oder Enza behandelt wurden, bestimmten CTCs und analysierten den AR-V7-Status in Korrelation mit dem PSA PFS

Das mediane PSA-PFS betrug 17 Monate für CTC-und 6 Mo. für CTC+ Patienten (p < 0,01) und 9 Mo

In der multivariaten Analyse blieben für CTC+ Patienten

01) und 10 Mo. für CTC+/ AR-V7-vs. 6 für CTC+/ AR-V7+ (p = 0,07)

UV für den AR-V7-Status ergaben ebenfalls keinen signifikanten Unterschied für das OS

van der Poel 5 , F. Giesel 6 , M. Graefen 1 , M. Eiber

Department of Urology, Antoni van Leeuwenhoek Hospital-the Netherlands Cancer Institute

V07.3, 3K05.13, 3K05.17

Fi02.5, V13.9

Ergebnisse: Einer, der im PET/ CT ermittelten Parameter, mit Einfluss aufs Gesamtüberleben war der läsionale mittlere SUV max identifiziert werden. Ein signifikanter Unterschied im Gesamtüberleben konnte ab einem mittleren SUV max von über 17 festgestellt werden. Wir teilten die Patienten daraufhin in 2 Gruppen, oberhalb und unterhalb dieses Grenzwertes, ein. Das mediane Gesamtüberleben in diesen beiden Gruppen unterschied sich signifikant (7 vs. 15 Monate (p = 0,01)). Schlussfolgerungen: Ein erhöhter mittlerer SUV max , also eine erhöhte PSMA-Expression der Metastasen im PET/ CT, geht mit einem verlängertem medianen Gesamtüberleben einher.

Einleitung: Gem/Cis (G+C) ist die bevorzugte Systemtherapie bei fortgeschrittenen Urothelkarzinomen ( UC), wobei es keine geeignete Möglichkeit zur Vorhersage des Ansprechens gibt. V1, Splicevariante von HYAL-4, zeigt sich in UC hochreguliert und unterhält den malignen Phänotyp. Wir untersuchten, ob V1 die Chemoresistenz in UC beeinflusst. Methodik: 2 Kohorten (K1: 86 Proben (normal = 34; UC = 52); K2: 44 Proben von Patienten mit MIBC, welche G+C zur Behandlung eines UC erhielten). Die V1 Expression wurde mittels RT-qPCR und IHC bestimmt. HYAL-4-Wildtyp (Wt) und V1 wurden stabil exprimiert oder unterdrückt in normalen und UC Zelllinien. Transfizierte Zellen wurden hinsichtlich ihrer Sensitivität gegenüber einer Behandlung mit G+C beurteilt. Die Chemosensitivität von G+C resistenten Tumoren, gegenüber einer kombinierten Behandlung mit Tetrahydrouridine ( TU) und G wurde in einem UC-Xenograft Modell untersucht Ergebnisse: In K1 zeigten sich die V1 Transkriptions-und IHC Level signifikant erhöht (6-13x) in UC-Gewebe gegenüber Kontrollproben (p < 0,001) und 7 × erhöht in MIBC (P = 0,0087). In K2, konnte eine 3,5 × Erhöhung in MIBC-Proben gezeigt werden, welche ein Therapieversagen gegenüber G+C zeigten. V1-exprimierende urotheliale Zellreihen und UC-Zellreihen zeigten sich resistent gegenüber G. Bei Einsatz des CDA Inhibitors TU zeigte sich eine Sensitivitätssteigerung. Im Xenograft-Modell zeigte G (25-50 mg/kg) eine UC-Wachstumsinhibierung, jedoch nicht in V1-expremierenden Tumoren. Die Kombination aus G(25 mg/kg) und TU (20 mg/kg) stoppte das Tumorwachstum in V1-expremierenden Tumoren. Schlussfolgerung: V1 ist ein Einflussfaktor der G Resistenz in UC und ist ein Prädiktor für das G+C Versagen. Ein möglicher Ansatzpunkt dieses zu überwinden scheint die kombinierte Gabe mit TU. Heinrich-Heine-Universität Düsseldorf, Klinik für Urologie, Düsseldorf, Germany; 2 Heinrich-Heine-Universität Düsseldorf, Klinik für Hals-Nasen-Ohrenheilkunde, Düsseldorf, Germany; 3 Universität Duisburg-Essen, Klinik für Kinderheilkunde III, Essen, Germany; 4 Heinrich-Heine-Universität Düsseldorf, Biologisch-Medizinisches Forschungszentrum ( BMFZ), Düsseldorf, Germany; 5 Helmholtz Zentrum München-Deutsches Forschungszentrum für Gesundheit und Umwelt, Immunoanalytics: Tissue Control of Immunocytes, München, Germany Objective: Tools for examining voided urine in patients with bladder cancer ( BC) lack accuracy, cost-effectiveness, objectiveness, or simplicity. Our objective is to evaluate the accuracy of photodynamic procedures for detecting BC cells in voided urine using Hexaminolevurinate( HAL). Materials and methods: Voided urine was collected preoperatively from 121 patients undergoing transurethral resection of bladder tumor ( BC: n = 42, no BC: n = 29), and transurethral resection of prostate and transurethral lithotripsy (Control group: n = 50). Half of urine samples was incubated with HAL, and the rest was incubated without treatment. The intensity of fluorescence at 635 nm (emission wave length) by 430 nm (exiting wave length) was evaluated using a spectrophotometer. The difference between the intensity of HAL-treated and the HAL-untreated samples was calculated. Results: Area under the curve, sensitivity, and specificity of HFC were 0.83, 69.1% (29/42), and 94.0% (47/50), respectively. The sensitivities and specificities of fluorescence in situ hybridization ( FISH) and PDD-HAL were 57.1% (4/7) and 57.1% (4/7) and 72.7% (8/11 ) and 63.6% (7/11), respectively. The intensity of PDD-HAL was significantly correlated with the number of abnormal chromosomes (r = 0.5, p = 0.02). The sensitivities and specificities of conventional cytology and PDD-HAL were 67% (20/30) (low grade: 44% (7/16), high grade: 93% (13/14)) and 73.3% (22/30) and 78.9% (14/18 ) (low grade: 56% (9/16), high grade: 93% (13/14)) and 66.7% (12/18) , respectively. Conclusion: HFC had higly accuracy. HFC was more effective in detecting LG tumors than cytology. Therefore, PDD-HAL can be used as a diagnostic tool for BC using voided urine. Background: Disease recurrence and progression remain major challenges in the treatment of NMIBC. BL enhanced transurethral resection of bladder cancer ( TURBT) is an approach to increase accurate staging as well as complete resection. Methods: We performed a comprehensive search in several medical literature databases including randomized trials. Participants (pts) included had high level of suspicion or 'visible diagnosis' for primary or recurrent urothelial carcinoma of the bladder. According to the Grading of Rec-ommendations Assessment, Development and Evaluation ( GRADE) approach, the certainty of evidence was rated. Results: We identified 16 randomized controlled trials including 4325 pts, comparing BL versus WL TURBT. BL may reduce the risk of disease recurrence over time (hazard ratio ( HR) 0.66, 95% confidence interval ( CI) 0.54 to 0.81; low certainty of evidence ( CoE). For pts with low, intermediate and high risk NMIBC this corresponds to 150 (66 fewer to 27 fewer), 380 (152 fewer to 59 fewer) and 610 (211 fewer to 76 fewer) fewer recurrences per 1000 pts when compared to WL TURBT, respectively. BL may have little or no effect on the risk of disease progression over time ( HR 0.65, 95% CI 0.50 to 0.84; low CoE) . For patients with low, intermediate and high risk NMIBC this corresponds to 2 (1 fewer to 0 fewer), 50 (25 fewer to 8 fewer) and 170 (81 fewer to 25 ewer) fewer progressions per 1000 pts. Conclusions: Although this review identified 16 randomized controlled trials addressing the objective of this review, the certainty of evidence on the results is low to very low. In the future methodological rigorous trails should be conducted.

The " COVID-19 Pandemic Gap" and its influence on oncologic outcomes of primary and recurrent bladder cancer Introduction: Effect of deferred diagnosis and treatment of bladder cancer ( BC) patients due to the coronavirus-19 ( COVID-19) pandemic is currently not clarified. The objective of this study was to evaluate outcomes of COVID-19 pandemic resulting from of delayed diagnosis, staging and treatment of primary and recurrent BC and to create feasible triage decisions. Material and methods: A retrospective single center analysis of all patients, who underwent diagnostic procedures and surgical treatment because of BC during January 2019 and December 2020. Comparison between year 2019 and 2020 were assessed with Poisson-test. Categorical variables are reported as frequencies and percentages and were compared using chi-square or Fisher's exact tests, as appropriate to show differences between 2019 and 2020. Results: Due to COVID-19 lockdown significantly fewer (diagnostic and therapeutic) endoscopic procedures were performed in the first half of the year 2020 compared with 2019 (p = 0.002). In patients with primary diagnosis of BC, a significant increase of high-grade tumors (p < 0.001) as well as advanced tumor stages (p = 0.014) was noticed during 2020. On the contrary, patients with recurrent BC undergoing surveillance at our institution showed no adverse outcomes regarding tumor stage and grade comparing between 2020 and 2019. Discussion and conclusions: The COVID-19 pandemic led to a deferred oncological diagnosis and treatment of BC. Adverse outcomes with increased rates of advanced and aggressive tumors in patients with primary BC requires more awareness in clinical urologic practice and should be timely treated. However, in recurrent BC an individual risk stratification in order to avoid worse outcome during COVID-19 pandemic seems to be justified. Results: 425 men with prostates ranging in size from 20-150cc were treated with Aquablation Therapy. Outcomes from the seven questions from the IPSS questionnaire were analyzed for prostates < 100cc, prostates >100cc, prostate anatomy with median lobe, and prostate anatomy without median lobe. Regardless of subgroup, all outcomes are consistent and a significant improvement from baseline. Specifically, improvements in frequency, urgency, and nocturia demonstrate bladder function improvement. Patients entering treatment with severe incontinence, ISI score >4, and regardless of prostate size, showed a reduction in incontinence during patient follow-up. Conclusions: Aquablation Therapy showed remarkable bladder function improvement following the index procedure. Additionally, men with severe incontinence showed a reduction in incontinence post-procedure. Der Einfluss der Energiedichte (kJ/g) auf die Früh-und Langzeitergebnisse der high-Power HoLEP ist kaum untersucht. 1515 Patienten, die zwischen 2006-2017 eine HoLEP (70 W;1,4J;50 Hz) erhielten, wurden retrospektiv anhand der Energiedichte/Enukleatgewicht in Quartilen (Q) stratifiziert (< 1,9 kJ/g (1.Q), 2-2,7 kJ/g (2. Q), 2,8-3,8 kJ/g (3.Q), 3,9-16 kJ/g (4. Q)), und anhand perioperativer Charakteristika und des Querschnitt Follow-ups (F/u) verglichen. Präoperativ unterschieden sich die Pat. signifikant hinsichtlich des PSA (8, 5 mg/dl (Interquartilsabstand ( IQR) 4, (9) (10) (11) (12) (13) (14) 8) Purpose: Medical treatment of lower urinary tract symptoms( LUTS) secondary to benign prostatic obstruction( BPO) targets prostate size, to prevent disease progression, and prostate smooth muscle tone for rapid relieve of LUTS. Holmium laser enucleation of the prostate( HoLEP) is a size-independent method for surgical treatment of LUTS/ BPO in medication-refractory patients and offers durable long-term results with reduced perioperative morbidity. As up to 50% of patients receive medical treatment for LUTS/ BPO prior to surgery, we analyzed the impact of alphablockers and 5-alpha-reductase-inhibitors(5-ARI) on outcomes and perioperative morbidity in patients undergoing HoLEP for LUTS. Materials and methods: We retrospectively collected data of 1,057 patients who underwent HoLEP for LUTS secondary to BPO between 2013-2018. Patients were divided into group 1 (no medication), group 2 (α-blockers), group 3 (5-ARI and α-blockers). Perioperative parameters, safety and short-term functional outcomes were assessed and analyzed. Results: Patients in group 3 had significantly lower IPSS and PSA compared to patients in group 1 and 2. Perioperative Clavien-Dindo grade ≥ II complications were seen in 4.0% of all patients (42/1,057). There was no difference in perioperative complications between all groups (p = 0.943). Functional outcome was assessed 30 days post-surgery. There was improvement in median IPSS of 9, 8 and 7 points for groups 1-3, with improvement of QoL for all groups. Median Q max showed improvement of 10, 12 and 9.5 ml/s for groups 1-3. Conclusions: Although preoperative LUTS medication does not impair efficacy of HoLEP with acceptable perioperative morbidity, the time gap between medical therapy and surgical treatment may favor an earlier response.

3K08.10 Chirurgische Effizienz der "Ein-Lappen"-Technik vs. "Drei-Lappen"-Technik für die Holmium Laser Enukleation der Prostata ( HoLEP) Hintergrund: Holmium-Laser-Enukleation der Prostata ( HoLEP) ist sicher und effektiv. Unklarheit herrscht hinsichtlich, verschiedener Operationstechniken. Unser Ziel war es, die Drei-Lappen-Technik( TL) mit der neueren Ein-Lappen-Technik( OL) hinsichtlich chirurgischer Effizienz zu vergleichen. Methoden: Es wurde eine retrospektive Analyse von 1475 Patienten durchgeführt, die zwischen Januar 2017 und Juni 2020 mittels HoLEP bei BPH aufgrund von BPO unterzogen. Propensity-Score-Matching ergab eine Kohorte von n = 528 (n = 264 HoLEP in Drei-Lappen-Technik ( TL), n = 264 HoLEP in Ein-Lappen-Technik ( OL)). Primärer Endpunkt: chirurgische Effizienz des OP-Technik. Sekundärer Endpunkt: perioperatives Outcome, frühe funktionelle Ergebnis und perioperative Komplikationen (nach Clavien Dindo). Ergebnisse: Baseline-Charakteristika beider Subkohrten waren vergleichbar. Mediane Operationszeit (52,0 min vs. 83,5 min; p < 0,001), Enukleationszeit (18,0 min vs. 35,0 min; p < 0,001) und Morcellationszeit (9,0 min vs. 12,0 min; p < 0,001) waren signifikant kürzer für OL. Die chirurgische Effizienz war zugunsten von OL in Bezug auf eingesetzte Laserenergie, Operationsgeschwindigkeit, Enukleationsgeschwindigkeit, Enukleationseffizienz und Operationsleistung (jeweils p < 0,001). OL zeigte eine signifikant höhere Korrelation von PV zur Enukleationseffizienz als TL (p < 0,001). Das frühfunktionelle Outcome ( IPSS und Qmax) war besser nach OL (jeweils p < 0,05). Die Rate perioperative Komplikationen war vergleichbar (p = 0,485) Schlussfolgerung: Die Ein-Schleifen-Technik ist schneller und effizienter als die klassische Drei-Schleifen-Technik. Im Gegensatz zur TL zeigte OL mit zunehmender PV eine konstant verbesserte chirurgische Effizienz. OL ist daher insbesondere bei Riesenprostata eine wertvolle Alternative. S92 Der Urologe · Suppl 1 · 2021 3K08.11 Einfluss der "early release" Technik während der Holmiumlaser-Enukleation der Prostata ( HoLEP) auf frühe postoperative funktionelle Ergebnisse Background: DARO is a structurally distinct androgen receptor inhibitor approved for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) based on significantly prolonged metastasis-free survival compared with PBO (median 40.4 vs 18.4 months; hazard ratio [ HR] 0.41; 95% CI 0.34-0.50; P < 0.0001) and a favorable safety profile in the phase III ARAMIS trial. Following unblinding at the primary analysis, crossover from PBO to DARO was permitted. Methods: Patients (pts) with nmCRPC receiving ADT were randomized 2:1 to DARO (n = 955) or PBO (n = 554). Iterative parameter estimation ( IPE) and rank-preserving structural failure time ( RPSFT) analyses were performed as pre-planned sensitivity analyses and generated a Kaplan-Meier curve for the PBO arm that predicts what would have been observed in the absence of crossover. Results: After unblinding, 170 pts (30.7%) crossed over from PBO to DARO. Final analysis of the combined double-blind and open label periods was conducted after 254 deaths (15.5% of DARO and 19.1% of PBO pts) and showed a statistically significant OS benefit for DARO vs PBO ( HR 0.69; 95% CI 0.53-0.88; P = 0.003). Results from the IPE ( HR 0.66; 95% CI 0.51-0.84; P < 0.001) and RPSFT ( HR 0.68; 95% CI 0.51-0.90; P = 0.007) analyses were similar to those from the intention-to-treat population, showing that the impact of PBO-DARO crossover was small. Additional analyses will be presented. Conclusions: Early treatment with DARO in men with nmCRPC is associated with significant improvement in OS regardless of pts crossing over from PBO to DARO. The safety profile of DARO continued to be favorable at the final analysis, and discontinuation rates at the end of the doubleblind period remained unchanged (8.9% with DARO and 8.7% with PBO). 1 (10.9, 29.4) CI confidence interval; HR hazard ratio. a ENZA+ ADT; b PBO+ ADT; c Assessed by independent central review or death within 24 weeks of treatment discontinuation; d HR <1 favors ENZA; e Of those with detectable PSA or measurable soft tissue disease at baseline; Difference >0 favors ENZA. This study was funded by Astellas Pharma Inc. and Pfizer Inc., the co-developers of enzalutamide. Medical writing and editorial assistance were provided by Lianne Young, BSc (Hons), and Jane Beck, MA, from Complete HealthVizion, funded by the study sponsors.Background: To evaluate the impact of time to castration resistance ( TTCR) in metastatic hormone-sensitive prostate cancer (mHSPC) patients on overall survival ( OS) in the era of combination therapies for mHSPC. Material and methods: Of 213 mHSPC patients diagnosed between 01/2013-12/2020 and subsequent development of metastatic castration resistant prostate cancer (mCRPC), 204 eligible patients were analyzed after applying exclusion criteria. mHSPC patients were classified into TTCR < 12 vs. 12-18 vs. 18-24 vs. >24 months and analyzed regarding OS. Moreover, further OS analyses were performed after developing mCRPC status according to TTCR. Logistic regression models predicted the value of TTCR on OS. Results: Median follow-up was 34 months. Among 204 mHSPC patients, 41.2% harbored TTCR < 12 months vs. 18.1% 12-18 months vs. 15.2% 18-24 months vs. 25.5% >24 months. Median age and PSA at prostate cancer diagnosis was respectively 67 years and 61 ng/ml. No differences in patient characteristics were observed (all p > 0.05). According to OS, TTCR < 12 months patients had the worst OS, followed by TTCR 12-18 months, 18-24 months and >24 months, in that order (p < 0.001). After multivariable adjustment, a 4.07-, 3.31-and 6.40-fold higher mortality was observed for TTCR 18-24 months, 12-18 months and < 12 months patients, relative to TTCR >24 months (all p < 0.05). Conversely, OS after developing mCRPC was not influenced by TTCR stratification (all p > 0.05). Conclusion: Patients with TTCR < 12 months are at the highest OS disadvantage in mHSPC. This OS disadvantage persisted even after multivariable adjustment. Interestingly, TTCR stratified analyses did not influence OS in mCRPC patients. 

The phase 2 TRITON2 (NCT02952534) and phase 3 TRITON3 (NCT02975934) studies are evaluating rucaparib in patients with BRCA+ mCRPC. The TP53 tumour suppressor gene is among the most frequently mutated genes in human cancers, and alterations in TP53, PTEN, and RB1 are associated with poor prognosis in mCRPC. We present data on co-occurring alterations in TRITON2 patients with BRCA+ mCRPC treated with rucaparib. Materials and methods: Patients received rucaparib after progressing on 1-2 lines of androgen receptor-directed and 1 taxane-based therapy. Objective response rate ( ORR) and prostate-specific antigen ( PSA) response rate were assessed. Tissue and/or cell-free DNA assays were used for comprehensive genomic profiling. Results: Genomic data were available for 114/115 patients with BRCA+ mCRPC (visit cutoff: 23.12.2019), of whom 36.8% (42/114) had a co-occurring alteration in TP53 and 34.2% (39/114) in PTEN. RB1 loss was observed in 12.3% (14/114) and more frequent in patients with measurable disease (18.0%, 11/61) than in those without (5.7%, 3/53). Patients with and without TP53 mutations had similar demographic and disease characteristics, but visceral disease was more prevalent in patients with TP53 mutations (54.8 %; 23/42) than in those without (29.2 %; 21/72). ORR and PSA response rates were similar in BRCA+ patients with or without TP53 mutation, with a non-significant trend towards lower response rates in patients with TP53 alterations. Conclusions: Results from TRITON2 showed antitumor activity of rucaparib in patients with BRCA+ mCRPC with or without co-occurring alterations in TP53. Additional demographics and efficacy analyses in subgroups with co-occurring alterations in TP53, PTEN, and RB1 will be reported. Background: There is a rising number of men diagnosed with NEPC associated with poor prognosis and limited treatment options. This may be caused by improved histological diagnosis, increasing number of therapy lines and the advent of new antiandrogens. Methods: We retrospectively analyzed all NEPC patients (pts) treated between 2012 and 2020 according to age, prior therapy, NSE and PSA levels, progression free survival ( PFS), overall survival ( OS) and overall response rate ( ORR) following chemotherapy (CTx), calculated using Kaplan Meier method. Results: Of 138 prostate cancer (PCa) pts undergoing systemic therapy, 17 pts with NEPC (12.3%) were identified. 9 pts presented with treatment induced t-NEPC and 8 with de novo-NEPC. Median age was 70 years ( IQR 13.5) . In pts with t-NEPC the median number of prior therapies was 2 with median time from first PCa diagnosis to neuroendocrine differentiation being 5.5 years. Besides lymph node and bone metastases, pts presented hepatic (n = 7), pulmonary (n = 5) and cerebral (n = 2) metastases. At time of NEPC diagnosis, mean levels of NSE and PSA were 160 µg/l and 2.86 ng/ ml, respectively. Following NEPC diagnosis, all pts were treated with platinum-based CTx as first-line treatment (11 received carboplatin/etoposide, 3 cisplatin/etoposide and 3 docetaxel/carboplatin). Median PFS was 6.3 months (95% CI 3.9-12), median OS after diagnosis of NET was 13 months (95% CI 7-NR), median OS after start of platin-based CTx was 12.3 months (95% CI 5.0-NR) and ORR was 47%. Best response was observed for pts being treated with carboplatin/etoposide. Conclusion: In PCa pts with visceral metastases, low PSA values and elevated NSE, the presence of a t-NEPC should be considered. Platin-based CTx is the treatment of choice. However, prognosis is poor. Anhand zirkulierender Tumorzellen (CTCs), wurde mittels qRT-PCR das Genexpressionslevel von PSMA, der Androgenrezepor ( AR) Splicevariante AR-V7 und weiterer, für die NED relevanter Gene bestimmt ( XX). Ergebnisse: Verglichen mit gesunden Kontrollen ( HC) exprimieren Patienten mit fortgeschrittenem mCRPC FOXA1 und weisen signifikant stark erhöhte SYP und ENO2 Geneexpressionslevel auf (p < 0,001 und p < 0,0001). Unterteilt man die Patientengruppe in AR-V7 pos und AR-V7 neg, war kein Unterschied bezüglich der Expression von PSMA, SYP und ENO2 festzustellen. AR-V7 neg Patienten wiesen jedoch signifikant höhere FOXA1 Level auf (p < 0,001). Schlussfolgerung: Sinkendes FOXA1 bei gleichzeitig erhöhtem SYP und ENO2 Level gilt als begünstigender Faktor für NED. Patienten mit einem vergleichbaren Genexpressionsmuster unterliegen dem Risiko einer NED. Daher sollte eine zusätzliche Biotherapie gegen neuroendokrine Tumoren diskutiert werden. Genexpressionsanalysen aus CTCs stellen hiermit ein sinnvolles diagnostisches Vorgehen bei fortgeschrittenem mCRPC und für die Prognose der PSMA-RLT dar.

Hintergrund: Die roboterassistierte Nierenteilresektion ist an einigen Zentren auch bei komplexen Tumoren die Therapie der Wahl. Um diese Methode weiter zu etablieren ist es notwendig, diese Technik zu standardisieren und innovativ weiterzuentwickeln. In diesem Video soll gezeigt werden, dass durch Verbesserung der einzelnen OP-Schritte der Funktionserhalt deutlich verbessert werden kann bei gleichzeitiger Senkung der Komplikationsrate. Methode: Im 1. von 5 wesentlichen Operationsschritten wird die Bedeutung der Doppler-und KM-Sonographie im Zusammenhang mit der Indocyaningabe bei selektiver Gefässabklemmung gezeigt. In weiteren Schritten die Verbesserung der Exzisionstechnik, der Urinomprophylaxe, der Verbesserung der Nahttechnik sowie die Möglichkeit des retroperitonealen Zugangs. Ergebnisse: Von 1/2009 bis 12/2020 wurden 950 roboterassistierte Nierenteilresektionen durchgeführt. Die ersten 800 Patienten wurden mit den letzten 150 Patienten verglichen, bei denen eine Urinomprophylaxe bei komplexen Tumoren und eine spezielle Nahttechnik zum Parenchymverschluss eingeführt wurde. In der ersten Gruppe traten ca. 5 % Urinome auf, bei 4 % kam es zu Komplikationen wie Nachblutung, bei denen eine Bluttransfusion bzw. Nephrektomie nötig war. Bei den letzten 150 Patienten war weder ein Urinom noch eine transfusionspflichtige Nachblutung zu verzeichnen. Zusammenfassung: Ständige Verbesserung der Operationstechnik und zunehmende Erfahrung bei der roboterassistierten Nierenteilresektion kann die Komplikationsrate auf ein Minimum reduzieren. Standardisierte Technik, hohe Bildauflösung und feine Instrumente können mit Doppleroder KM-Sonografie und Indocyaningrün gut funktionierendes Nierengewebe optimal erhalten bei gleichzeitig präziser Exzision des Nierentumors. Introduction: Urethrorectal fistula is an uncommon complication resulting from surgery, radiation or trauma. In this video we present our experience in managing a patient with urethro-rectal fistula following laparoscopic prostate adenomectomy.

A 71 year old male developed a large urethrorectal fistula one month following laparoscopic prostate adenomectomy in different hospital. An attempt to close the fistula with a OTSC clip in the previous hospital was unsuccessful. Rectoscopy showed a 3.5 cm fistula opening at the level of the prostatic cavity with OTSC clip in situ. We demonstrate our robot assisted surgical technique of closure of urethrorectal fistula with omental flap interposition. A diversion colostomy was performed in the same sitting. Results: The patient was placed in supine position in a 20 degree Trendelenburg position. A typical 5 trocar setup was used. The bladder neck was opened ventrally and the clip was removed. A modified radical prostatectomy was performed followed by omental flap mobilization. The large rectal defect was closed using interrupted sutures. The omental flap was fixed posterior to urethra in a tension free manner. The urethrovesical anastomosis was performed in standard manner including lateral narrowing of the bladder neck. Postoperative cystography showed a water tight anastomosis on the 8th postoperative day. Rectoscopy and colostomy closure was performed 3 months later. Conclusions: Interposition of omental flap during the treatment of complicated fistulas supports the healing process because of its rich vascular and lymphatic supply, together with its resistance to infection. The maneuverability and flexibility of the DaVinci instruments helps the surgeon to perform these fine steps precisely. Objective: A 64 year old diabetic patient, presented to our clinic suffering from erectile dysfunction ( ED). A 3-pieces of inflatable penileprosthesis ( IPP) was inserted. He was satisfied and used the device efficiently. Patient suffered from a minor lower abdominal blunt trauma. Followed by a suddenonset of lower abdominal pain and gross hematuria, the pain subsided later. Also, he suffered from irritative and obstructive lower urinary tract symptoms ( LUTS)associated with intermittent hematuria for 2 months, before seeking medical care. During that period he was using the device without any difficulty. On examination,no signs of infection was discovered, with normal device inflation and deflation. A flexible cystoscopy showed the reservoir is completely inside the bladder Methods: A revision procedure was done, staring with lower midline abdominal incision, identifying the bladder, cystostomy and removing of the 3K07.14 Hutterer G. C.3K06.5 Hwang E. C. V17.5